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1
InTroduCTIon
This thesis includes studies about developmental, behavioral and psychiatric charac-
teristics in children with Prader-Willi syndrome (PWS). Endocrinologists Prader, Labhart, 
and Willi were the first describing the combination of neonatal hypotonia, short stature, 
hypogonadism, hyperphagia and obesity, developmental delay and cognitive impair-
ment in 1956 (1). It was not until the 1980s that behavioral and psychiatric problems in 
adults with PWS were investigated (2). However, studies about psychiatric disorders in 
children are very limited and the few publishes are case reports. 
This chapter provides an overview of the genetic cause, developmental course, behav-
ioral phenotype,  and psychiatric disorders in children with PWS. Subsequently, the 
objectives of the studies described in the following chapters are presented. Finally, an 
overview is presented of the Dutch PWS Cohort Study. 
1.1 Prader-Willi syndrome
PWS is a neurogenetic developmental disorder caused by the absence of expression of 
genes on the paternally inherited chromosome 15 at the locus q11-q13, due to a pater-
nal deletion (DEL), maternal uniparental disomy (mUPD), imprinting defects or paternal 
chromosomal translocation. Occurrence is not associated with gender, race or social-
economic status. The estimated birth incidence is 1:15,000 (3, 4). Main characteristics are 
hypotonia, hypogonadism, short stature if not treated with growth hormone, obesity, 
intellectual disability with an IQ between 50-80 (5) and behavioral problems. Character-
istic facial features include narrow temporal distance and nasal bridge, almond-shaped 
eyes, strabismus, a thin-upper lip,  and hypopigmentation of hair, eyes, and skin, relative 
to other family members (6, 7). Children with PWS have sweet personalities, but the 
syndrome is also characterized by behavioral problems, social difficulties and psychiat-
ric symptoms (8, 9). At birth, the infant has typically a low birth weight for gestational 
age and severe hypotonia causing failure to thrive. During childhood, however, mostly 
between the age of two and five years, there is a change towards increasing weight 
and the development of hyperphagia which can lead to excessive eating behavior and 
severe obesity. 
1.2 Genetic cause
1.2.1 History
Until 1981, the diagnosis of PWS was solely based on the appearance of a combination 
of symptoms listed in the consensus diagnostic criteria (10). In 1981, the chromosome 
affected in patients with PWS was first identified (11). It was shown that the majority of 
patients with PWS have a deletion in chromosome 15. In 1982, it was discovered that 
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this deletion only affected the paternally inherited chromosome (12). To date, PWS is 
defined as the lack of expression of paternally inherited genes sited on chromosome 
15 locus q11-13. Another term for the locus 15q11-13 on chromosome 15 is the ‘Prader-
Willi region’. Expression of the genes in the Prader-Willi region van be due to a deletion, 
an mUPD, an imprinting center defect (ICD) or a translocation (13-17). 
1.2.2 Genomic Imprinting
Genes are segments of deoxyribonucleic acid (DNA), carrying the genetic information 
that is used in the development and functioning of all living organisms. Genes are 
located on chromosomes, of which humans have 23 pairs in the nucleus of each cell 
in their body. Children inherit 23 chromosomes from their father and 23 chromosomes 
from their mother, which form the 23 pairs in each cell. Chromosome 15 is one of these 
23 chromosomes. 
In healthy subjects, the Prader-Willi region of the maternally inherited chromosome 15 
is silenced by a process called imprinting, whereas this region of the paternally derived 
chromosome is expressed. Gene imprinting is a mechanism by which part of a chromo-
some is imprinted or silenced during gametogenesis, which leads to a different expres-
sion according to the parent of origin. Abnormal or absent expression of paternally 
derived genes on the Prader-Willi region causes PWS. PWS is one of the first discoveries 
of a genomic imprinting disorder in humans (18). 
1.2.3 Deletion, maternal uniparental disomy, imprinting center defect and translocation
A paternal deletion is the most common chromosomal defect in PWS and present in 
70% of patients (13, 15). The defect occurs either as a large type I deletion or as a smaller 
type II deletion. Maternal uniparental disomy (mUPD) is the second most frequent 
cause of PWS and has been reported in 25% of patients (19). In children with mUPD, the 
paternally inherited Prader-Willi region on chromosome 15 is absent, while two copies 
of the maternally inherited regions on chromosome 15 (which are both imprinted) are 
present. In a small number of cases (less than 5%), PWS results from an ICD (17, 20). 
These individuals have apparently normal chromosomes 15 of biparental inheritance, 
but the paternal chromosome carries a maternal imprint. This leads to a complete loss 
of the paternally expressed genes in the Prader-Willi region. Recent studies showed 
changing rates of the incidence in genetic subtypes: an increasing percentage up to 
50% due to mUPD is seen, probably due to increased maternal age (21, 22). In less than 
1% of patients, part of the paternally inherited chromosome is situated on another 
chromosome, this is called a translocation (13, 23, 24). For a schematic overview of the 
chromosomal defects, see Figure 2. 
General introduction and aims of the thesis 13
1
1.2.4. Correlations between genotype and phenotype
Since it is known that PWS can be caused by different genotypes, differences between 
the phenotypes of these subtypes have been studied and a number of differences 
have been found, especially between the two largest groups, the deletion and mUPD 
genotypes. Table 1 shows the main differences that were indicated between the two 
genotypes.  
figure 1. Schematic overview of the chromosomal defects described in Prader-Willi syndrome
P=paternally derived chromosome, M=maternally derived chromosome, mUPD=maternal uniparental 
disomy, ICD=imprinting center defect
Table 1. Differences between patients with a deletion and an mUPD 
Traits Deletion mUPD
Cognitive functioning (25-27)
 Performal IQ (PIQ)*
 Verbal IQ (VIQ)* 
 Visuospational skills
 Coding ability
65 (47-86)
61 (43-79)
+
+
62 (42-82)
70 (58-82)
-
-
Psychiatric illness (28, 29) +/- +
Behavioral problems (30-33)
 Self-injury
 Food stealing
 Compulsive behavior
 Pervasive developmental disorders (PDD)
+
+
+
+/-
+/-
+/-
+/-
+
Post term deliveries (34) +/- +
Hypopigmentation (35) + -
*Data presented as mean (CI95%)
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1.3 Prader-Willi syndrome in different phases of life
1.3.1 The fetus and neonate
During pregnancy, mothers report lack of fetal activity, which is in most cases also 
notified by obstetricians. Furthermore, the rate of polyhydramnios is elevated. The 
frequency of induced labor is high in PWS and often results in caesarian section (36, 
37). Both premature and post term deliveries are frequently observed, and there is also 
significantly greater risk of premature birth for babies with PWS due to mUPD compared 
with babies with PWS due to a deletion (38). Birth weight of full term PWS babies is 
generally lower than average. On the other hand, birth length of full term babies with 
PWS is mostly within the normal range (38).
In infancy, the most consistent clinical feature is marked central hypotonia, which causes 
decreased movements, a head lag, lethargy with decreased arousal, weak or absent cry, 
and poor reflexes, including a poor suck that leads to feeding difficulties and failure to 
thrive (39). Problems with thermoregulation and hypogonadism with genital hypoplasia 
are evident at birth and throughout life (40). Facial dysmorphic features in PWS are a nar-
row bifrontal diameter, almond shaped yes, a thin downturned upper lip and a narrow 
nose (10).
The uniform presence of hypotonia in infants with PWS has led to the recommendation 
that all newborns with persistent hypotonia should be tested for PWS (7).
1.3.2 The infant
After the neonatal phase, hypotonia becomes gradually less marked, although feeding 
difficulties remain and poor weight gain is typically noted on standard infant growth 
charts. Despite the low weight, excessive body fat is found in infants with PWS by skin-
fold measurements (41), dual energy-x-ray absorptiometry, and double labeled water 
(42). Conversely, lean body mass measurements are decreased in PWS infants, correlat-
ing with a 30% lower energy expenditure as compared to healthy individuals (42).
Gross motor and language milestones are delayed in infants with PWS. Early milestones 
are reached on average at double the normal age (43, 44). 
1.3.3 The child
In general, children with PWS are described as friendly, easy going and affectionate (45). 
However, in childhood simultaneously with the change in eating pattern, children with 
PWS start to show significant maladaptive behavioral and emotional characteristics 
including temper tantrums, automutilation (skin picking), stubbornness, mood lability, 
impulsivity, argumentativeness, and inappropriate social behavior (46). Autism spec-
trum disorder, attention deficit/hyperactivity symptoms, and insistence on sameness 
are common and of early onset (31, 47). Individuals with PWS have sleep-disordered 
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breathing, including central and obstructive sleep apnea, abnormal arousal, abnormal 
circadian rhythms in rapid eye movement (REM) sleep, reduced REM latency, and abnor-
mal response to hypercapnia as well as excessive daytime sleepiness (48-50). Obesity 
can worsen the sleep disorder (51, 52). 
A significant weight gain begins typically during early childhood, between 2 and 4 years 
of age (53). During later childhood, a seemingly insatiable appetite develops (53-55). 
Food seeking is common, and if intake is not controlled externally, this will result in 
extreme obesity. Children with PWS have an abnormal body composition with a rela-
tively high body fat percentage and low lean body mass, which contributes to exercise 
intolerance. Due to muscle imbalance, children with PWS may have genu valgum and 
often develop scoliosis (56). 
Cognitive disability becomes more evident by school age. The average intelligence 
quotient (IQ) is 70, but even children with low to normal IQs almost all have learning 
difficulties (57-59).
1.3.4 The adolescent
Failure of spontaneously completed puberty and late or absent development of beard 
and body hair in males, and menarche and menses in women with PWS have been de-
scribed (60, 61). But, early pubarche and precocious puberty, although more rarely, were 
also found in these patients (40). Failure of spontaneous puberty has generally been 
attributed to hypothalamic dysfunction, but might also be caused by a combination of 
both hypothalamic dysfunction and primary hypogonadism (62). Spontaneous growth 
velocity is impaired and the pubertal growth spurt may be lacking, which both con-
tribute to a decreased adult height. Typical adolescent rebelliousness and behavioral 
problems are common in PWS, and are particularly food-related. Psychiatric symptoms 
might occur in adolescence, mostly psychosis and affective disorders. Adults with mUPD 
are most at risk for a psychosis (28).
1.3.5 The adult
Characteristic behaviors in adult patients with PWS are temper tantrums, self-injury, 
impulsiveness, lability of mood, inactivity and repetitive speech (63). Morbidity in adults 
with PWS includes marked obesity, metabolic diseases, sleep apnea and lipolymphoe-
dema. Adults with PWS are generally incapable of living independently (64). 
Median adult height is 145 cm for women and 155 cm for men (65, 66). In adults with 
compromised pubertal development and absent pubertal onset, secondary sex charac-
teristics are often absent or incomplete (65, 67). There are, however, a few case reports of 
pregnancy in females with PWS (68, 69), but paternity in PWS has never been reported.
The adult population of today was usually diagnosed relatively late, when obesity was 
already present. So no studies are available on the clinical picture of PWS patients 
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who have been diagnosed early in life by genetic testing and who were treated from 
infancy onwards, with diet, exercise, growth hormone and hormonal substitution. Com-
plications of severe obesity, such as diabetes mellitus type II or respiratory insufficiency 
frequently occur and may lead to an early death (67, 70). However, if severe obesity can 
be avoided, patients with PWS may have a reasonable life expectancy (71). To date, the 
majority of patients are diagnosed during the first months of life by genetic testing. An 
earlier diagnosis should allow earlier introduction of care aiming to reduce morbidity 
and improve quality of life.
1.4 Growth hormone treatment in children with PWS
In 2002, the Dutch national growth hormone (GH) trial for children with Prader-Willi 
syndrome was started to find the effects of GH on growth, body composition, activity 
level and psychological development. At first, children were treated in a randomized 
GH controlled trial (RCT), lasting 1 year for infants and 2 years for prepubertal children. 
After the RCT, children were subsequently followed during continuous GH treatment in 
a cohort study (for study designs see Appendix 1). To date, infants from 6 months until 
3 years of age are still included in the Dutch PWS Cohort study and followed during GH 
treatment until adult height and beyond.
Several studies, including the Dutch national GH trial showed that GH treatment is an 
effective and safe treatment in children with PWS, both on the short and on the long 
term (72-88). GH treatment improves height gain, which results in a normal adult height, 
particularly when GH treatment is started before onset of puberty. GH treatment is also 
found to improve head-circumference, body mass index, respiratory function, physical 
performance, resting energy expenditure, bone mineral density and body composition 
by decreasing body fat percentage and increasing lean body mass (74, 78, 79, 81-84, 
89). Furthermore, GH treatment improves psychomotor development in the very young 
children with PWS and cognition after long-term GH treatment, and it has psychological 
and behavioral benefits (27, 44, 87). There were no adverse effects of GH treatment on 
glucose homeostasis, blood pressure and serum lipids (75, 90, 91).
At the end of 2002, GH treatment was registered and reimbursed for children with PWS 
and to date all children with PWS in the Netherlands are treated with GH. 
1.5 Psychiatric disorders
PWS is associated with a higher risk of psychiatric problems (28, 92). Individuals with 
an mUPD subtype are more prone to a psychosis than those with a DEL (28, 92-94). The 
prevalence of psychosis varies in earlier reports: one study found psychosis in 100% of 
adults with an mUPD (28), but more recent studies reported a prevalence between 13 
and 62% in adults with mUPD, while this was 13% in adults with a DEL (92, 95, 96). The age 
at onset of psychotic disorders varied between 13 and 19 years (92), but a Dutch report 
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described two 8 year old boys with an mUPD who suffered from a psychotic episode 
(97). The onset of psychotic symptoms are characterized by a sudden onset, agitation 
anxiety, abnormal thoughts or beliefs, and sometimes by auditory hallucinations (93). 
Affect disorders is the second major psychiatric disorder in PWS, sometimes combined 
with a psychosis. Although reports about psychiatric disorders in adults with PWS are 
increasing, knowledge about the presence and progression of psychiatric problems 
during childhood is still very limited.   
1.6 Behavioral phenotype
Children with PWS are described as friendly, easy going and affectionate during the 
first years of life (45). However, simultaneously with the change in eating pattern, the 
behavioral phenotype may also change in childhood showing significant maladaptive 
behavioral and emotional characteristics including temper tantrums, auto mutilation 
(skin picking), stubbornness, mood lability, impulsivity, argumentativeness, and inap-
propriate social behavior (98-105).
During childhood, ritualistic behavior (such as the need to tell, know or ask some-
thing, insistence on routines, hoarding and ordering objects and repetitive actions 
and speech), compulsive symptoms, autism spectrum disorder, and manipulative and 
controlling behavior are reported (9, 104, 106-110). The prevalence of some behaviors 
differs between patients with a DEL and mUPD. Maladaptive behavior and skin-picking 
are more common in those with a DEL than mUPD (111, 112), but the severity of compul-
sions is not different between the genetic subtypes (113, 114). In contrast, those with 
an mUPD seems to be more prone for autism spectrum disorder (114-116), but little 
is known about the earlier development of social cognition, i.e. the Theory of Mind in 
children with PWS. The critical periods for a deterioration of the behavioral and emo-
tional disturbances in children with intellectual disability are adolescence and young 
adulthood (117), but there were no specific data for children with PWS.  Furthermore, 
although GH treatment is a routine treatment in most developed countries, no studies 
had investigated the effect of long-term growth hormone treatment on behavior and 
adaptive functioning in children with PWS.
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1.7 This thesis
Recent studies described the increased prevalence of behavioral and psychiatric 
disorders in individuals with PWS, mainly in adults. Present study was conducted to 
investigate behavioral and psychiatric disorders in children and adolescents with PWS 
to improve our understanding of the mental development and its pathology during 
childhood and to investigate if early signs and symptoms of psychiatric disorders could 
prevent a further deterioration of the disorder.
The primary aims of the studies described in this thesis were to investigate:
- if, and if so, what symptoms within the psychiatric domain occur in children with 
PWS
- age at onset of psychiatric symptoms
- differences in psychiatric symptoms between children with a deletion and mUPD
- development of psychiatric symptoms over time
- predictors and stressors of psychiatric disorders
- cognitive functioning such as visual-motor integration over time
- effect of growth hormone treatment on behavior and adaptive functioning
- if precursors and metabolites of dopamine and serotonin system are predictors of 
psychiatric symptoms in children with PWS
For this study, children with genetically confirmed PWS, aged 7 to 17 years, who par-
ticipate in the Dutch PWS Cohort Study were asked for participation. We choose this 
age range as little is known about psychiatric disorders in childhood and adolescence, 
but also to warrant that particular questionnaires and tasks could be performed by the 
children themselves. Structured interviews were performed with children with PWS and 
their parents once every 2 years between 2011-2013 to assess psychiatric symptoms, 
behavioral disturbances, and visual-motor integration. An overview of the PD-study and 
its testing materials is depicted in more detail in Appendix 1. Two chapters in this thesis 
describe the long-term effects of growth hormone treatment on behavior and adap-
tive functioning. Participants of these 2 studies originated from the Dutch randomized 
controlled growth hormone trial. Appendix 2 describes the design for both the Dutch 
PWS Cohort Study and Dutch randomized controlled growth hormone trial. 
1.8 Aims of the studies and outline of the thesis 
This thesis presents a detailed description of the studies performed to improve the 
knowledge about PWS and the care for patients with PWS. The aims of the studies de-
scribed in this thesis were to evaluate various characteristic aspects in children with PWS 
during their development, such as social functioning, mental health and the presence of 
psychotic symptoms, behavior, adaptive functioning, and visual-motor integration. The 
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study population consisted of children with PWS, who participated in the Dutch PWS 
Cohort Study. Study designs are described in Appendix 1 and 2. 
Chapter 1 gives an introduction about PWS and the topics described in this thesis.
Chapter 2 describes the prevalence of behavioral problems and psychiatric disorders in 
children with PWS, at baseline and after 2 years of follow-up. 
Chapter 3 reports characteristics of Autism Spectrum Disorder in children with PWS, by 
outlining the level of social cognitive functioning, i.e. the Theory of Mind, and symptoms 
of Autism Spectrum Disorder.
Chapter 4 presents behavioral characteristics and the effect of long-term GH treatment 
in children with PWS studied in a 2-year randomized controlled trial and during 8 years 
of follow-up.
Chapter 5 describes the adaptive functioning and the effect of long-term GH treatment 
in children with PWS in a randomized controlled trial and during 7 years of follow-up. 
Chapter 6 reports the visual-motor integration in children with PWS, at baseline and 
after 2 years of follow-up. 
Chapter 7 presents depressive symptoms and its relation with dopamine and serotonin 
system in children with PWS.
Chapter 8 discusses the results and conclusions in the light of the current literature and 
presents clinical implications of the study results.
Chapter 9 contains an English and a Dutch summary of the results described in this 
thesis.
Chapter 10 contains lists of abbreviations and publications. It further contains the PhD 
portfolio, CV and acknowledgements.
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aPPendIx 1: PSyChIaTrIC dISorderS In ChILdren WITh PWS (Pd-STudy)
In November 2010, the study ‘Psychiatric disorders in children with PWS ‘ (PD-study)’ 
was started parallel to the Dutch PWS Cohort Study (Appendix 2). Children who partici-
pated in the Dutch PWS Cohort Study and their parents were invited for assessment of 
behavior and mental health at baseline and after 2 years. Children were examined at the 
Sophia Children’s Hospital Rotterdam, and in home setting by the author of this thesis. 
The PD-study was conducted in collaboration with Dr. P.J.L. Collin, child-psychiatrist 
(Koraalgroep, Gastenhof, Sittard/ de Hondsberg, Oisterwijk), Dr. D. Fekkes, biochemist 
(Erasmus Medical Center Rotterdam), Prof. dr. W.M.A. Verhoeven, psychiatrist (Vincent 
van Gogh Institute, Venray), and Prof. dr. J.I.M. Egger, neuropsychologist (Vincent van 
Gogh Institute, Venray). 
The following assessments were performed in the Sophia Children’s Hospital Rotterdam 
and in home setting:
– Diagnostic Interview Schedule for Children (DISC-IV) (118)
– Theory of Mind Test (ToM test) (119)
– Diagnostic Interview Social and Communication disorders (DISCO) (119)
– Compulsive Behaviour Checklist (CBC) (122)
– Visual-motor Integration Test (VMI) (121)
– Children’s Depression Inventory (CDI) (123)
Additionally, blood collected during the yearly control was examined to investigate 
possible predictors in the dopamine and serotonin system correlated, to psychiatric 
disorders in children with PWS.
Until 01-09-2014, 75 Dutch children were included in the PD-study. Children had to 
meet the following criteria:
Inclusion criteria:
– Genetically confirmed diagnosis of PWS;
– Age between 7 and 17 years;
Exclusion criteria:
– Non-cooperative behavior
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aPPendIx 2: duTCh naTIonaL PWS STudIeS
Project Coordination
Both the Dutch multicenter randomized controlled GH trial (Dutch GH RCT) and the 
multicenter follow-up study (the Dutch PWS Cohort study) are coordinated by the Dutch 
Growth Research Foundation, Rotterdam, the Netherlands. The PWS research team 
consists of three MD-researchers, a neuroscientist, a psychologist, and a research nurse. 
Three-monthly, 18 hospitals throughout The Netherlands are visited by one of the two 
MD-researchers and the research nurse, where children are examined, in collaboration 
with the local pediatrician or pediatric endocrinologist (Figure 2). Standardized measure-
ments take place at the Erasmus University Medical Center / Sophia Children’s Hospital 
Rotterdam, The Netherlands, at start, at 6 and 12 months and subsequently once a year.
duTCh Gh rCT
Infants
The Dutch GH RCT was performed from April 2002 to October 2009. The RCT infant 
group consisted of 61 children aged between 6 months and 3 years at start of study. 
Stratified for age, they were randomized into either a GH treated group or a control 
figure 2. Participating centers
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group for the duration of one year (Figure 3). The GH treated group received somatropin 
1 mg/m2 per day, whereas the control group was not treated with GH. From 12 months 
of study onwards, all children were treated with somatropin 1 mg/m2 per day and were 
prospectively followed in the Dutch PWS Cohort study in collaboration with pediatri-
cians or pediatric endocrinologists throughout The Netherlands. (Figure 2)
Prepubertal group
The RCT prepubertal group consisted of 47 children; girls aged between 3 and 12 years 
with Tanner breast stage < 2 and boys between 3 and 14 years with Tanner genital stage 
figure 3. Design of the multicenter randomized controlled GH trial and the Dutch PWS Cohort study
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< 2 and a testicular volume < 4 ml. Stratified for BMI, children were randomized into 
either a GH treated group or a control group for the duration of 2 years (Figure 2). The 
GH treated group received somatropin 1 mg/m2 per day , whereas the control group was 
not treated with GH. Dietary advice and exercise training were offered to both groups 
and started three months prior to study in order to minimize a priori between group dif-
ferences. From 24 months of study onwards, all children were treated with somatropin 1 
mg/m2 per day and were prospectively followed in the Dutch PWS Cohort study in col-
laboration with pediatricians or pediatric endocrinologists throughout the Netherlands.
The onGoInG duTCh PWS CohorT STudy
As GH treatment has been shown to improve body composition, bone mineral density, 
motor functioning, the Dutch GH RCT was stopped in October 2009. Since 2009, 46 
infants between 6 months and 3 years were directly included in the Dutch PWS Cohort 
study for follow-up during long-term GH treatment until final height. All children were 
treated with somatropin 1 mg/m2 per day and were prospectively followed in the Dutch 
PWS Cohort study in collaboration with pediatricians or pediatric endocrinologists 
throughout the Netherlands. To date, the Dutch PWS Cohort Study has shown the ben-
eficial effect of long-term GH treatment on body composition and cognition, and has 
resulted in new insight in testicular and ovarian functioning in children with PWS. 
Dutch PWS Cohort Study
Until 01-06-2014, 162 Dutch children with PWS were included in the RCT GH trial and 
the Cohort Study (Figure 3). For both studies, children had to meet the following criteria:
Inclusion criteria:
– Genetically confirmed diagnosis of PWS;
– Age between 6 months and 16 years;
– Maximal bone age of less than 14 years in girls, or 16 years in boys.
Exclusion criteria:
– Non-cooperative behavior;
–  Extremely low dietary intake of less than minimal required intake according to 
guidelines set by the World Health Organization;
– Medication to reduce weight (fat); 
–  In children above 3 years of age: height above 0 SDS, unless weight-for-height is 
above 2 SDS;
– Previous treatment with GH (not applicable for the Dutch PWS Cohort study)
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abSTraCT
Psychiatric disorders such as psychosis are highly prevalent in adults with Prader-Willi 
syndrome (PWS). However, knowledge about the presence and progression of psychiat-
ric disorders in children with PWS is very limited. 
Sixty-one children with PWS aged 7 to 17 years were tested using the Diagnostic Inter-
view Schedule for Children (DISC) and Compulsive Behaviour Checklist (CBC), and 38/61 
were retested after 2 years. Prevalence of psychiatric disorders and the association with 
age, gender, genetic subtype, and total IQ were assessed. In addition, occurrence and 
characteristics of compulsions were determined.
Prior to the study, two boys were known with psychotic symptoms and treated with 
antipsychotics. At baseline, none scored positive for psychotic disorder. During the 
follow-up, only one boy with known psychotic symptoms required a dose adjustment of 
his antipsychotic medication. After 2 years, none of the children had a psychotic disor-
der according to the DISC. Oppositional defiant disorder (ODD) was the most common 
diagnosis and present in 20% of children with PWS, and this was not associated with age 
(β= -0.081,p=0.546), gender (β= 0.013,p=0.923), genetic subtype (β=-0.073,p=0.584), or 
total IQ (β=-0.150,p=0.267). The most common compulsions were hoarding and fixed 
hygiene sequences. 
In our large group of 61 children with PWS, the majority had no psychotic disorder and 
no progression was found during 2-year follow-up. ODD was present in 20% of children. 
No changes in the prevalence of psychiatric disorders were found during the 2-year 
follow-up study and genetic subtype was not related to psychosis, depression, or ODD.
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InTroduCTIon
Prader-Willi syndrome (PWS) was first described in 1956 (1). The estimated birth inci-
dence rate is 1:15.000 (2, 3).  The genetic cause lies in the absence of expression of genes 
on the paternal chromosome 15q11-q13 (4). Deletion (DEL) occurs in approximately 70% 
of people with PWS, 25% is affected by maternal uniparental disomy (mUPD) and the 
rest is due to imprinting defects or translocation in the PWS region. PWS is characterized 
by hypotonia, short stature, hypogonadism, intellectual disability, behavioral problems 
and higher risk for psychosis. 
The prevalence of a psychiatric disorder in individuals with intellectual disability is 
higher than in healthy references. Almost 30% of adolescents and young adults with 
an intellectual disability meet the criteria for at least one DSM-IV diagnosis (5). Anxiety, 
mood disorder and disruptive disorder occur in 18%, 3% and 16%, resp. (5). PWS is also 
associated with a higher risk of psychiatric problems (6-8). Individuals with the mUPD 
subtype are more prone to a psychosis than those with a DEL (6, 7, 9). Different preva-
lences of psychosis has been reported: although one study found psychosis in 100% of 
adults with an mUPD (6), more recent studies reported prevalences between 13 and 
62% in adults with mUPD, while this was 13% in adults with a DEL (7, 10, 11). The age 
at onset of psychotic disorders varied between 13 and 19 years (7), but a Dutch report 
described two 8 year old boys with an mUPD who suffered from a psychotic episode 
(12). Knowledge about the presence and progression of psychiatric problems during 
childhood in PWS remains scarce, as most studies outlining psychiatric problems were 
performed in adults with a wide age range.  
Behavioral problems in PWS include hyperphagia, skin picking, temper tantrums, 
stubbornness, manipulative and controlling behavior, obsessive-compulsive features, 
and difficulties in changing routines (13-16). The prevalence of some behaviors differs 
between those with a DEL and mUPD. Maladaptive behavior and skin picking are more 
common in those with a DEL than mUPD (17, 18), but the severity of compulsions is not 
different between the genetic subtypes (19, 20). The critical periods for a deterioration 
of the behavioral and emotional disturbances in children with intellectual disability are 
adolescence and young adulthood (21), but there is no data specific for children with 
PWS. 
We hypothesized that psychiatric disorders such as psychosis and depression, op-
positional defiant disorder (ODD) and compulsions are present in children with PWS, 
and that their prevalence of psychiatric disorders increases with age. We expected that 
subjects with mUPD would be more prone to psychosis and those with DEL to depres-
sion and oppositional defiant disorder.
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MeThodS
For the present study, we invited parents of children aged 7 to 17 years who were 
enrolled in the Dutch PWS Cohort Study, to participate in this study. The Dutch PWS 
Cohort Study is a study investigating long-term effects of growth hormone treatment in 
children with PWS (22). Screening for psychiatric disorders was performed twice, i.e. at 
baseline and after 2 years. 
A total of 69 children with PWS were eligible for participation, 61 of whom agreed to 
participate in the first assessment, resulting in a response rate of 88%. In the second 
assessment, 44 children who also completed the first assessment were eligible for par-
ticipation and 38 children completed the second assessment, resulting in a response 
rate of 86% (17 children excluded due to a follow-up period less than 2 years). Parents 
of 6 children did not respond. None of the participants dropped out because of lack of 
internet to complete the tests, severe illness, or psychiatric disorders such as psychosis. 
The genetic diagnosis of PWS was confirmed in all participants by methylation test, the 
genetic subtype was known in all but 2 participants. All participants were treated with 
Genotropin 1 mg/m2/day. This study was approved by Medical Ethics Committee of the 
Erasmus Medical Center Rotterdam. Written informed consent was obtained from all 
parents or carers, informed consent was obtained from children of 12 years or older, and 
assent below the age of 12 years.
Screening for psychiatric  disorders
The Dutch translation of the Diagnostic Interview Schedule for Children (DISC) (23) is 
a structured diagnostic interview to investigate more than 30 psychiatric diagnoses 
using the DSM-IV (24) and ICD-10 (25) in children and adolescents. The DISC has been 
used as a screening instrument for psychiatric disorders to prevent extensive psychiatric 
evaluations (26). Major diagnostic modules of the DISC are anxiety, mood disorders, dis-
ruptive behavior disorders, substance use, schizophrenia, and miscellaneous disorders. 
Disruptive behavior disorders include ADHD, oppositional defiant disorder and conduct 
disorders. 
Most DISC questions are short and not very complicated. The DISC assesses the presence 
of diagnoses occurring within the past month, the past year, and between the age of 5 
years and the current year (‘whole-life’ module). Responses to DISC questions are mostly 
limited to ‘yes’ and ‘no’, although some have an additional ‘sometimes’/ ‘somewhat’ 
response option or a close-ended frequency choice. 
The paper-version of DISC is known to be an extensive interview by virtue of its length, 
branching and skipping instructions, and multiple time frames (current, past year, and 
lifetime questions). The internet-based DISC has the facility to skip modules or sections 
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automatically, depending on the answer given or the modules selected for the study. 
The use of the internet-based DISC minimizes therefore interviewer and editor error. 
In this study, we used the parental self-administered internet-based version of the DISC, 
which covers an age range of 6 to 17 years. The child version was too complicated for 
children with an intellectual disability. Parents completed the DISC in home setting 
at start and after approximately 2 years. An advantage of the internet version is the 
convenience to complete the questionnaire at the preferred moment. To limit the load 
for the parents, we restricted the questionnaire to the most relevant diagnoses and 
excluded the modules ‘substance use disorders’ and ‘miscellaneous disorders’ (diagnos-
ing anorexia nervosa/bulimia nervosa, elimination disorders, pica, trichotillomania). Five 
major disorders were assessed: anxiety, disruptive behavior, mood, schizophrenia and 
tic. As the module schizophrenia included the major criteria for other psychotic disor-
ders, namely delusions, hallucinations, and grossly disorganized or catatonic behavior, 
we studied the presence of these items to screen for other psychotic disorders. We did 
not calculate the scores of the ‘whole-life’ module because of the unreliable answers of 
parents to recall behavior of their child from the age of 5 years onwards, which could 
be more than 10 years ago for our oldest adolescents. During the study, children with 
suspected psychiatric problems were referred to a child-psychiatrist (PC).
Compulsions
People with intellectual disability have a different compulsive profile than healthy refer-
ences. For that reason, we used a test specifically designed for people with intellectual 
disability, the Compulsive Behavior Checklist (CBC) (27). The CBC was administered via a 
structured interview with parents. The CBC describes the 25 items of compulsions that 
are grouped according to 5 categories: ordering (arranging objects), completeness (clos-
ing doors), cleaning (washing hands), checking/touching (tapping floor), and grooming. 
We assessed the item ‘insists on activities/chores at a certain time’ twice, namely includ-
ing food-related and non-food related compulsions. In other words, if a child insisted 
on having dinner at 6 pm, this was scored as a positive answer in the food-related, but 
negative in the non-food related way. 
The CBC also aligns the extent of interference with daily life and the response to parents’ 
interruption of a compulsion. Each item and extent of the interference with daily life 
were scored as nominals (absent=0, present=1). The child’s response after interruption 
of a compulsion by parents was scored as ordinals (0=never, 1= rare, 2=occasional, 
3=often).   
Cognitive functioning
Cognitive testing was annually performed in prepubertal children and biennially in 
pubertal children using the Wechsler Intelligence Scale for Children-Revised (WISC-R) 
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by an experienced psychologist (28). The method of cognitive testing in our children 
with PWS has been described in detail (29). 
Data-analyses
Age and intelligence at baseline are presented as median and interquartile range (IQR). 
The prevalence of the most common diagnoses in children with PWS  is presented. 
Wilcoxon rank sum test was used to test the characteristics of the study group at start 
and after 2 years. McNemar’s test was used to test the difference between prevalence 
of diagnoses within the DISC at start and after 2 years. Multiple linear regression was 
performed to assess the association between age, gender (1=boys, 2=girls), genetic 
subtype (1=deletion, 2=mUPD), intelligence, and presence of a psychiatric disorder 
(0=absent, 1=present). Data of the Compulsive Behavior Checklist were listed and oc-
currence of compulsions were presented as percentages. McNemar’s test was used to 
test the difference in occurrence of compulsions, extent of interference in daily life, and 
child’s response after interruption of a compulsion by parents at start and after 2 years. 
Multiple linear regression tested the association between occurrence of ODD and extent 
of interference of compulsions in daily life and genetic subtype, after adjustment for 
age and gender.  Mann-Whitney U test was used to test the difference in skin-picking 
between genetic subtypes. Statistical analyses were performed with SPSS 20.0 (SPSS 
Inc., Chicago, IL). A p-value of <0.05 (two-tailed) was considered statistically significant.
reSuLTS
Baseline
Median (interquartile range (IQR)) age of the 61 children with PWS was 11.8 (8.8-14.3) 
years and 36 (59%) were male (Table 1). Twenty-five had DEL (41%), 33 mUPD (54%), 
one an imprinting defect, and in two children the genetic subtype was unknown. Me-
dian (IQR) total IQ was 62 (55-73). Family psychiatric history was absent in 40 children 
(66%), present in first-degree relatives in 7 (11%) children (i.e. 1 parent with psychosis, 
2 parents with depression, 2 sibs with ADHD and 2 sibs with autism spectrum disorder) 
and in second-degree relatives in 11 children (18%) (i.e. 4 with depression, 3 with autism 
spectrum disorder, 3 with ADHD, and one with borderline personality disorder).
Psychosis
Prior to the study, two boys with mUPD had psychotic symptoms at the age of 8 and 9 
years and had started with antipsychotics and antidepressants (PC). Psychotic or mood 
disorders were absent in the family of both children. Fifty-nine of 61 children (97%) were 
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never diagnosed with a psychotic disorder. Based on the DISC, none had schizophrenia 
or other psychotic symptoms, including adolescents older than 13 years.
Depression
One 10-year old boy with a DEL (2%) who did not use psychotropic medication scored 
positive for depression. Family psychiatric history of this boy was absent for mood 
disorders.
Other psychiatric disorders
Prior to the study, two other boys had started with antipsychotics (one also combined 
with antidepressants) because of increased irritability, anxiety and temper tantrums 
with aggressiveness without psychotic symptoms at the age of 9 and 11 years (PC). Due 
to severe rigidity in routines and repeated questioning, one 13-year old girl had started 
with a selective serotonin reuptake inhibitor.
Oppositional Defiant disorder (ODD)
According to the DISC, 14 (22%) children scored positive for disruptive behavior disor-
ders and 2 (3%) for anxiety and disruptive behavior disorder. Ten of 16 children (16% of 
total group) with a disruptive behavior scored positive for ODD, 1 (2% of total group) 
for ODD and ADHD, and 1 (2% of total group) for ODD and conduct disorders. ODD was 
the most common disorder and found in 20% of children with PWS. The presence of 
symptoms within ODD are presented in Figure 1 for children who fulfilled the criteria of 
Table 1. Characteristics of the study group
Baseline
N (male) 61 (36)
Age (years) 11.8 (8.8-14.3)
Genetic subtype (n (%))
        Deletion 25 (41) 
        UPD 33 (54) 
        ICD/Translocation 1 
        Unknown 2 
Total IQ  62 (55-73) 
Symptoms of children with psychotropic medication  
        Psychotic symptoms 2 
        Irritability, anxiety, temper tantrums 2 
        Severe rigidity    1 
Age and total IQ are expressed in median (IQR); genetic subtype and symptoms of children with 
psychotropic medication are expressed in N. 
40 Chapter 2
ODD. The presence of ODD was not associated with age (β= -0.081, p=0.546), gender (β= 
0.013, p=0.923), genetic subtype (β= -0.073, p=0.584) or total IQ (β= -0.150, p=0.267). 
Other diagnoses
Three (5%) children scored positive for anxiety disorder, 1 (2%) for anxiety and mood 
disorder, but 41 (67%) had no psychiatric diagnosis. Anxiety disorders consisted of 
specific phobias for needles and thunder, and separation anxiety. Two of 16 children (3% 
of total group) scored positive for attention deficit hyperactivity disorder (ADHD), and 2 
(3% of total group) for conduct disorders. The most common diagnoses are depicted in 
Table II. None of the children scored positive for panic disorders, agoraphobia, general-
ized anxiety disorder, social phobia, obsessive-compulsive disorder within the module 
anxiety, tic disorders, or mania/hypomania within the module mood disorders. 
Compulsions according to the Compulsive Behavior Checklist (CBC)
Compulsions are depicted in Table III. The most prominent compulsions were hiding, 
collecting or hoarding objects (37%), and insisting on doing hygienic steps in a fixed se-
quence and starting at beginning of sequence if interrupted (27%). Thirty-six percent of 
children met the item ‘insists activities/chores on a certain time’ including food-related 
activities, but 15% met this item without food-related activities. 
Skin picking occurred in 68% of the children and no significant difference in prevalence 
was found between children with DEL and mUPD. In 27% of children with PWS, compul-
symptoms
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figure 1. Symptoms within oppositional defiant disorder (ODD) for children with PWS who fulfilled the 
criteria of ODD.
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Table 3. Compulsions in children with PWS (n=61) 
Items Occurrence in %
Ordering compulsions
     Objects in a certain pattern
     Arranges certain items in one spot
     Wants chair in fixed arrangement
     Wants/arranges peers to sit in certain chairs
     Uses same chair or location when in particular room
     Insists on activities/chores at a certain time  
         food related 
         non-food related 
18
20
7
5
15
36
15
Completeness/Incompleteness compulsions
     Insists on closing doors, cupboards
     Removes all items from closet, purse etc.
     Repeatedly removes then replaces items
     Empties/wants containers emptied
     Puts garments on and off; hangs up and removes clothes 
     Insists on certain chore, resists letting others
12
2
3
7
0
15
Cleaning/Tidiness compulsions 
    Fixed hygiene sequence; restarts if interrupted 
    Cleans body part(s) excessively
    Insists on picking up bits; ‘lint picking’ 
    Often picks/rips objects if not prevented
    Insists certain (‘cleaning’) activity be done
    Hides away, collects/hoards particular objects
27
3
2
12
2
37
Checking/Touching compulsions
  Repeatedly opens and closes doors/drawers  
  Touches or taps items repeatedly
  Touching/stepping pattern
  Unusual sniffing
0
2
2
2
Deviant grooming compulsions
   Picks at face/body to point of gouging skin
   Checks hair, face/excessive mirror checking
   Inappropriately cuts/pulls/calmly pulls our hair 
68
2
7
Extent of interference with daily living
   Compulsions take more than an hour a day (if not prevented)
   Compulsions significantly interfere with the person’s normal routine
   Compulsions significantly interfere with usual social activities
   Compulsions significantly interfere with relationship with others 
 
27
20
15
12
The child’s response after interruption of a compulsion by parents Never Rare Occasional Often
   Halts momentarily, then resumes compulsive activity
   Waits until caregiver left the immediate area, then resumes
   Becomes angry, may hit or kick caregiver who intervene
   Becomes upset, may bite self, hit self, or headbang
25
30
50
83
5
5
20
3
8
8
20
12
62
57
10
2
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sions took more than an hour a day if not prevented, in 20% it interfered with the child’s 
normal routine, in 13% with usual social activities, and in 12% in relationships with 
others. Most common responses after parents’ interruption of a compulsion was halting 
momentarily, before resuming compulsive activity (63%), or waiting with resuming until 
the caregiver left the immediate area (57%). Seventy percent of children with PWS never 
or rarely became angry, and would not hit or kick the parent who intervened, and 83% 
neither became upset, nor bite themselves or head banged (Table III). No association 
was found between occurrence of ODD in the past year and extent of interference by 
compulsions in daily life, i.e. compulsions taking more than one hour per day (β= -0.083, 
p=0.615), compulsions interfering with normal routine (β= 0.120, p=0.507), compulsions 
interfering with social activities (β= -0.019, p=0.923), and compulsions interfering with 
relationships with others (β= 0.205, p=0.254), resp. The occurrence of compulsions were 
not different between the genetic subtypes. These results were adjusted for gender 
and age, as it is known that rituals and routines are part of the normal development in 
childhood. 
Follow-up after 2 years
In the second assessment after 2 years, 38 children participated and this group did not 
significantly differ from the initial group in gender, genetic subtype and total IQ (p=1.00, 
p=0.317, p=0.614, resp.). 
Psychosis
The two boys with known psychotic symptoms prior to the present study were still on 
antipsychotic medication. One of them had reappearing psychotic symptoms in the 
pre-psychotic phase and required a dose adjustment due to a higher bodyweight. None 
of the other children had signs of schizophrenia or other psychotic symptoms during 2 
years of follow-up. 
Depression
One 14-year old boy with a DEL who scored negative for depression at start, scored 
positive for depression after 2 years but did not use psychotropic medication.
Other psychiatric disorders
ODD
The prevalence of ODD did not significantly differ during the study (Table II). After 2 
years, 6 of 38 children (16%) scored positive for disruptive behavior disorders, and 4 
(11%) for anxiety disorders and disruptive behavior disorders. The ODD diagnosis of 
some children had changed after 2 years: 4 children remained positive, 4 children who 
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scored positive at start had a negative score, 4 children who scored negative at start had 
a positive score, and 26 children remained negative.
Other diagnoses
The prevalence of ADHD, conduct disorders, and anxiety did not significantly differ from 
start of the study (Table II). Three of 38 children (8%) scored positive for anxiety disor-
ders, 1 (3%) for mood disorders, but 22 (58%) did not have signs of psychiatric disorders. 
After 2 years, none of the children scored positive for panic disorders, agoraphobia, 
generalized anxiety disorder, social phobia, obsessive-compulsive disorder within the 
module anxiety, tic disorders, or mania/hypomania within the module mood disorders. 
Compulsions according to the CBC
Four boys (11%) who scored negative at start for compulsive disorders had a positive 
score after 2 years.  Three were known with a DEL and one had an mUPD. After 2 years, 
no significant difference was found in the frequency of the compulsions, extent of the 
interference in daily life, or response to parents’ interruption of a compulsion.
dISCuSSIon
In this study, we investigated the presence and progression of psychiatric disorders in 
a large group of 61 children with PWS aged 7 to 17 years in a 2-year longitudinal study. 
Schizophrenia or other psychotic disorders were rare in children with PWS: two of 61 
children (3%) had psychotic symptoms prior to the study and 59 of 61 children (97%) 
did not have psychotic symptoms. Concerning the other psychiatric disorder disorders, 
oppositional defiant disorder (ODD) was most common (20%), followed by ADHD (5%), 
conduct disorders (5%), specific phobia (5%) and separation anxiety (5%). The two most 
frequent compulsions were hiding objects or collecting/hoarding particular objects 
(37%), fixed hygiene sequence, and restarting if interrupted (27%). Although most chil-
dren resumed the compulsions after interruption or after the parents left the immediate 
area, most children were not aggressive towards the parents or themselves. The preva-
lence of psychiatric disorders did not increase by age. Psychosis was not associated with 
the mUPD subtype,  and depression and ODD were not associated with DEL.
Psychosis
In contrast to our expectations, we did not find schizophrenia or other psychotic symp-
toms in the majority of the 61 children with PWS. This is in contrast to earlier studies 
reporting a high prevalence of 13% to 62% for psychosis in adults with PWS caused by 
an mUPD (7, 10, 11). These findings could be explained by several factors.
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First, the aim of our study was to investigate the presence of psychiatric disorders in chil-
dren with PWS. Our study group is therefore young and it is likely that our participants 
were less vulnerable for psychosis and mood disorders. However, the age at onset of 
psychosis has been reported in the age range of 13 to 19 years (7), but none of our par-
ticipants above the age of 13 years had a psychosis except one boy with psychotic symp-
toms. Second, all children with PWS in our study were followed closely and referred to a 
child-psychiatrist (PC) when psychopathology was presumed. Early start of psychotropic 
medication and adjusted guidance by a multidisciplinary team may have prevented a 
psychosis. In our study, two children who were showing mood instability, increased ir-
ritability, and anxiety were treated with antipsychotics and remained stable during the 
2-year follow-up. This is in line with a previous study, which reported no psychotic epi-
sodes in adults with PWS after a psychosis or those who were at risk for psychosis due to 
the mUPD subtype (30). Antipsychotics such as Risperidone and Aripiprazole has been 
described to be effective in reducing irritability in children and adolescents with autism 
(31, 32). Because it turned out that the boy with relapsing psychotic symptoms in the 
pre-psychotic phase required a dose adjustment, we advise regular check calculations 
of psychotropic dosage in order to prevent relapse of psychotic symptoms, especially in 
case of weight gain. Third, the absence of schizophrenia or other psychotic symptoms in 
the majority of our children might be due to improved diagnostic tools and treatment 
in PWS, including the beneficial effect of long-term growth hormone treatment on the 
mental state. Our study group had been treated with growth hormone for many years 
prior to this study. It can not be excluded that long-term growth hormone played a role 
in the neurodevelopment, leading to a lower risk for psychotic symptoms. We previ-
ously demonstrated that growth hormone treatment improved cognition in children 
with PWS, particularly in those with lower cognitive functioning (33). Another research 
group showed that growth hormone enhances cell-to-cell communication in the central 
nervous system by increasing connexin-43 expression, which is a biomarker for gap-
junction formation in the brain (34). Also, the current generation of children with PWS 
seems to differ from the earlier generation, i.e. in body composition and development 
(22) due to the early detection and multidisciplinary care of physiotherapy, speech 
therapy, diets and family support. 
It is remarkable that the 2 boys with psychosis prior to this study were known with an 
mUPD.  The association between mUPD and psychosis has been described previously 
(6, 7). In our analysis this association was not significant, most likely due to the small 
numbers of children with psychosis. 
ODD
No studies have screened for ODD in PWS. We found an ODD prevalence of 20% in 
children with PWS, which was not associated with genetic subtype. It is well known 
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that people with mild to moderate intellectual disability have less compensational skills 
to cope with daily challenges of life compared to healthy peers, and that this leads to 
behavioral problems. One explanation might be that some symptoms of ODD, such as 
arguing with adults or easily losing temper, result from overestimation by the environ-
ment. The prevalence of ODD in children with PWS was in the same range as it has been 
reported that ODD occurs in 16% of individuals with intellectual disability and 3-4% of 
children without an intellectual disability (5). A child with ODD causes stress in a family 
(35, 36). It is therefore important to be aware of the high prevalence of ODD in children 
with PWS in order to prevent overestimation of the child’s capacity with regard to lan-
guage skills, emotional skills and social functioning. It also means that families require 
practical advices how to approach their child. Overestimation could be decreased by 
using adjusted learning programs at school, breaking down large tasks into clearly 
defined small steps, or allowing more time to rest. Communication with the child with 
PWS should be clear and concise by describing tasks simply, using short sentences, and 
avoiding abstract language (29). 
Compulsions
We found a high rate of hoarding/collecting objects and insisting on (hygienic) routines 
in children with PWS. This is in line with earlier studies showing the presence of compul-
sions in individuals with PWS (14, 37). In children with PWS aged 7 to 17 years, we did 
not find a difference in the extent of compulsions between the genetic subtypes, which 
is in line with a study in young children with PWS (37). 
We assessed the item ‘insists on activities/chores at the same time’ twice, namely for 
food-related and non-food related ‘compulsions’. It is doubted if food-related compul-
sions should be seen as compulsions, as it seems that hyperphagia is due to pathology in 
appetite regulating hormones (e.g. ghrelin or oxytocin disturbances). However, children 
with PWS show a compulsive aspect in hyperphagia such as being rigid about the time 
of eating and what is being eaten. Also, the smallest changes in the eating ritual could 
lead to mood fluctuations, temper tantrums, and aggressiveness. Thus, the item ‘insists 
on activities/chores at the same time’ for food-related is presented in this study to show 
the impact of food on this behavior.
We interviewed parents with the Compulsive Behavior Checklist (CBC) to assess the 
compulsive profile in their children. In the CBC, we also asked the parents to indicate 
how frequent the child continues with the compulsion after an interruption. Many par-
ents answered with ‘always’. However, ‘often’ was the highest score in the questionnaire. 
It is thus very likely that the results underestimated the child’s response to interruption 
of a compulsion. 
Although skin picking is considered not to be a compulsive disorder but rather behavior 
specific to PWS (38), this item was assessed to determine its prevalence. In our study, 
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skin picking was present in two-third of children with PWS and no significant difference 
in prevalence was found between children with DEL and mUPD. These findings are in 
contrast to reports describing more skin picking in children with a DEL than mUPD (17, 
39, 40). 
Our study results have implications for the treatment and guidance of children with 
PWS. However, our study is limited by the lack of a control group. In the Netherlands, as 
in most Western European countries, growth hormone treatment is nowadays standard 
treatment for children with PWS. This challenges the possibility to conduct a new RCT in 
children without GH treatment. However, countries where GH treatment has not been 
standardized yet, do have the possibility to investigate the prevalence of psychiatric 
disorders in children with PWS without growth hormone treatment. 
In our study, screening for psychiatric disorders have been performed twice during 2 
years. Although the tests were applied twice, all children were regularly examined in 
the Dutch PWS Cohort Study by the Dutch PWS team and pediatricians. During the 
consultations, behavior and mental health were always evaluated. It is therefore unlikely 
that major psychiatric disorders were missed. 
In conclusion, in our large group of 61 children with PWS, the majority of children had no 
schizophrenia or other psychotic symptoms and no progression of psychotic symptoms 
was found during 2-year follow-up. Oppositional defiant disorder (ODD) was the most 
common diagnosis and found in 20% of children with PWS. The most common com-
pulsions were hoarding and fixed hygiene sequence. No changes in the prevalence of 
psychiatric disorders were found during the 2-year follow-up study and genetic subtype 
was not related to psychosis, depression, or ODD. 
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abSTraCT
In order to evaluate the social cognitive functioning in children with Prader-Willi syn-
drome (PWS), Theory of Mind (ToM) and symptoms of Autism Spectrum Disorder were 
evaluated. Sixty-six children with PWS aged 7 to 17 years were tested using the Theory 
of Mind test-R and the Diagnostic Interview for Social Communication disorders. We 
tested the correlation between Total ToM Standard Deviation Score (Total ToM SDS) and 
genetic subtype of paternal deletion or maternal uniparental disomy, and total IQ, ver-
bal IQ and performal IQ. Prevalence and symptoms of Autism Spectrum Disorder were 
assessed. Median (interquartile range) of total ToM SDS of those aged 7 to 17 years was 
-3.84 (-5.73, -1.57). Their Total ToM SDS correlated with total IQ (β= 0.662, p< 0.001,adj. 
R2=0.407), in particular with verbal IQ (β= 0.502, p= 0.001, adj.R2=0.409), but not with 
performal IQ (β= 0.241, p>0.05, adj.R2=0.259). No difference in Total ToM SDS was found 
between children with deletion and maternal uniparental disomy (β=-0.143, p>0.05, adj.
R2= -0.016). Compared to the reference group of healthy children aged 7 to 12 years, 
children with PWS in the same age group had a median ToM developmental delay of 4 
(3-5) years. One third of children with PWS scored positive for Autism Spectrum Disorder. 
Most prominent aberrations in Autism Spectrum Disorder were focused on maladaptive 
behavior. Our findings demonstrate a markedly reduced level of social cognitive func-
tioning which has consequences for the approach of children with PWS, i.e. adjustment 
to the child’s level of social cognitive functioning. 
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InTroduCTIon 
Prader-Willi syndrome (PWS) is a neurogenetic developmental disorder caused by the 
absence of paternal expression of genes in chromosome 15 at the locus q11-q13, either 
by paternal deletion (DEL), maternal uniparental disomy (mUPD), imprinting defects or 
paternal chromosomal translocation (1). Its main characteristics are hypotonia, hypogo-
nadism, short stature, obesity, intellectual disability and a specific behavioral phenotype. 
Earlier studies described various behavioral characteristics, such as hyperphagia and 
food preoccupation, skin picking, compulsive behavior, and psychotic disorders (2-5). 
Differences in behavioral phenotype have been linked to the genetic subtype of individ-
uals with PWS. Those with mUPD seem more prone to Autistic Spectrum Disorder (ASD) 
than individuals with DEL (6-8). A recent study showed that impaired social functioning 
in subjects with mUPD was similar to that in subjects with Autism Spectrum Disorder (9). 
Children with ASD have an impaired Theory of Mind (ToM) development (10). The ToM 
describes the cognitive capacity to infer in the mental states of oneself (11) and others, 
and is an essential ability in social cognitive functioning and a core cognitive feature 
of ASD. The Theory of Mind has not been previously investigated in detail in children 
with PWS. One study tested three aspects of the ToM in a small group of young chil-
dren with PWS, who were participating as one of the comparison groups in their major 
study of ToM in children with Williams syndrome (12). They found that children with 
PWS performed better in false belief, an element of the ToM, than children with Williams 
syndrome. Another study found that the level of social adjustment, using the Social 
Attribution Task, in adults with PWS were more poorly than in those with comparable 
intellectual disability but similar to those with a pervasive developmental disorder (13). 
In order to evaluate the social cognitive functioning in children with Prader-Willi syn-
drome, the Theory of Mind and Autism Spectrum Disorder and their correlation were 
evaluated. 
We postulated that ToM development was delayed in most children with PWS, and 
expected that ToM scores would be less abnormal in children with DEL. We also hy-
pothesized that children with DEL are less prone to ASD than children with mUPD. For 
that reason, we assessed the prevalence and symptoms of Autism Spectrum Disorder in 
these children. 
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MeThodS
For the present study, we invited participants aged 7 to 17 years who participate in the 
Dutch PWS Cohort Study, a study regarding the long-term effects of growth hormone 
treatment in children with PWS (14). In the Dutch PWS Cohort Study, all participants 
were treated with Genotropin 1 mg/m2/day, cognitive functioning was measured bien-
nially, and anthropometry was performed annually. 
For the present study, a total of 76 children with PWS were eligible for participation, 66 
of whom agreed to participate, resulting in a response rate of 87%. 
The genetic diagnosis of PWS was confirmed in all participants by methylation testing. 
The genetic subtype was known in all but 2 participants.  
ToM
The Dutch ToM test-R (15) is a validated diagnostic instrument for healthy children 
between the age of 4 to 12 years old (10). It consists of 14 illustrated short stories which 
are divided into 3 developmental stages. Stage 1 covers recognition of emotions and 
the difference of reality and surreality (e.g. “actually” cycling and “dreaming” about 
cycling). Stage 2 covers the first manifestations of “belief”: “first-order belief” and “false 
belief”. “First-order belief” is the ability to understand one’s own mental state as “I think”. 
“False belief” is the individual’s comprehension of another person’s mistaken belief; 
for example if a character has not been informed that an object has been moved to 
another place. An example for testing the “false belief” is the following situation: person 
1 places an object in box 1 and leaves the scene. Person 2 transfers the object to box 2. 
When person 1 returns, the investigator asks the child where person 1 would look for the 
object. “False belief” is acquired if the child’s answer is box 1. If the child’s answer is box 
2, it suggests that the child is not able to make a judgment about another person’s false 
expectation. Stage 3 consists of questions about the “second-order belief”, i.e. inference 
of someone’s belief about another’s belief (e.g., “John thinks that Mary thinks it is going 
to rain and therefore she is taking the umbrella when she is going outdoors…”). 
The ToM- test-R includes 14 stories with a total of 33 questions and 3-pretence exercises. 
Scores are either 0 (failed) or 1 (passed), leading to a maximum of 36 points. A maximum 
of 12 points can be scored per stage. The ToM test-R has been validated for healthy 
children without intellectual disability in the age range of 4 to 12 years. 
In order to search for a screening instrument for ASD in children with PWS, the ToM 
test-R was chosen to evaluate social cognitive functioning.
The ToM test-R was performed at the children’s home or residence and the scores were 
verified by another researcher, which resulted in similar scores. 
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DISCO
The Dutch translation of the Diagnostic Interview Social and Communication disorders 
(DISCO), 11th revision, was used to diagnose ASD. DISCO (16) is a standardized semi-
structured, interviewer-based questionnaire for diagnosing ASD, and is based on the 
original validated DISCO of 2003 (17). It can accurately identify children with ASD, 
including children with intellectual disability (18). 
Only parents of children with PWS were interviewed for this study. DISCO was chosen 
because it diagnoses disorders within the broader “autism spectrum” (17). The diagnoses 
of the DISCO are based on DSM-IV-TR, the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition Text Revision (19). 
To reduce the duration of the test, questions used for the computer algorithms were 
asked during the interview. On average, the interview took 1.5 hours. It included the 
DISCO-sections on motor skills, communication skills and social-developmental skills, 
imagination, repetitive and stereotyped activities, maladaptive behavior, and inter-
viewer’s judgement of quality. 
The DISCO interview was performed in the hospital. Most of the items required an answer 
for past behavior (questions on “ever”) and present behavior (questions on “current”). 
As the diagnoses of ASD did not differ between the “current” and “ever” sections, we 
used only the “current” classification in the DISCO analysis. The assessment was scored 
manually by a trained observer (L.S.) using the algorithms of revised DISCO 11th revision. 
Cognitive functioning
To assess intelligence, we used a short form of the Wechsler Intelligence Scale for Chil-
dren-Revised, Dutch version (WISC-R). These subtests were vocabulary and similarities 
(verbal IQ subtests), block design and picture arrangement (performance IQ subtests). 
Children over 7 years of age were tested by an experienced psychologist with expertise 
in testing children with PWS (20). Good correlations have been found between the 
short-form IQ and the full-scale IQ for the WISC-R (21-23). 
The subtests’ scores were expressed as standard deviation scores (SDS), based on nor-
malized standard scores with a mean of 10, ranging from 1 (-3 SDS) to 19 (+3 SDS), on 
the basis of  Dutch population data for the same age (20). Total IQ score was calculated 
according to an equation based on the Dutch outpatient population reference (total IQ 
= 45.3 + 2.91 x vocabulary standard score + 2.50 x block design standard score), as has 
been used in other studies (24-26). Similarly, the vocabulary subtest was taken as the 
verbal IQ, the Block design as performance IQ.
This study was approved by Medical Ethics Committee of the Erasmus Medical Center 
Rotterdam. Written informed consent was obtained from all parents or carers, informed 
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consent was obtained from children of 12 years of age onwards, and assent below the 
age of 12 years.
Data Analysis
In the total study group aged 7 to 17 years, Total ToM scores in SDS (Total ToM SDS) 
are presented as median and interquartile range (IQR). The correlation of Total ToM SDS 
with genetic subtype of DEL or mUPD (coded as 1 = DEL, 2 = mUPD), and total IQ, verbal 
IQ and performance IQ was tested using multiple linear regression. Adjustments were 
made for age and gender. Spearman’s correlation was used to test the correlation be-
tween Total ToM SDS and IQ in children with PWS between 7-17 years. The difference in 
delay in ToM-age and Verbal IQ in children with PWS aged 7 to 12 years was tested with 
the Mann-Whitney U test. This age range was used because validated age-appropriate 
peer norms do only exist until the age of 12 years. The ToM developmental delay was 
calculated by subtracting ToM developmental age from the calendar age (ToM develop-
mental delay = Age – ToM developmental age).   
Children with PWS with a ToM score less than the mean for a four-year-old healthy child, 
were scored as a four-year-old child. The validated reference scores end at the age of 12. 
In the reference scores from the age of 10 onwards, an overall plateau for ToM score is 
shown indicating that ToM development in healthy children is completed at the age of 
10 years. Therefore, we presumed that ToM development is completed from 10 years of 
age onwards in healthy children. We calculated the Total ToM SDS for those aged 13 to 
17 using the reference score for healthy 12 years olds. The median (IQR) scores per stage 
of the ToM were calculated to evaluate which stages were impaired in children with PWS. 
With regard to DISCO analyses, we firstly analyzed the individual DISCO results to diag-
nose the presence or absence of ASD. Fisher’s exact test was used to test whether the 
diagnosis of ASD was different between genetic subtypes, and between the diagnosis of 
ASD and gender. Secondly, we assessed DISCO symptoms which occurred in more than 
fifty percent of the PWS group. To determine the relation between the most prominent 
symptoms and ToM SDS, and most prominent symptoms and genetic subtype, the 
Fisher’s exact test was used. For this analysis, correction for multiple testing was made 
and a p-value of 0.006 was considered as significant. Thirdly, we assessed symptoms in 
the ASD which occurred in less than ten percent (least frequent symptoms) of our study 
group. 
Mann-Whitney U test was used to test the association between BMI SDS and Total ToM 
SDS (group 0= Total ToM SDS >2, group 1= Total ToM SDS<2), and the association be-
tween BMI SDS and ASD diagnosis (group 0=negative ASD diagnosis, group 1 = positive 
ASD diagnosis).
The correlation of Total ToM SDS and ASD was tested using Fisher’s exact test.
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Statistical analyses were performed with SPSS 20·0 (SPSS Inc., Chicago, IL). 
All statistical tests were two-sided, and a p-value ≤ 0.05 was considered statistically 
significant. 
Results
Characteristics
We included a total of 66 children with confirmed PWS and a median (IQR) age of 11 
(9-14) years; twenty-five children with DEL (38%), 34 with mUPD (52%) and 5 with an 
imprinting defect (7%). Characteristics of the study group are presented in Table 1.
ToM 
Sixty-six children were tested with the ToM test-R. Six children were excluded from test-
ing due to severe attention deficiency and/or insufficient language development. These 
six children did not significantly differ from the rest of the group in terms of age, gender, 
genetic subtype, total IQ and body mass index SDS.
Median Total ToM SDS in the group aged 7 to 17 years was -3.84 (-5.73, -1.57). Their Total 
ToM SDS was correlated with total IQ (β= 0.662, p< 0.001, adj. R2= 0.407), in particular 
with verbal IQ (β=0.502, p= 0.001, adj. R2=0.409) but not with performance IQ (β= 0.241, 
p>0.05, adj. R2=0.259). Total IQ and verbal IQ remained significant after additional ad-
justment for gender and age. Total ToM SDS was not correlated with genetic subtype 
table 1. Characteristics of the study group
PWS 
N
Age (yr)
Gender
Male
Female
Height SDS
Weight for height SDS
BMI SDS
Total IQ
Age (years) at start GH treatment 
Duration (years) of GH treatment 
Genetic subtype
 Deletion
 UPD
 ICD
 Unknown 
66
11 (9, 14)
36 (55%)
30 (45%)
0.09 (-1.07, 1.05)
1.12 (0.14, 1.12)
1.44 (0.46, 2.44)
61 (54, 74)
4.66 (2.47, 6.72)
7.00 (5.00, 7.25)
25 (38%)
34 (52%)
5 (7%)
2 (3%)
Data are expressed as median (IQR); genetic subtype is expressed in N (%); BMI = Body Mass Index
60 Chapter 3
(β=-0.143, p>0.05, adj.R2 = -0.016). Total ToM SDS was significantly correlated with IQ in 
the total group aged 7-17, r= 0.592, p <0.001.
Figure 1a shows the distribution of Total ToM SDS per age. As an IQ score of 70 is the 
cut-off level for intellectual disability, we labeled total IQ score as total IQ > 70 or total 
IQ <70. In contrast to children with an IQ <70, children with an IQ > 70 tend to score a 
ToM score > -2 SDS. Figure 1b shows the distribution of Total ToM SDS per age, divided 
in those with an ASD diagnosis and those without.
In the subgroup of 39 children aged 7 to 12 years, the median (IQR) age was 9 (7-11) 
years. Their median ToM developmental age was 5 (4-6) years, resulting in a median 
delay of ToM development of 4 (3-5) years. The ToM developmental delay increased with 
age (p<0.001) and the verbal IQ decreased with age (p=0.05). The delay of ToM per age 
in children is depicted in Figure 2a, the Verbal IQ per age in Figure 2b. 
The ToM test indicates of 3 stages of development which can reach a maximum score of 12 
per stage. The median (IQR) score for stage 1 of the ToM test, the recognition of emotions 
and difference of reality and surreality, was 10 (9-11), for stage 2, the ‘first-order belief’ and 
‘false belief’ the score was 8 (6-10) and for stage 3, the ‘second-order belief’, it was 5 (2-8).
DISCO
Parents of 66 children were interviewed using the DISCO. Twenty-four out of 66 children 
(36%) scored positively for ASD, 7/25 (28%) having DEL and 14/34 (58%) having mUPD. 
The prevalence of ASD diagnosis did not differ between children with DEL and mUPD 
(Fisher’s exact, 2-tailed, p>0.05).
ASD diagnosis was neither associated with total IQ (Fisher’s exact, 2-tailed, p>0.05), and 
not different between boys and girls (Fisher’s exact, 2-tailed, p>0.05). 
The most prominent aberrations within ASD which occurred in at least fifty percent 
of children with PWS were maladaptive behavior and routines. Children tended to 
interrupt conversations, talk to strangers and skin pick. In addition, children tended to 
pretence play alone and were taking literal interpretation of expressions. Parents found 
their children with PWS clumsy and poor in motor coordination (Figure 3a).
Less than ten percent of the parents reported that their child had problems in making 
contact with others shown such as nodding their head, reacting to visitors, and cuddling 
with family. Repetitive activities as motor restlessness and fascination for light, sparkling 
object, sounds, spinning objects, parts of objects, abstract characteristics of objects as 
color or shape, and restriction of food were also only present in less than ten percent in 
our group (Figure 3b). 
None of the most prominent symptoms were related to Total ToM SDS and the preva-
lence of these symptoms did not significantly differ between the DEL and mUPD group.
ToM and ASD in PWS 61
3
figure 1a. Total ToM SDS in children with PWS, labeled by Total IQ
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figure 1b. Total ToM SDS in children with PWS, labeled by ASD diagnosis
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Total ToM SDS = Total Theory of Mind Standard Deviation Score, PWS= Prader-Willi Syndrome, TIQ = Total 
IQ, ASD= Autism Spectrum Disorder. Total IQ: x = Unknown, ○ = TIQ <70, ● = TIQ >70. ASD: ○ = negative, ● 
= positive. 
62 Chapter 3
figure 2a. Delay in ToM development  
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figure 2b. Verbal IQ in Standard Score (SS)
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Figure 2 depicts the boxplots at age 7-12; data of those aged 8, 10 and 12 are depicted in the background 
as these groups were small (n = 3, 3, and 4, resp). 
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figure 3a. Most prominent symptoms within ASD in children with PWS using the DISCO
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figure 3b. Least frequent symptoms within ASD in children with PWS using the DISCO  
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No association was found between BMI SDS and Total ToM SDS, and BMI SDS and ASD 
diagnosis, both p-values > 0.05.The presence of ASD in children with PWS did not differ 
significantly between those with a ToM SDS <-2 (impaired) and those with ToM SDS >-2 
(normal), p>0.05.
dISCuSSIon 
In order to evaluate social functioning in children with PWS, we tested the Theory of 
Mind (ToM), i.e. the ability to infer in the mental state of oneself and others. In addition, 
we tested for Autism Spectrum Disorder. Our results show that children with PWS have 
severely impaired ToM. ToM score was positively related with Total IQ, especially with 
verbal IQ. We found no difference in ToM score between children with DEL and those 
with mUPD. 
Additionally, 36% of children with PWS scored positively for Autism Spectrum Disorder 
(ASD) and there was no significant difference in prevalence of ASD between genetic sub-
types of DEL and mUPD in our group. Within ASD, symptoms of maladaptive behavior 
were most prominent in children with PWS.
ToM
No study has yet reported the ToM in children with PWS. ToM testing is useful to detect 
the child’s ability to empathize and therefore their ability in social cognitive functioning. 
To determine the impairment in ToM, we calculated the ToM developmental delay. In 
aged 7 to 12 years, median ToM developmental delay was 4 years and the delay was in-
creasing as the child aged. Because 6 of the 66 children did not accomplish the ToM test-
R due to attentive deficiency and language impairment, the median ToM developmental 
delay in children with PWS might be even larger. Based on these results, we advise family 
and carers to be aware of the younger ToM developmental age of the child with PWS.  
To evaluate the degree of impairment in ToM, we studied the 3 stages of the ToM test. 
The fairly high score of 10 out of 12 in stage 1 of the ToM test, recognition of emotions 
and difference in reality and surreality, suggests that these cognitive abilities are not 
major difficulties in these children.
The median score of 8 out of 12 for stage 2, a test of “first-order belief” and “false belief”, 
suggests that miscommunication could occur during interaction with children with PWS 
when “first-order belief” and “false belief” are used. It is therefore essential to name what 
one is thinking and not to use words figuratively. 
The poor score for stage 3, “second-order belief” shows that thoughts as “person 1 did 
that because person 1 thought that person 2 thought…” are impaired and poorly de-
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veloped in children with PWS. The ToM test is a validated test; however, the individual 
stages of the ToM have not been specifically validated. Although the individual stages 
of the ToM provides an insight in the development of each stage of the Theory of Mind, 
results of the individual stages should be interpreted with caution. 
We found that ToM score was positively related to total IQ, in particular to verbal IQ, 
which is in accordance with earlier reports on ToM testing in subjects with an intellectual 
disability (10, 27, 28). This raises the question if the impaired ToM score in this study 
group is affected by PWS specifically, or by the intellectual disability due to PWS. Future 
studies in children with various types of intellectual disability are needed to delineate 
whether the ToM developmental delay in children with PWS is related to the syndrome 
or to the intellectual disability. 
Our findings on ToM are essential in the approach of these children. Both children with 
DEL and mUPD are delayed in ToM development, which might result in overestimation 
of their empathetic abilities. This is in line with earlier findings (7), except that these 
investigators found the problem mainly in children with mUPD. Due to the relatively 
stronger verbal development of children with mUPD compared to those with DEL, 
children with mUPD are often overestimated in their ability to feel empathy for others. 
As major impairments were in the manifestations of the ToM, starting from ‘first belief’ 
and ‘false belief’, carers should adjust their communication and mention why and what 
they are thinking. For example, instead of saying “Clean up your toys” to the child with 
PWS, the caretaker should say: “Put your toys in the basket after five minute, because 
grandmother will visit us and I want the house to be tidy”. Communicating as in the last 
sentence will be much clearer for children with PWS because the caretaker’s thinking is 
said aloud which is much easier for the child to understand why it should clean up the 
toys. This insight into the social cognitive development of the child with PWS is impor-
tant to understand the child and to adjust ones attitude to the child’s needs to prevent 
frustration and bursts of emotional disturbance such as temper tantrums.   
Autism Spectrum Disorder
In our study, thirty-six percent of children with PWS fulfilled the criteria of ASD, more 
precisely 29% of children with DEL and 41% of those with mUPD. Although these per-
centages between the genetic subtypes seem to differ, this was not significant. These 
percentages correspond to the reported overall ASD rate of 36.5%; in which 29% of the 
individuals had DEL and 43.8% in individuals an mUPD (6, 29). These percentages were 
significantly different. One explanation could be the effect of growth hormone therapy 
in children with PWS. Most participants in earlier studies were adults, who had not been 
treated with growth hormone during childhood (6, 7). Nowadays, growth hormone 
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treatment is part of the routine care for Dutch children with PWS. It has been shown that 
growth hormone improves the lean body mass and physical strength in children with 
PWS (14, 30). Another study showed that growth hormone treatment prevents deterio-
ration of certain cognitive skills on the short term and improves cognitive functioning 
including abstract reasoning and visuospatial skills, especially in those with mUPD who 
had a greater deficit (26). Therefore, as growth hormone treatment improves cognitive 
functioning especially in children with mUPD, a smaller difference in prevalence of ASD 
between the genetic subtypes might be result.
Remarkably, none of the children between the age of 7 to 9 scored positively for ASD. 
Various factors might explain this finding. Firstly, the behavioral phenotype and the 
developmental delay of PWS becomes more clear as the child ages and the difference in 
cognitive ability increases between the child with PWS and their siblings or peers. Thus, 
symptoms in ASD might be easier to detect at an older age.
Secondly, before the age of 10, the behavioral phenotype and developmental delay 
might be more accepted by family and carers. During infancy and childhood, the child 
with PWS improves with major steps in their development: e.g. they manage to eat in-
dependently after a period of tube feeding; they become physically stronger and learn 
to walk or even to do sports (e.g. cycling on tricycle, doing judo) after severe neonatal 
hypotonia. It is therefore likely, that the medical disorder of PWS is “overshadowing” the 
autistic symtomatology (31). Family and carers are therefore accepting much more of 
the behavioral phenotype during childhood, because the child improves significantly in 
developmental skills within the first ten years. 
Our study group consists of children with PWS with a fairly normal BMI SDS. We show 
that BMI SDS is not related with the level of Theory of Mind and ASD rates.  As children 
with PWS who are treated with growth hormone are less obese and have a normal 
stature, their improved appearance will contribute to the risk of overestimation of their 
empathetic abilities by the environment.
No correlation was found between Total ToM SDS and most prominent symptoms, we 
conclude that the ToM test-R is not a valuable screening instrument for ASD in children 
with PWS, presumably due to the emphasis on maladaptive behavior in this group. 
Overall
Because the Theory of Mind considers the level of empathy, it evaluates the social cogni-
tive functioning, which is a dysfunction in ASD. Our results, however, show that children 
with PWS have a different behavioral phenotype compared to children with typical 
autism. The most prominent symptoms within ASD were symptoms in maladaptive be-
havior and routines. On the other hand, some of the major autistic characteristics such 
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as obsessions about light and sound were barely seen in children with PWS. Neither did 
they struggle to make contact with others, especially when the person was accompanied 
with a pet. However, they seem to have difficulty in sensing a stranger’s personal space 
and tend to invade it without noticing. We may therefore conclude that impairments in 
social cognitive functioning in children with PWS are related to impairments in social 
reciprocity (6, 7) and not in making contact. 
Ritualistic and compulsive behavior, another main feature of ASD, were described in 
earlier studies in individuals with PWS (32, 33), but we did not find these. It might be 
that the early signs of ASD in PWS rely on these symptoms of ritualistic and compulsive 
behavior, and that the sensitivity of the DISCO, which was used to test for ASD in this 
study, was insufficient to detect them. Future studies concerning screening for Autism 
Spectrum Disorder in PWS should therefore focus on rigidity in routine and structure, 
and compulsive behavior in children with PWS.
In our study group, 39% of children had a deletion and 52% had a mUPD. Earlier studies 
reported a DEL: mUPD ratio of 70:30 (34, 35). This higher frequency of mUPD type PWS is 
most likely related to a higher maternal age, in line with previous studies (36, 37). 
As PWS is a rare disorder, our sample size is relatively small, especially in the subgroup 
analyses. This might be considered as a limitation of the study. However, because our 
study group consisted of children and adolescents only, it is a relatively large group in 
terms of a pediatric PWS population. 
In conclusion, the ToM development is severely delayed in children with PWS, and those 
aged 7 to 12 years, an average ToM developmental delay of 4 years is found. Maladaptive 
behavior seems to be the most prominent behavior within Autism Spectrum Disorder 
in children with PWS. These findings highlight the need to adjust to their level of social 
cognitive functioning to prevent overestimation in children with PWS.   
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abSTraCT
Information on behavior of children with Prader-Willi syndrome (PWS) and the effect of 
growth hormone (GH) treatment is scarce. Parents report less problem behavior during 
GH treatment.
Forty-two pre-pubertal children, aged 3.5 to 14 years were studied in a randomized 
controlled GH trial (RCT) during 2 years, followed by a longitudinal study during 8 years 
of GH treatment. Behavior was measured annually by the Developmental Behavior 
Checklist (DBC) and a Dutch questionnaire to evaluate social behavioral problems, the 
Children’s Social Behavior Questionnaire (CSBQ).
Problem behavior measured by the DBC in children with PWS was similar compared 
to peers with comparable intellectual disability. Scores on ‘Social disabilities’ subscale 
were however significantly higher compared to the DBC total score (p<0.01). A lower 
IQ was associated with more self-absorbed behavior, more communication problems 
and more problem behavior in general. Problem behavior measured by the CSBQ was 
similar compared to peers with comparable intellectual disability, but children with 
PWS scored significantly higher on the ‘Not tuned’, ‘Understanding’, and ‘Stereotyped’ 
subscales than the CSBQ total score (p<0.05 for all subscales and p=0.001 for ‘Not tuned’ 
subscale). There were no significant effects of GH treatment during the RCT and 8 years 
of GH treatment.
Social problems were most pronounced within problem behavior in PWS. In contrast to 
our expectations and parents reports, our study shows no improvement but also no de-
terioration of behavioral problems in children with PWS during long-term GH treatment.
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InTroduCTIon
Prader-Willi syndrome (PWS) is a neurodevelopmental disorder resulting from the 
absence of expression of paternally expressed genes on chromosome 15 at the locus 
q11-q13, caused by paternal deletion, maternal uniparental disomy (mUPD), imprinting 
errors, or by chromosomal translocation (1). PWS is characterized by a number of signs 
and symptoms, including muscular hypotonia, hypogonadism, short stature, obesity, 
psychomotor delay, neurobehavioral abnormalities, and cognitive impairment (2).
During the first years of life, children with PWS are described as friendly, easy going and 
affectionate (3). However, in childhood simultaneously with the change in eating pat-
tern, children with PWS start to show significant maladaptive behavioral and emotional 
characteristics including temper tantrums, automutilation (skin picking), stubbornness, 
mood lability, impulsivity, argumentativeness, and inappropriate social behavior (4-11). 
Obsessive-compulsive symptoms and autism spectrum disorder are also known in 
children with PWS (10, 12-14). 
Long-term continuous growth hormone (GH) treatment is an effective and safe treat-
ment for children with PWS (15). GH treatment has beneficial effects on anthropomet-
rics, body composition, cognition, activity level and motor development, but little is 
known about the effect of GH treatment on behavioral problems. Two studies described 
the effect of GH treatment on behavior in PWS. One study included 12 children (age 
range 4.5 to 14.6 years) in a cross-over design who were randomized to either GH or 
placebo intervention for 6 months (16). The second study included 54 children (age 
range 4 to 16 years) who were randomized to GH treatment or untreated control group 
with a cross-over in the second year for the control group (17). Both studies could not 
find behavioral differences between GH treatment and control groups when they used 
structured questionnaires. This lack of effect could be due to either a lack of GH-effect, 
or because the study periods were too short to find a significant effect. 
In the present study, we investigated the effect of GH treatment on behavior in 42 chil-
dren with PWS during a 2-year randomized controlled GH trial (RCT) and during 8 years 
of continuous GH treatment. First, we used the Developmental Behavior Checklist for 
children with intellectual disability (DBC) to assess problem behavior in children with 
PWS compared to children with comparable intellectual disability. As we suspected 
that most problems would be within social skills, we also used a Dutch questionnaire to 
evaluate social behavioral problems compared to children with comparable intellectual 
disability, the Children’s Social Behavior Questionnaire (CSBQ).
Based on clinical experience and parental reports during GH treatment, we hypothesized 
a decrease in problem behavior in GH-treated compared to untreated children with PWS 
and a sustained effect during 8 years of continuous GH treatment.
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MeThodS
In April 2002, a multicenter, Randomized Controlled Trial (RCT) was started, investigat-
ing the effects of GH treatment versus no GH treatment on growth, body composi-
tion, activity level, and psychosocial development in children with PWS (Multicenter, 
randomized, controlled growth hormone study in children with Prader Willi Syndrome: 
effects on growth, body composition, activity level and psychosocial development. IS-
RCTN49726762/NTR628). After stratification for age and body mass index (BMI), children 
were randomly assigned to either the GH treatment group or no treatment-group for 2 
years. Details of the allocated group were given on cards contained in sequentially num-
bered, opaque, sealed envelopes, which were generated by an independent statistician. 
Twenty-four children were randomly assigned to the GH treatment group, 18 children 
to the untreated group.
Forty-two children were included in this study. All participants fulfilled the following 
inclusion criteria: (i) genetically confirmed diagnosis of PWS; (ii) age between 3 and 12 
years (girls) or 14 years (boys) at start of study; (iii) bone age < 14 years (girls) or 16 years 
(boys); (iv) prepubertal at start of study, defined as Tanner breast stage < 2 for girls and 
testicular volume < 4 ml for boys (10). After the RCT, all children were treated with GH 
and investigated in the Dutch PWS Cohort study.
The primary objective of our study was to investigate the effects of GH treatment on 
behavior. The secondary objective was to study factors associated with this behavior. Be-
havior was measured annually in the 42 pre-pubertal children with PWS during the RCT 
and during 8 years in the Cohort study. Two children dropped out of the Cohort study. 
One during the first year of GH treatment because of family problems, and the other 
during the third year of GH treatment, because of very high IGF-I levels, even with a low 
GH dose. The data of these children were included in our analysis until they dropped out.
Biosynthetic GH (Genotropin; Pfizer Inc., New York, NY), dose 1.0 mg/m2/day (~0.033 
mg/kg/day), was administered sc once daily at bedtime in children of the treatment 
group during the RCT and in all children during the Cohort study. All children were naïve 
to GH treatment at start of the RCT. The study protocols were approved by the Medical 
Ethics Committee of the Erasmus MC, Rotterdam, The Netherlands. Written informed 
consent was obtained from the parents and from children older than 12 years and assent 
in children younger than 12 years of age. This study was conformed with the Helsinki 
Declaration of 1975, as revised in 2000 and 2008 concerning Human and Animal Rights.
Behavior
Behavior was measured by two parent questionnaires, the Developmental Behavior 
Checklist for children with intellectual disability (DBC) (18) and a Dutch questionnaire to 
evaluate social behavioral problems in children with intellectual disability, the Children’s 
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Social Behavior Questionnaire (CSBQ) (18, 19). We choose these two questionnaires to 
compare in more detail behavior in children with PWS and children with intellectual dis-
ability (DBC), and to investigate problem behavior related to pervasive developmental 
disorders in children with PWS compared to children with intellectual disability (CSBQ). 
It has been shown that part of the behavioral characteristics are based on social behav-
ioral problems (14, 20-23). The questionnaires were completed by the main caregiver 
and were completed in the Sophia Children’s hospital in Rotterdam, the Netherlands, or 
in home setting. The questionnaires could not be completed for all children because of 
language or logistic problems.
DBC. This is a 96-items checklist for all levels of intellectual disability, completed by par-
ents or caregivers to assess emotional or behavioral problems over the last 6 months in 
children aged 4–18 years. It contains five subscales: Disruptive Antisocial, Self Absorbed, 
Communication disorder, Anxiety, and Social disabilities. A total problem behavior score 
was calculated by combining all subscale scores. Subscale scores were converted to SDS 
according to age and gender. We used reference data for Dutch children with intellectual 
disability (IQ between 59 and 70), as we considered the IQ of this reference population 
to resemble children with PWS. The questionnaire employs a 3-point rating scale (0=not 
true, 1=somewhat or sometimes true, 2=very true or often true) for each item. A higher 
score on the test, implies more problem behavior.
Items of the Anxiety subscale were included in the total problem behavior score, but 
these scores were left out when we analyzed the subscales individually. We considered 
the items in this subscale not representative for anxiety behavior in children with PWS 
because some items in this subscale were food related, for example ‘lack of appetite’ and 
‘being a picky eater’. 
CSBQ. The CSBQ is a 49-item parent questionnaire and aims to assess problem behavior 
in children with milder forms of pervasive developmental disorders. It has standardized 
norms for Dutch children aged 4-18 years without intellectual disability and with intel-
lectual disability (IQ between 51 and 70). The CSBQ covers a wide range of problems 
in different domains of development, mainly social problems. It specifies six problem 
dimensions: ‘not optimally tuned to the social situation (Not tuned)’, ‘reduced contact 
and social interest (Contact)’, ‘difficulties in understanding social information (Social Un-
derstanding)’, ‘orientation problems in time, place or activity (Orientation)’, ‘stereotyped 
behavior (Stereotyped)’ and ‘fear of and resistance to changes (Changes)’. A total social 
problem behavior score was calculated by combining all subscale scores. The ques-
tionnaire employs a 3-point rating scale (0=not true, 1=somewhat or sometimes true, 
2=very true or often true) on each item. A higher score implies more problem behavior. 
Subscale scores and the total score were converted into SDS according to Dutch refer-
ences with intellectual disability, and for the CSBQ also into SDS according to healthy 
Dutch references.
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To investigate the effect of long-term GH treatment on behavior, we assessed behavior 
during 8 years of GH treatment. Children who had been in the untreated control group 
of the RCT were on average 2 years older at start of GH treatment, than those who had 
been in the treatment group of the RCT. All children had at least 8 years of GH treatment: 
children who started in the control group had 8 years of GH treatment at the end of our 
study, but children who started in the treated group had 10 years of continuous GH 
treatment (2 years during the RCT followed by 8 years in the longitudinal study). 
Anthropometry and cognition
Secondary endpoint of this study was to assess which factors were associated with the 
behavioral characteristics. Height was assessed by a Harpenden stadiometer and weight 
by an accurate scale. BMI (kg/m2) was calculated. Height and BMI were converted into 
standard deviation scores (SDS), according to Dutch references for age (24, 25). Growth 
Analyser Version 3.0 software was used to calculate BMI, height, weight for height and 
BMI SDS (www.growthanalyser.org). IGF-1 levels were not included in this study due to 
changing assays and reference values over the last years. In the Netherlands, GH treat-
ment is standard treatment for all children with PWS until they reach final height. No GH 
stimulation test was therefore performed before the start of GH therapy. 
Cognition was measured by WPPSI-R or WISC-R, depending on age, and an intelligence 
quotient (IQ) was calculated as described earlier (26).
Data Analysis
Statistical analyses were performed with SPSS 20.0 (SPSS Inc. Chicago, IL). Age, BMI SDS, 
head circumferences, and IQ are presented as median and interquartile range (IQR). 
Friedman’s ANOVA was used to test for differences within the subscales of the DBC. Cor-
relations between scores on the behavioral subscales and the total scores at baseline 
and age, IQ, BMI SDS and head circumference SDS were calculated by Spearman’s corre-
lation coefficient or linear regression analysis. Gender and genotypic differences on the 
behavioral subscales and the total scores at baseline were calculated by Mann-Whitney 
U tests.  
To analyze the effect of GH treatment during the RCT and the longitudinal study, Linear 
Mixed Models for repeated measurements (27) was used with GH treatment and time as 
factors (GH treatment coded as: 1=GH treatment group; 0=control group; time coded 
as 0=baseline; 1= after 1 year and 2=after 2 years of study) in the RCT and time (time 
coded as: 0 = baseline, and 1=after 1 year, 2= after 2 years, …, 8= after 8 years of GH 
treatment) as factors in the longitudinal study. As the CSBQ has standardized norms for 
both children with and without intellectual disability, scores on all subscales and the 
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CSBQ total score were also standardized compared to these two reference groups in the 
longitudinal study. 
The effects of age, gender, genotype, anthropometric measurements, IQ on behavior 
during GH treatment were determined by using these variables as factors (in case of 
nominal or ordinal variables) or covariates (in case of scale variables) in the model.
reSuLTS
Baseline characteristics
At start of the RCT, the median (interquartile range, IQR) age of 42 children with PWS 
was 6.4 (4.9 to 7.6) years (Table 1). Children had a baseline BMI SDS between 0 and +2 
SDS and a head circumference between 0 and -2 SDS. Sixteen children (38 %) had a dele-
tion of chromosome 15q11-q13, 20 (48 %) an mUPD, and 3 an imprinting center defect. 
Three children had a positive methylation test, but the underlying genetic defect was 
unknown. There were no significant differences in age, BMI, head circumference, and IQ 
between the treatment (n=24) and untreated group (n=18). The baseline characteristics 
for the treatment and untreated group are presented in Table 1. 
Table 1. Baseline characteristics
Total group GH-treated Untreated controls p-value
N (male) 42 (19) 24 (12) 18 (7)
Age (years) 6.4 (4.9, 7.6) 6.0 (4.6, 7.5) 6.7 (4.9, 7.7) 0.438
Height SDS -2.6 (-3.3, -2.0) -2.4 (-3.1, -1.8) -2.5 (-3.1, -1.9) 0.899
Weight for height SDS 1.3 (0.4, 2.0) 0.8 (0.1, 1.8) 1.6 (0.9, 2.3) 0.071
BMI SDS 1.1 (0.4, 1.7) 0.8 (0.1, 1.6) 1.3 (0.9, 1.8) 0.084
Head circumference SDS -0.8 (-1.4, -0.4) -0.9 (-1.7, -0.3) -0.7 (-1.2, -0.2) 0.461
IQ 65 (59, 83) 62 (59, 75) 74 (62, 84) 0.323
Genetic subtype
 Deletion 16 (38%) 11 (46%) 5  (28%)
 mUPD 20 (48%) 8   (33%) 12 (67%)
 Imprinting 3 2 1
 Unknown 3 3 0
Age at start of GH treatment
(years)
7.0 (5.5, 8.9) 6.0 (4.6, 7.5) 8.7 (6.9, 10.2)
Age, BMI SDS, Head circumference SDS and IQ are expressed in median (IQR); genetic subtype is 
expressed in n(%), GH=growth hormone. The p-value is shown for analyses between the GH-treated 
group and untreated controls.
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Behavior at baseline
DBC standardized for children with intellectual disability
None of the subscale scores were significantly different from 0 SDS, indicating that 
problem behavior in children with PWS was not different from children with comparable 
intellectual disability.
We investigated if children with PWS had particular characteristics within their problem 
behavior which were more prominent than their overall problem behavior. Social Dis-
abilities SDS was significantly higher than the other subscales (Disruptive Antisocial 
behavior and Self absorbed behavior: p= 0.004, Communication disorders: p=0.046), 
indicating relatively more social problems compared to the other subscales of the DBC 
in children with PWS (Figure 1A).  
Children with a smaller head circumference had more problems in social abilities (β=-
0.356, p=0.003) and scored higher on total problem behavior (β=-0.244, p=0.048). We 
found significant associations between the IQ and the Self-absorbed subscale score (β=-
0.022, p=0.023) and the Communication disorder subscale score (β=-0.024, p=0.029), 
indicating that children with a lower IQ showed more self-absorbed behavior and had 
more communication problems. A lower IQ was associated with a higher DBC total score 
indicating more problem behavior (β=-0.024, p=0.020), also after correction for head 
circumference (β=-0.022, p=0.026). We did not find any association between DBC total 
score or its subscales and gender, genetic subtype, and BMI SDS. Behavioural problems 
were not correlated with age at start of GH treatment. The highest scores were found 
on the following items of the DBC: ‘keeps a strict order in certain items or activities’, 
‘easily crying’, ‘easily distracted’, ‘inactive’, ‘no sense of danger’, ‘likes doing things on his/
her own’. 
CSBQ standardized for children with intellectual disability
Children with PWS scored similar to children with intellectual disability in all subscales. 
We also investigated if children with PWS had particular characteristics within problem 
behavior related to pervasive developmental disorder which were more prominent than 
their overall problem behavior. Scores on the Not Tuned, Social Understanding and 
Stereotyped behavior were significantly higher than the CSBQ total score (p<0.05 for 
Understanding and Stereotyped subscales and p=0.001 for Not tuned subscale) (Figure 
1B). 
Children with a smaller head circumference had more difficulties in orientation (Ori-
entation: β=-0.352, p=0.037). Children with a lower IQ had more difficulties in social 
understanding (Understanding: β=-0.028, p=0.045), had more problems in stereotyped 
behavior (Stereotyped: β=-0.034, p=0.045) and scored higher on total problem behavior 
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figure 1. Behavior at baseline
fig. 1a Behavior at baseline measured by the DBC, standardized for children with intellectual disability
This figure shows the median SDS of the DBC subscales and the DBC total score SDS and their 
interquartile range (IQR) at baseline in children with PWS compared to a reference group with a 
comparable intellectual disability. 0 SDS is indicated by a dotted line.
fig. 1b Behavior at baseline measured by the CSBQ, standardized for children with intellectual disability
This figure shows the median SDS of the CSBQ subscales and the CSBQ total score SDS and their IQR at 
baseline in children with PWS compared to a reference group with a comparable intellectual disability. 0 
SDS is indicated by a dotted line.
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(β=-0.031, p=0.033). Older children had more problems in social understanding (Un-
derstanding: β=-0.203, p=0.004) and in stereotyped behavior (Stereotyped: β=0.247, 
p=0.004). Children with a deletion had more difficulties in social understanding (Un-
derstanding: β=-0.769, p=0.015 and after correction for IQ and age, β=-0.683, p=0.025), 
had more stereotyped behavior (Stereotyped: β=-0.937, p=0.015 and after correction 
for IQ and age, β=-0.832, p=0.025) and were more resistant to changes (Changes: β=-
0.856, p=0.025) than children with an mUPD. We did not find any association between 
the other subscales or CSBQ total score and gender or BMI SDS. Behavioural problems 
were not correlated with age at start of GH treatment. The highest scores were found on 
the following items of the CSBQ: ‘can/will only talk about one’s own interests’, ‘does not 
understand jokes’, ‘takes things literally’, ‘has trouble doing two things at the same time’, 
‘needs to be reminded what needs to be done’, ‘easily changing mood’, ‘gets angry eas-
ily’, ‘sees no danger’, ‘does not distinguish between known and unknown people’, ‘blows 
things up’, ‘keeps nagging/does not know when to stop’.
Randomized Controlled Trial
Effects of GH treatment versus no treatment on behavior
DBC standardized for children with intellectual disability
Figure 2A shows the mean estimated SDS of the DBC subscales, the DBC total score SDS 
and their 95% confidence intervals in GH-treated versus untreated controls with PWS. 
At baseline, there were no significant differences in subscale and the DBC total scores 
between the two groups. 
After 2 years, scores between the GH-treated and untreated children were not signifi-
cantly different. This indicates that GH treatment had no effect and that problem behav-
ior measured by the DBC remained similar to children with a comparable intellectual 
disability in both groups. We found no significant effects of gender or genetic subtype 
on the DBC total score over time.
CSBQ standardized for children with intellectual disability
Figure 2B shows the mean estimated SDS of the CSBQ subscales, the CSBQ total score 
SDS and their 95% confidence intervals in GH-treated versus untreated controls with 
PWS. At baseline, there were no significant differences in subscale and the CSBQ total 
scores between the two groups. 
After 2 years, scores between the GH-treated and untreated children were not signifi-
cantly different. This indicates that GH treatment had no effect and that social problem 
behavior measured by the CSBQ remained similar to children with intellectual disability 
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figure 2. Behavior during the RCT
fig. 2a DBC during RCT, standardized for children with intellectual disability
This figure shows the mean estimated SDS of the DBC subscales and the DBC total score and their 95% 
confidence intervals during the 2 year-RCT in 24 GH-treated children (in black) versus 18 randomized 
untreated controls (in gray) with PWS. The DBC is standardized for children with intellectual disability. No 
significant difference was found in all subscales between baseline and after 2 years.
fig. 2b CSBQ during RCT, standardized for children with intellectual disability
This figure shows the mean estimated SDS of the CSBQ and the CSBQ total score and their 95% 
confidence intervals during the 2 year-RCT in 24 GH-treated children (in black) versus 18 randomized 
untreated controls (in gray) with PWS. The CSBQ is standardized for children with intellectual 
disability. No significant difference was found in all subscales between baseline and after 2 years.
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in both groups. We found no significant effects of gender and genetic subtype on the 
subscales or the CSBQ total score over time. 
Long-term GH treatment
DBC standardized for children with intellectual disability
During 8 years of GH treatment, scores on all subscales and the DBC total score did not 
significantly change (Figure 3A). 
CSBQ standardized for children with intellectual disability
During 8 years of GH treatment, scores on all subscales and the CSBQ total score did not 
significantly change (Figure 3B). 
CSBQ standardized for healthy children
After 8 years of follow-up, the CSBQ total score was significantly higher than at baseline 
(estimated mean SDS (95% confidence interval) after 8 years versus at baseline: 1.686 
(0.856, 2.517) versus 0.708 (0.032, 1.385), p= 0.042). However, there was no difference 
between children who started with GH treatment or no treatment at baseline (p=0.139). 
After 8 years of follow-up, scores on the other subscales of the CSBQ were not significant 
different from baseline. The estimated mean SDS (95% confidence interval) per subscale 
after 8 years of follow-up and at baseline were as follow: Not tuned (1.280 (0.286, 2.273) 
versus 1.181 (0.650, 1.711), p=0.986),  Contact (1.331 (0.734, 2.126) versus 1.430 (0.426, 
2.235), p=0.617),  Orientation (2.131 (1.264, 2.998) versus 1.661 (1.050, 2.273), p=0.984), 
Social Understanding (2.587 (1.784, 3.390) versus 2.012 (1.352, 2.672), p=0.297),  Stereo-
typed (1.208 (-0.081, 2.497) versus 2.130 (1.416, 2.844), p=0.280),  Changes (1.646 (0.812, 
2.480) versus 0.737 (0.060, 1.414), p=0.051).
We previously reported the effects of 8 years GH treatment on somatic outcomes such 
as body composition (15).   
dISCuSSIon
Our study investigated the effect of GH treatment on behavior in children with PWS dur-
ing a 2-year randomized controlled trial and during 8 years of continuous GH treatment. 
In contrast to parental reports and our clinical experience, we did not find a reduction 
in problem behavior measured by the DBC and CSBQ in GH-treated children compared 
to untreated controls with PWS. Behavioral problems were stable and remained similar 
to baseline during 8 years of GH treatment. Children with PWS showed similar problem 
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behavior as a reference population with a comparable intellectual disability, also during 
GH treatment.
Against our expectations, we could not find an effect of GH treatment on behavior. 
Next to parental reports and our clinical experience with respect to improvements of 
behavior during GH treatment, our expectation to find a positive effect of GH treatment 
on behavior in children with PWS was also based on our recent finding that long-term 
GH treatment improves cognitive functioning in these children. In our earlier study, we 
showed that GH treatment prevents deterioration of certain cognitive skills in children 
with PWS on the short-term and significantly improves abstract reasoning and visuo-
spational skills during four years of GH treatment. Furthermore, children with a greater 
deficit had more benefit from GH treatment (26). Thus, it seems that behavior in children 
with PWS is not clearly influenced by GH treatment, in contrast to the cognitive func-
tioning. The earlier findings of a beneficial effect of GH treatment on cognition are in line 
with those in short children born small for gestational age (SGA). In short children born 
SGA, a significant improvement of cognition was found during long-term GH treatment, 
while attention deficits, especially accurateness and impulsiveness did not change dur-
ing GH treatment (28, 29). The authors concluded that attention deficits were related to 
being born SGA, and we might draw a similar conclusion for behavioral problems being 
related to PWS.
Another explanation why we could not find an effect of GH treatment on behavior might 
be the type of questionnaires we used in our study. Parents had to score behavior of 
their children with PWS on a 3-point scale (‘0=not true’, ‘1=sometimes or somewhat true’ 
or ‘2= often true or very true’) in both questionnaires. On this sort of scale it is only pos-
sible for parents to indicate if certain behavior occurs often, sometimes or never in their 
child. As PWS is associated with certain typical behavioral problems, for example temper 
tantrums, obsessive-compulsive and preservative behavior (2), all children display this 
behavior to a greater or lesser extent. These typical behavioral problems might get 
milder during GH treatment, but will probably never completely disappear. Thus, par-
ents will never score ‘0’ on these particular behavioral problems, thereby saying that this 
behavior never occurs in their child. It is therefore very likely, that also if the behavioral 
problems in their child decreased during GH treatment, parents scored in the same way 
as before start of treatment. On the other hand, most parents did notice subtle changes, 
which they reported during their visits to our hospital. These are in line with those of 
a 2-year GH-controlled study in children with PWS (17), in which parents reported im-
proved behavior during GH treatment in open interviews, while this was not the case in 
the untreated controls. Structured behavioral questionnaires with a 3-point scale after 6 
and 12 months, however, did also not show differences in behavior between GH treated 
and untreated patients. As reported by several studies, GH treatment has a beneficial 
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effect on muscle strength and tone (30, 31). Concerns have been raised if these improve-
ments could worsen characteristics of PWS, such as deterioration of temper tantrums or 
aggressiveness. One study showed that abrupt-ceasing of GH treatment for six months 
led to a successive deterioration in behavioral problems in children with PWS (32). In 
another 12-month, randomized double-blind, placebo-controlled, cross-over study in 
12 children with PWS, no improvement or deterioration in behavior was found either 
using the Behavior Assessment System for Children (BASC) and Child Behavior Checklist 
(CBCL), except of a significant increase on the hyperactivity scale on the BASC (16). Our 
study did not find an improvement in behavior, but it might be argued that we did also 
not find a deterioration during 8 years of GH treatment as normally seen over time, 
which strengthens the arguments for the use of GH treatment in children with PWS to 
improve body composition, motor abilities and cognition (15, 26, 30). To our knowledge, 
our study is the first study investigating the long-term effect of GH treatment in a large 
group of 42 children with PWS. As we did find a beneficial effect of GH treatment on 
cognition in our earlier study, in which intelligence was scored in a broad scale (26), it 
cannot be excluded that long-term GH treatment has an effect in preventing deteriora-
tion of problem behavior as the questionnaires used might not be sufficiently sensitive. 
Future research investigating the effect of long-term GH treatment on behavior should 
include more sensitive questionnaires and/or a control group. 
In our study, behavioral problems in children with PWS measured by the DBC were com-
parable to those of children with intellectual disability. However, scores on the socially 
related subscale of the DBC, ‘Social disabilities’, were higher than the other subscales. 
This indicates that there is relatively more socially-related problem behavior in children 
with PWS. This was confirmed by our results on the CSBQ, which is a checklist that is 
developed to assess social problem behavior in children in more detail, in particular 
pervasive developmental disorders (PDD). Children with PWS experienced particularly 
more problems in being tuned to the social situation, understanding social information 
and stereotyped behavior. Social impairment is typically found in patients with PWS and 
many of their social behaviors appear to be on the same continuum of social deficits 
found in autism spectrum disorder (e.g., social withdrawal, poor peer relationships, 
lack of empathy) (33). Poor peer relationships, lack of friends, immaturity, weakness in 
coping skills, and a preference for solitary activities are all reported in individuals with 
PWS (1, 6, 14, 34, 35). One other study assessing PDD in children and adults with PWS, 
compared patients with PWS to controls with intellectual disabilities (20). Patients with 
PWS showed elevated scores on a PDD-questionnaire in patients with PWS compared 
to the controls. 
Our finding of more problems in social behaviour has implications in the approach and 
guidance of children with PWS. Although the current (GH) treatment and multidisci-
plinary support has improved the bodycomposition and therefore the appearance of 
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this group children, we should be aware not to overestimate them in their social abilities. 
Children with PWS are less capable in dealing with daily challenges and overestimation 
could easily lead to stress and agitation causing misbehavior as temper tantrums or 
increased compulsive behavior. It is therefore important to determine the social skills 
of children with PWS, especially when overestimation by the environment is suspected.
Remarkably, we found more problems in social understanding, stereotyped behavior 
and resistance to changes in children with a deletion compared to children with an 
mUPD. Earlier studies reported an increased prevalence of autistic characteristics in 
children with mUPD (20, 23, 36). It might be that parents of children with an mUPD 
are more aware of the autistic features within PWS, which has led to a more structured 
approach in daily life. Parents of children with a deletion might not have expected these 
autistic features and therefore reported more problems within PDD. 
In our study group, 38% of children had a deletion and 48% an mUPD. Earlier studies 
reported a DEL: mUPD ratio of 70:30 (1, 37). The higher frequency of the mUPD type in 
our study group is most likely related to an increasing maternal age in the Netherlands, 
which in line with other countries in Western Europe (38, 39). 
Although problem behavior in children with PWS was not significantly different 
compared to children with similar intellectual disability over time, it was significantly 
increased compared to healthy references. This suggests that problem behavior dete-
riorates over time in children with intellectual disability and that this is not PWS-specific. 
Our study shows that problem behavior in children with PWS is in many aspects similar 
to children with a comparable intellectual disability. However, they display more prob-
lems in social understanding. Problem behavior remains stable in both GH-treated and 
untreated children with PWS. Thus, in contrast to our experience and parents reports, 
our study shows no improvement but also no deterioration of behavioral problems in 
children with PWS during long-term GH treatment. 
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abSTraCT
The aim of this study was to investigate the effect of growth hormone treatment on 
adaptive functioning in children with Prader-Willi syndrome. Vineland Adaptive Behavior 
Scale (VABS) was assessed during a randomized controlled trial (RCT) and after 7 years 
of growth hormone treatment. In the RCT, 75 children (42 infants and 33 prepubertal 
children) with Prader-Willi syndrome were included. Subsequently, 53 children were 
treated with long-term growth hormone. Our study demonstrates a marked delay in 
adaptive functioning in infants and children with Prader-Willi syndrome, which was as-
sociated with older age and lower intelligence. Results of the multiple linear regression 
show that the earlier growth hormone treatment was started during infancy, the better 
the adaptive skills were on the long-term.
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InTroduCTIon
Prader-Willi syndrome (PWS) is a neurogenetic developmental disorder caused by the 
absence of expression of genes on the paternally inherited chromosome 15 at the locus 
q11-q13, due to a paternal deletion (DEL), maternal uniparental disomy (mUPD), imprint-
ing defects or paternal chromosomal translocation. Main characteristics are hypotonia, 
hypogonadism, short stature, obesity, intellectual disability and behavioral problems. 
The average IQ in PWS varies between 50 and 80 (1, 2). Consequently, individuals with 
PWS have impairments in language, social and motor abilities (2-5). The ability to deal 
with daily activities required in the personal and sociocultural environment is defined as 
adaptive functioning and is an essential part of the behavioral phenotype (6). In addi-
tion, the adaptive functioning is related to age. It varies among genetic syndromes and 
is dependent on the level of intellectual disability (7). 
Only few studies investigated the adaptive functioning in persons with PWS. A previous 
study in PWS concluded that motor abilities are more impaired than communication, 
daily living skills and socialization when tested with the Vineland Adaptive Behavior 
Scale (VABS) in a mixed age-group (7). Another study showed that those with mUPD 
scored lower in daily living skills than those with DEL (8). However, this study group was 
not age-specific, because participants were aged 3 to 50 years, and it was not reported 
whether growth hormone (GH) treatment was used. Impairments in adaptive function-
ing have a great impact on the independence of an individual with PWS and the burden 
for the family. Insight in the adaptive functioning of children with PWS will therefore 
improve the understanding and guidance of this group, by families and professionals 
in medical care. 
In the last decade, children with PWS have been treated with growth hormone in many 
developed countries. In our previous studies, we found a beneficial effect of GH treat-
ment on motor skills (9, 10). Long-term GH treatment improves also cognitive function-
ing in children with PWS (11). One study found that a higher intelligence correlated 
with a higher level of adaptive functioning as measured with the Vineland Adaptive 
Behavioral Scale (VABS) in people with intellectual disability (12). However, no study 
investigated if the improved motor and cognitive skills during GH treatment also result 
in improvement in adaptive functioning in children with PWS. 
In this study, we hypothesized that GH treatment might have beneficial effects on the 
development of adaptive functioning in children with PWS. In addition, we expected 
that a younger age at start of GH treatment would result in better adaptive function-
ing. We therefore investigated the level of adaptive functioning without GH treatment, 
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the effect of GH treatment and variables associated with the development of adaptive 
functioning during long-term GH treatment.
MeThodS
Participants
We included 75 children with PWS, 42 infants and 33 prepubertal children. All partici-
pants had a genetically confirmed diagnosis of PWS and were naïve to GH treatment at 
start of the RCT. All infants were below the age of 3.5 years. Prepubertal children fulfilled 
the following inclusion criteria: 1) age between 3.5 and 12 years or 14 years in girls and 
boys, resp.; 2) Tanner breast stage of 2 or less for girls and testicular volume less than 4 
ml for boys (13). Characteristics about the participants are shown in the Results section.
Measures
Vineland Adaptive Behavior Scale (VABS)
The Dutch version of the VABS was used to determine the level of adaptive behavior in 
children with PWS (6). The VABS is a standardized structured interview with the primary 
caretaker to assess the adaptive behavior in four domains, which are communication (re-
ceptive, expressive, and written), daily living skills (personal, domestic, and community), 
socialization (interpersonal relationships, play and leisure time, and coping skills), and 
motor skills (gross and fine). VABS-items were rated on a 3-point rating scale (0=never, 
1=sometimes or partially, 2=usually or habitually). Items that were not permitted to chil-
dren with PWS, such as food preparation or bathing independently, were scored as 0 as 
these resulted in a similar practical consequence, namely that parents need to supervise 
and help in performing the task. The VABS has a high reliability and validity (14). The 
VABS expanded form provides a detailed analysis of the level of adaptive functioning 
and is suitable for use in case of intellectual disability (15). Tests were performed by a 
qualified medical investigator (STL).
Cognitive functioning
Cognitive testing was annually performed in prepubertal children and biennially in 
pubertal children. All cognitive measurements described in this study were performed 
by an experienced psychologist. The psychologist was blinded for the randomization. 
Cognitive functioning in children between the age of 0-3.5 years was assessed with the 
Bayley Scales of Infants II-NL (BSID II) (16) and results have been described (5). The scores 
were expressed in mental and motor developmental age (in months). The mental scale 
consists of items in relation to visual and auditory information processing, language 
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development, memory, eye-hand coordination, imitation and problem solving and the 
motor scale in gross and fine motor skills. 
Cognitive functioning in children between 3.5-7 years was tested with the Wechsler 
Preschool and Primary Scale of Intelligence – Revised Dutch version (WPPSI-R) short 
form (17), including  the four subtests of Vocabulary and Similarities (verbal IQ tests), 
and Block design and Picture completion (performal IQ tests). 
In children over 7 years of age, a Wechsler Intelligence Scale for Children-Revised (WISC-
R) was performed (18). The method of cognitive testing in prepubertal children with 
PWS has been described in detail (11). In short, total IQ score was calculated according 
to an equation based on the Dutch outpatient population reference (total IQ = 45.3 + 
2.91 x Vocabulary standard score + 2.50 x Block design standard score), as has been used 
in other studies (11, 19, 20). The vocabulary subtest was taken as the verbal IQ, the Block 
design as performal IQ. 
Procedures
Randomized Controlled Trial
In April 2002, a multicenter randomized controlled trial (RCT) was started in infants and 
prepubertal children with PWS (21). The trial investigated the effects of GH treatment 
versus no GH treatment on growth, body composition, activity level, and psychosocial 
development. After stratification for age and body mass index, infants and children 
were randomly assigned to either GH treatment (1 mg/m2/day) or no treatment. The 
RCT lasted one year for infants and two years for prepubertal children. Adaptive and 
cognitive functioning were measured annually during the RCT.
Follow-up during 7 years of continuous GH-treatment
After the RCT, all infants and children were treated with GH and followed in the Dutch 
PWS Cohort Study (10). Biosynthetic GH (Genotropin; Pfizer Inc., New York, NY; 1 mg/
m2/day) was administered sc once daily at bedtime in children of the treatment group 
during the RCT and in all children during the cohort study. 
To investigate the effect of long-term GH treatment on adaptive functioning, parents of 
children who had been treated with GH for 7 years and who were still on GH treatment 
were asked to participate in a VABS test in 2013. In 2013, 42 children of the former infant 
group were eligible for the reassessment of the VABS test but six children were excluded: 
one child had died, three children had dropped-out during the follow-up study, and 
two participants did not respond. In the former prepubertal group, 33 children were eli-
gible for the reassessment of the VABS test but sixteen children were excluded: ten had 
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stopped GH treatment due to attainment of adult height, and six children had stopped 
during the follow-up study for various reasons.  
The study was approved by Medical Ethics Committee of the Erasmus Medical Center 
Rotterdam. Written informed consent was obtained from all parents or caretakers and 
children of 12 years and older, and assent of children younger than 12 years.
Data analysis
Developmental age equivalent to the raw score of the VABS test was used as the age of 
adaptive functioning. The delay in developmental age in years was calculated by the 
formula: age - developmental age. Non-parametric testing was used, and median and 
interquartile range (IQR) are presented for age and developmental age. 
Mann-Whitney U test was used to test the difference in developmental age in all four 
domains of the VABS between the GH-group and untreated group during the RCT. To 
analyze the long-term effects of GH treatment, Linear Mixed Modeling was used with 
GH treatment and time as factors (GH treatment coded as: 1=GH treatment group, 0= 
untreated group; time coded as: 0= start of RCT, 1= one year after start of the RCT, 2= 
two years after start of the RCT, 3 = after 7 years of GH treatment). 
Multiple linear regression was performed at start of the RCT and after 7 years of GH 
treatment. At baseline, we studied the association between delay in adaptive function-
ing with the variables age, mental developmental age and motor developmental age 
in infants with PWS, after adjusting for gender (coded as: 1=boys, 2=girls) and genetic 
subtype (coded as: 1=deletion, 2=mUPD). Total IQ, verbal IQ and performal IQ were 
used as variables of intelligence in prepubertal children with PWS. To investigate the 
association between age at start of GH treatment and delay on adaptive functioning 
independently of the change in IQ over time, we adjusted for baseline IQ and IQ in 2013. 
Statistical analyses were performed with SPSS 20.0 (SPSS Inc., Chicago, IL). All statistical 
tests were two-sided. A p-value of <0.05 was considered statistically significant.
reSuLTS
Randomized Controlled Trial
Baseline characteristics
In the RCT, 75 children with PWS (42 infants and 33 prepubertal children) were included 
(Table 1). At start of the RCT, the median (IQR) age was 1.58 (1.15-2.81) years in infants 
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and 6.66 (5.13-7.49) years in prepubertal children. In the infant group, 20 (48%) had a 
deletion, 21 (50%) an mUPD, and in one (2%) the underlying genetic defect was not 
identified. In the prepubertal children, 15 (45%) had a deletion, 14 (42%) an mUPD, 2 
(6%) an imprinting center defect (ICD), and in 2 (6%) the underlying genetic defect was 
not identified. Median (IQR) mental developmental age of the infants was 1.2 (0.8-1.7) 
years and median motor developmental age 0.9 (0.7-1.3) year. In prepubertal children, 
the median (IQR) total IQ was 68 (61-85). 
Table 1 shows the developmental age and delay per domain for infants and prepubertal 
children. Figure 1 shows the correlation between age and developmental age for all 
participants at baseline. For communication, daily living skills and socialization the de-
velopmental age is normally similar to the age until the maximum of 19 years. In the PWS 
group, the maximal age was 14 years, so normally the developmental age should be 14 
years. However, none of the children with PWS scored higher than a developmental age 
of 8 years. This maximal developmental age is depicted in Figure 1 at 8 years, with the 
arrow representing the expected developmental age in healthy children. In contrast, the 
developmental age in motor skills normally increases until the age of 6 years and should 
remain similar after the age of 6 years (represented by the arrow). As shown in Figure 
1, most children with PWS did not reach the age-appropriate developmental age, espe-
Table 1. Baseline characteristics and adaptive functioning
Infants Prepubertal children
N (male) 42 (23) 33 (15)
Age (years) 1.58 (1.15-2.81) 6.66 (5.13-7.49)
Genetic subtype
 Deletion
 UPD
 ICD/Translocation
 Unknown
Cognitive functioning
 Developmental mental age (years)
 Developmental motor age (years)
 Total IQ
Adaptive functioning (years)
Communication 
 delay
Daily living skills 
 delay
Socialization
 delay
Motor skills
 delay
20
21
0
1
1.2 (0.8-1.7)
0.9 (0.7-1.3)
1.25 (0.85-1.56)
0.53 (0.22-0.81)
1.21 (0.77-1.79)
0.50 (0.25-0.78)
1.00 (0.75-1.42)
0.71 (0.48-1.26)
0.87 (0.60-1.56)
0.72 (0.53-1.08)
15
14
2
2
68 (61-85)
3.42 (2.67-4.34)
2.61 (1.92-4.00)
3.75 (2.96-4.75)
2.57 (1.76-3.74)
3.08 (2.21-4.04)
3.09 (2.52-4.58)
3.00 (2.54-4.50)
3.17 (2.16-4.57)
Data are expressed as median (IQR); genetic subtype is expressed in N.
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cially after infancy. With increasing age, the gap between the developmental age and 
age-appropriate developmental age increased and a wide variation of developmental 
age was found, especially in the domain communication and socialization. 
In infants, older age was associated with more delay in all domains of adaptive function-
ing (communication: p= <0.001, daily living skills: p= <0.001, socialization: p= <0.001, 
motor skills: p= <0.001, resp.) (Table 2a). A lower mental developmental age (years) was 
associated with more delay in adaptive functioning (communication: p= <0.001, daily 
living skills: p= <0.005, socialization: p= <0.05, resp.), except in motor skills (p= 0.392). 
A lower motor developmental age (years) was also associated with more delay in com-
munication (p= <0.05) and motor skills (p= <0.001). 
In prepubertal children, older age was associated with more delay in adaptive function-
ing (communication: p= <0.001, daily living skills: p= 0.001, socialization: p= <0.001, 
motor skills: p= <0.001, resp.) (Table 2b). A lower total IQ was associated with more 
delay in adaptive functioning (communication: p= 0.001, daily living skills: p= 0.001, 
socialization: p= 0.001, motor skills: p= <0.001, resp.), especially a lower verbal IQ (com-
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figure 1. The relation between age and developmental age per domain of the VABS test at baseline.
Dev age= developmental age. The line of identity (45o) represents  the maximal developmental age in 
normal development and is similar to age, except in motor skills in which the maximal developmental age 
is 6 years. 
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Table 2. Delay in adaptive functioning at baseline. 
A. Infants (n=42)
delay in communication delay in daily living skills 
Model a Model b Model C Model a Model b Model C
ß P ß P ß P ß P ß P ß P
Age 0.771 <0.001 1.292 <0.001 1.739 <0.001 0.831 <0.001 1.092 <0.001 1.452 <0.001
Mental dev age -0.653 <0.001 -0.674 <0.001 -0.328 0.033 -0.463 0.004
Motor dev age -0.458 0.011 -0.255 0.166
Overall P-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adj. R2   0.579 0.726 0.854 0.687 0.718 0.811
delay in socialization delay in motor skills
Model a Model b Model C Model a Model b Model C
ß P ß P ß P ß P ß P ß P
Age 0.883 <0.001 1.178 <0.001 1.495 <0.001 0.803 <0.001 1.090 <0.001 1.802 <0.001
Mental dev age -0.433 0.004 -0.387 0.023 -0.360 0.032 -0.100 0.392
Motor dev age -0.388 0.052 -1.048 <0.001
Overall P-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adj. R2   0.684 0.744 0.785 0.626 0.664 0.891
Dev age = developmental age. Age, dev ages, and delay in years. Adjusted for gender and genetic subtype. 
B. Prepubertal children (n=33)
delay in communication delay in daily living skills 
Model a Model b Model C Model a Model b Model C
ß P ß P ß P ß P ß P ß P
Age 0.917 <0.001 0.644 <0.001 0.645 <0.001 0.903 <0.001 0.564 0.001 0.562 0.001
Total IQ -0.455 0.001 -0.494 0.001
Verbal IQ -0.295 0.027 -0.374 0.010
Performal IQ -0.237 0.076 -0.207 0.190
Overall P-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adj. R2   0.738 0.760 0.747 0.703 0.690 0.676
delay in socialization delay in motor skills 
Model a Model b Model C Model a Model b Model C
ß P ß P ß P ß P ß P ß P
Age 0.922 <0.001 0.656 <0.001 0.654 <0.001 0.930 <0.001 0.623 <0.001 0.617 <0.001
Total IQ -0.437 0.001 -0.464 <0.001
Verbal IQ -0.344 0.010 -0.443 <0.001
Performal IQ -0.168 0.190 -0.085 0.407
Overall P-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Adj. R2   0.758 0.766 0.756 0.790 0.828 0.841
Dev age = developmental age. Age, dev ages, and delay in years. Adjusted for gender and genetic subtype. 
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munication: p= <0.05, daily living skills: p= <0.05, socialization: p= 0.01, motor skills: p= 
<0.001, resp.). 
Neither gender, nor genetic subtype were associated with delay in adaptive functioning 
in infants and prepubertal children. 
Short-term GH treatment
GH treatment for 1 or 2 years, in infants and prepubertal children respectively, had no ef-
fect on delay in adaptive functioning versus no treatment (in communication (p= 0.645, 
p= 0.262, resp.), daily living skills (p= 0.295, p= 0.366, resp.), socialization (p= 0.605, p= 
0.219, resp.) and motor skills   (p= 0.727, p= 0.311, resp.). 
Long-term continuous GH treatment
Former infant group
Thirty-six children of the former infant group were investigated by the VABS test after 
at least 7 years of GH treatment. Median (IQR) age of the former infant group was 10.18 
(8.59-12.96) years. The developmental age in communication was 4.88 (3.99-6.35) years, 
in daily living skills 5.09 (3.88-5.79) years, in socialization 3.58 (2.58-4.17) years, and in 
motor skills 3.58 (3.08-4.02) years. Median (IQR) duration of GH treatment had been 
7.79 (6.24-9.86) years. After 7 years of GH treatment, the delay in the former GH-treated 
infant group of the RCT was significantly less than in the former untreated group for all 
four domains, i.e. for communication (p<0.001), daily living skills (p<0.001), socialization 
(p<0.001) and motor skills (p<0.001), indicating that long-term GH treatment improves 
adaptive functioning if GH treatment is started in infancy. The multiple linear regres-
sion showed that an earlier age at start of GH during infancy was associated with less 
developmental delay in communication (β= 0.533, p= 0.018), daily living skills (β= 0.440, 
p= 0.041), socialization (β= 0.503, p= 0.048) and motor skills (β= 0.706, p= 0.003) (Table 
3), after adjustment for change in IQ in time. In other words, an earlier age at start of GH 
treatment in infancy was associated with improved adaptive functioning. 
Former prepubertal group
In seventeen children of the former prepubertal children group, VABS test was per-
formed after long-term GH treatment. Median (IQR) age of participants of the former 
prepubertal group was 15.87 (15.14-16.34) years. They had a developmental age in com-
munication of 4.92 (3.66-7.66) years, daily living skills 6.66 (5.58-8.13) years, socialization 
4.75 (3.38-5.83) years, and motor skills 3.92 (3.34-4.50) years. Median (IQR) duration of 
GH treatment had been 8.75 (8.56-10.73) years.
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No effect of long-term GH treatment was found in delay of adaptive functioning be-
tween the former GH-treated and the untreated group of the RCT, except for daily living 
skills (p= 0.012). 
No association was found between delay in adaptive functioning and age at start of 
GH treatment, after adjustment for difference in IQ in time (total IQ at start and total 
IQ in 2013). The results between delay in adaptive functioning and age at onset of GH 
treatment were as follow: in communication: β=0.114, p=0.642, daily living skills: β= 
-0.257, p=0.528, socialization: β= -0.249, p=0.511, and motor skills: β= -0.456, p=0.238.
Table 3. Delay in adaptive functioning after 7 years of GH treatment in children with PWS.
A. Children who started GH treatment in infancy (n=36)
 
delay in 
communication 
delay in daily living 
skills delay in socialization delay in motor skills
Model Model Model Model
ß P ß P ß P ß P
Mental dev age at start -0.209 0.324 -0.186 0.368 -0.267 0.276 -0.065 0.765
Motor dev age at start 0.156 0.470 0.436 0.045 0.438 0.085 -0.212 0.343
Total IQ in 2013 -0.591 <0.001 -0.471 <0.001 -0.333 0.022 -0.520 <0.001
Age at start of GH 0.533 0.018 0.440 0.041 0.503 0.048 0.706 0.003
Overall P-value <0.001 <0.001 <0.001 <0.001
Adj. R2 0.677 0.675 0.547 0.635
Dev age = developmental age. Age, dev ages and delay in years.  
B. Children who started GH treatment in childhood (n=17)
 
delay in 
communication 
delay in daily living 
skills delay in socialization delay in motor skills
Model Model Model Model
ß P ß P ß P ß P
Total IQ at start -0.622 0.019 -0.353 0.341 -0.521 0.146 -0.063 0.849
Total IQ in 2013 -0.421 0.131 0.190 0.658 0.353 0.384 0.651 0.123
Age at start of GH 0.114 0.642 -0.257 0.528 -0.249 0.511 -0.456 0.238
Overall P-value 0.020 0.706 0.447 0.409
Adj. R2 0.571 -0.166 -0.004 0.022
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dISCuSSIon 
In order to improve the daily care for children and adolescents with PWS, it is important 
to know the level of adaptive functioning of these children, and which variables can 
influence this functioning. Our results demonstrate a marked delay in adaptive func-
tioning in children with PWS, which increased with age and was inversely associated 
with IQ. Gender and genetic subtype had no significant effect on the delay in adaptive 
functioning. No effect of short-term GH treatment was found on adaptive functioning. 
However, children with long-term GH treatment who started GH treatment at a younger 
age during infancy had a significantly better adaptive functioning.
Results in relation to previous research 
The marked delay in adaptive functioning shows the need to adapt the approach of 
children with PWS. Children aged 14 years had a developmental age of around 6 years in 
communication and socialization, indicating that the adaptive functioning of prepuber-
tal children with PWS is less than half of healthy children. Social functioning in children 
with PWS has been described in earlier studies, and was also found to be significantly 
impaired compared to healthy peers (2, 22, 23). Additionally, social disabilities in PWS 
are more impaired than in other children with intellectual disability, indicating that the 
impaired social functioning is specific for PWS (24, 25). 
For daily living skills, the highest acquired level was nearly 8 years, which is also very 
much delayed. For motor skills, the maximal score for developmental age is normally 
reached at the age of 6 years. Because some children scored a developmental age be-
tween 5 and 6 years at an older age, we presume that some children with PWS are able 
to reach a nearly maximal developmental age in motor skills, but at a later age. 
Some children were able to perform some adaptive skills themselves such as personal 
care or helping in the house. However, this does not necessarily relieve the parental care. 
The majority of parents still need to supervise the children to make sure that they do 
their task in the right way and within a certain time limit, e.g. before the school bus ar-
rives. Additionally, due to the PWS-specific characteristics (26) as hypotonia and repeti-
tive behaviour, adaptive tasks might not be completed within the time limits in daily life 
which also requires special attention of parents. Studies about parental stress are very 
limited. One study described that parents of children with PWS are mostly stressed in 
case of behavioural problems (24) and had more somatization, phobic anxiety, obsessive 
compulsion, and anxiety problems than parents of healthy children who were matched 
in age, gender and IQ (22). Therefore, support for parents should incorporate knowledge 
about the delay of adaptive functioning in children with PWS and the consequences in 
daily life. 
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In the present study, short-term GH treatment had no effect on adaptive functioning 
in children with PWS. After long-term GH treatment, however, at a younger age during 
infancy starting GH treatment improved adaptive functioning. 
Such results were not found in prepubertal children, who started GH treatment after 
infancy. The lack of power in the prepubertal group might explain this result, as men-
tioned under the section Limitations. Alternatively, it might be that GH has a limited 
effect on adaptive functioning when it is started after infancy. These children might 
have gained such a large delay in adaptive functioning, that subsequent GH treatment 
did not affect adaptive functioning. 
A lower intelligence was correlated with more developmental delay in adaptive func-
tioning; regarding communication, daily living skills and socialization. Also, after 7 years 
of GH treatment a higher IQ was associated with less delay in adaptive functioning. 
Such an association was not found for baseline IQ, suggesting that adaptive function-
ing during long-term GH treatment is associated with current IQ and not with baseline 
IQ. Also, the largest effect of GH treatment on adaptive functioning was reached if GH 
treatment was started at a younger age during infancy. Thus, our data may indicate that 
GH treatment does not only improve bodycomposition (10) and intelligence (11), but 
also adaptive functioning after long-term treatment, particularly if it is started during 
infancy. 
In the present study we only focused on children with PWS who were treated with long-
term GH. As GH therapy is currently the standard treatment in most developed countries, 
children and young adults nowadays show major differences due to a combination of 
GH treatment (10), early diagnosis, and early start of medical and rehabilitative inter-
ventions. For example, communication skills are not only related to verbal intelligence, 
but also to the muscular facial anatomy and strength (3). GH is known to increase the 
muscle tone and promote physical activity (5), and therefore promotes articulation and 
motor control for optimal development of communication skills, which additionally 
promotes social interaction and physical tasks. These effects might be cumulative over 
time. Together with the early start of multidisciplinary care such as speech therapy, 
communication skills improve. Therefore, characteristics of children with PWS nowadays 
might differ significantly from adults with PWS who were diagnosed later in childhood/
adulthood and did not receive suitable treatment and guidance. 
Limitation and further research
Our study results have implications for the treatment of children with PWS. Early 
diagnosis of PWS provides the opportunity to start GH treatment and rehabilitative 
therapies at an early age to improve adaptive skills as much as possible, leading to more 
106 Chapter 5
independency of the person with PWS and less burden for the family in supporting the 
daily activities. However, our study is limited by the relative low number of prepubertal 
children in the long-term study as a result of discontinuation of GH due to attainment 
of adult height. A larger group of prepubertal children without GH treatment at start 
of the RCT would have resulted in a larger group with long-term GH treatment. In the 
Netherlands, as in most developed countries, GH treatment is nowadays a standard 
treatment for children with PWS. This challenges the possibility to conduct a new RCT 
in children without GH treatment. However, countries in which GH treatment has not 
been standardized yet, have the possibility to investigate the effect of GH treatment on 
adaptive functioning in a larger group.
In conclusion, children with PWS have a marked delay in adaptive functioning, which 
increases with age. A lower IQ is associated with more delay in adaptive functioning. For 
that reason, infants and children with PWS require adjusted guidance. Our study shows 
that starting GH treatment at an earlier age during infancy leads to better adaptive skills 
on the long-term.
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abSTraCT
Background
Prader-Willi syndrome (PWS) is characterized by hypotonia, hypogonadism, short stat-
ure, obesity, behavioral problems, intellectual disability, and delay in language, social 
and motor development. There is very limited knowledge about visual-motor integra-
tion in children with PWS.
Method
Seventy-three children with PWS aged 7 to 17 years were included. Visual-motor inte-
gration was assessed using the Beery Visual-motor Integration test at the start of the 
study and after two years. The association between visual-motor integration and age, 
gender, genetic subtype, and intelligence was assessed. 
Results
Children with PWS scored ‘very low’ (-3 standard deviations) in visual-motor integration 
and ‘below average’ (-1 standard deviation) in visual perception and motor coordina-
tion compared to typically developing children. Visual-motor integration was higher in 
children with a deletion (β= -0.170, p=0.037), in older children (β=0.222, p=0.009), and 
in those with a higher total IQ (β=0.784, p<0.001). Visual perception was higher with a 
deletion (β= -0.193, p=0.044) and higher IQ (β= -0.618, p<0.001), but motor coordination 
was only higher with a higher total IQ (β= 0.429, p=0.001). Visual perception and motor 
coordination were not associated with age or gender. There was a trend for visual-motor 
integration decline over the 2 year follow-up period (p=0.099). Visual perception and 
motor coordination did not change over the follow-up period. 
Conclusions
Visual-motor integration is very poor in children with PWS. Children scored higher on the 
time-limited subtests for visual perception and motor coordination than the combined 
test for visual-motor integration. Separation of visual-motor integration tasks into pure 
visual or motor tasks and allowing sufficient time to perform the tasks might improve 
daily activities, both at home and at school.
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InTroduCTIon
Prader-Willi syndrome (PWS) is a neurogenetic developmental disorder due to the lack 
of expression of genes on the paternally inherited chromosome 15 at the locus q11-
q13, due to deletion (DEL), maternal uniparental disomy (mUPD), imprinting defects 
or chromosomal translocation (1). PWS is characterized by hypotonia, hypogonadism, 
short stature, obesity, behavioral problems, intellectual disability, and developmental 
disabilities. Motor deficit is an important characteristic of PWS and is previously reported 
during pregnancy as lack in foetal activity by mothers and gynaecologists. After birth 
and during the first years of life, central hypotonia is the most marked characteristic. 
It causes decreased movements, a head lag, lethargy with decreased arousal, weak or 
absent cry, and poor reflexes, including a poor suck that leads to feeding difficulties and 
failure to thrive (2). Also during infancy and childhood, impaired gross motor skills and 
fine motor skills are reported in children with PWS, resulting in delayed developmental 
milestones (3-6). Some studies investigated motor development and its relation to body 
composition and growth hormone treatment in children with PWS (3, 6, 7). However, 
knowledge about visual-motor integration capacity of children with PWS remained very 
limited. 
Visual-motor integration (VMI) shows the extent in which visual perception (inter-
pretation of visual stimuli) and finger-hand movement are coordinated (8). VMI is an 
important contributor to academic skills which require eye-hand coordination, such as 
writing, mathematic formulations, and drawing. It requires accurate perception of visual 
spatial objects and monitoring of one’s own movement.  VMI skills are thus embedded 
in daily activities of school-aged children. Insight into VMI in childhood is therefore 
clinically relevant to optimize the approach and guidance of daily activities at school 
in children with PWS. To our knowledge, VMI in PWS has only been studied in two stud-
ies using the Beery-Buktenecia Developmental Test of Visual-motor Integration. The first 
research group concluded that VMI was more impaired in children and adolescents with 
PWS than age-matched typically-developing youngsters (9). The second research group 
found that individuals with the smaller type II DEL performed better on visual process-
ing than those with the larger type I DEL or mUPD (10). Both studies were performed 
in a relatively small group of individuals with PWS (21 and 12, resp.) and no separate 
assessment of visual processing and motor coordination were performed. The present 
study was conducted to investigate the level of VMI in more detail in a large group of 
children with PWS. 
The IQ-range in individuals with PWS varies between 50 to 80 (11, 12). VMI-testing in 
5-year old children with 22q11-deletion syndrome, who have a similar IQ as children 
with PWS, showed that VMI performance was below average compared to typically 
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developing peers (13). In children with 22q11-deletion syndrome, VMI and visual skills 
were correlated with total IQ, but not with motor coordination.
Earlier studies have found children with PWS to be stronger in performing visual spatial 
tasks than their peers with similar IQ (9), with individuals with a DEL scoring higher on 
the VMI than those with an mUPD (9, 14). However, these studies were performed in a 
group with a wide age-range, or in instances where it was not known if the participants 
were treated with growth hormone.
In our previous study, we found that visual processing deteriorated during 2 years in 
children without growth hormone treatment, but improved significantly after long-term 
growth hormone treatment, especially in those with a greater deficit (15). As growth 
hormone treatment is now a standard treatment in most developed countries, this 
might suggest that long-term growth hormone treatment not only improves visual 
processing, but might also improve VMI.  
The aim of our study was to determine the level of VMI. Secondly, we investigated which 
factors predicted the level of  VMI in children with PWS. We hypothesized that VMI in 
children with PWS is impaired compared to healthy references, but that children with 
DEL score higher than those with mUPD. In addition, we expected that VMI performance 
and visual perception would correlate with total IQ, and motor coordination with perfor-
mal IQ and that the level of VMI would decline over time in children with PWS compared 
to healthy references.
MeThodS 
For the present study, we enrolled children aged 7 to 17 years who participated in the 
ongoing Dutch PWS Cohort study, a study investigating the long-term effects of growth 
hormone treatment in children with PWS (16). Testing for visual-motor integration was 
performed at baseline and after 2 years. 
A total of 81 children with PWS were eligible for participation, 75 of whom agreed to 
participate, resulting in a response rate of 93%. In the second assessment, 54 children 
who also completed the first assessment were eligible to participate, and 52 children 
completed the second assessment, resulting in a response rate of 96%. Twenty-one 
children were excluded from the second assessment due to the follow-up period being 
less than 2 years, one died, and one child did not participate. 
The genetic diagnosis of PWS was confirmed in all participants by methylation testing. 
The genetic subtype was known in all but four participants. All children were treated 
with growth hormone (Genotropin 1 mg/m2/day). This study was approved by the Medi-
cal Ethics Committee of the Erasmus University Medical Center in Rotterdam. Written 
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informed consent was obtained from all parents or caretakers and children of 12 years 
of age onwards, and assent below the age of 12 years.
Visual-motor integration
Visual-motor integration was tested with the Beery-Buktenecia Developmental Test of 
Visual-motor Integration )(full-form) (Beery-VMI), which is designed to assess to which 
extent individuals can integrate their visual and motor abilities by copying geometric 
forms, organized in a developmental sequence. The Beery-VMI is valid for individuals 
aged 2 to 100 years to assess the written visual-motor functioning (8). The child was 
asked to copy thirty geometric forms, organized from simple to more complicated forms. 
No time limit was required for this test. Visual-motor integration has been investigated 
in 5-year old children with 22q11-deletion syndrome and small groups of children with 
PWS, confirming its feasibility (9, 10, 13).  
Visual Perception
The VMI Supplemental Test for Visual Perception is a test to assess visual performance 
by reducing motor requirements of the task to a minimum (8). A geometric form was 
presented to the child and we asked the child to point to the exact same geometric form 
within a group of other forms, organized from simple to more complicated. The testing 
time was limited to three minutes for thirty items.
Motor Coordination
The VMI Supplemental Test for Motor Coordination is a test to assess motor performance 
by reducing visual perceptual demands to a minimum (8). The child was asked to trace 
the stimulus forms with a pencil, staying between the double lined paths. Visual percep-
tion was minimised in this subtest by providing starting dots and paths as strong visual 
guides for the required motor performance. The test consists of thirty items ranging 
from simple to more complicated forms. All of the geometric forms were the same as the 
geometric figures used in the Beery-VMI. The testing time was limited to five minutes for 
thirty items. 
Only pencil and paper were allowed for all three tests. No corrections were allowed. All 
tests were only performed if the child could complete the three example forms after a 
brief description of the particular task. All three tests consisted of the same 30 geometric 
figures. The Beery-VMI is well validated and has a sound reliability of 0.92 for VMI, 0.91 
for  visual perception and 0.90 for motor coordination (8).
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Cognitive functioning
Cognitive testing was annually performed in prepubertal children and biennially in 
pubertal children using the short form of the Wechsler Intelligence Scale for Children-
Revised (WISC-R) (17). All cognitive measurements described in this study were per-
formed by an experienced psychologist. The methods of cognitive testing in prepubertal 
children has been described in detail (12). In summary, total IQ score was calculated 
according to an equation based on a Dutch outpatient reference population (total IQ = 
45.3 + 2.91 x vocabulary s-score + 2.50 x block design s-score), as used in other studies 
(15, 18, 19). The vocabulary subtest was used to assess verbal IQ, and the block design 
subtest was used for performal IQ.
Data-Analysis
Age and intelligence at baseline are presented as median and interquartile range (IQR). 
Results for VMI, visual perception and motor coordination are expressed as a standard 
score provided by the manual of the Beery-VMI according to an individual’s age. Stan-
dard scores consist of equal units of measurement with a mean of 100 and a standard 
deviation of 15. The standard score of performance was compared to a healthy refer-
ence group included in the manual, i.e. ‘average’ performance (standard score 90-109, 
includes 50% of the age group, equals 0 standard deviation), ‘below average’ (standard 
score 80-89, 16% of the age group, equals -1 standard deviation), ‘low’ (standard score 
70-79, 7% of the age group, equals -2 standard deviation), ‘very low’ (standard score <70, 
2% of the age group, equals -3 standard deviation) (8). The equivalent developmental 
age  to the raw score was calculated using the Beery VMI Raw Score Age Equivalents 
table (8). Multiple linear regression was performed to investigate the association be-
tween VMI and age, gender (1=boys, 2=girls), genetic subtype (1= DEL, 2=mUPD), total 
IQ, verbal IQ, and performal IQ. McNemar’s test was used to test for differences in gender 
and genetic subtype at baseline and after 2 years. Wilcoxon signed ranks test was used 
to test for differences in total IQ and standard scores for VMI, visual perception and mo-
tor coordination between the group at start and after 2 years. Statistical analyses were 
performed with SPSS 20·0 (SPSS Inc., Chicago, IL). A p-value of <0.05 (two-tailed) was 
considered statistically significant.
reSuLTS
Baseline
Median (interquartile range (IQR)) age of the 75 children with PWS was 11.8 (8.7, 14.1) 
years and 34 (45%) were male (Table 1). Thirty-one (41%) had DEL, 36 (48%) mUPD, four 
had an imprinting defect, and in four children the genetic subtype remained unknown. 
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Median (IQR) total IQ was 62 (56, 78), age at start of growth hormone treatment 4.5 (2.2, 
6.8) years and duration of growth hormone treatment 7.0 (6.0, 8.0) years. Characteristics 
of the study group are presented in Table 1.
Visual-motor integration
Children with PWS scored ‘very low’ (-3 standard deviations) in VMI with a median (IQR) 
standard score of 62 (45, 81). They scored ‘below average’ (-1 standard deviation) in 
visual perception and motor coordination with median scores of 81 (62, 89) and 80 (63, 
93), resp. The VMI standard scores of individual children with PWS according to age are 
presented in Figure 1 and the age equivalent to the VMI standard score according to age 
in Figure 2. 
Multiple linear regression showed that VMI was higher in children with a DEL (β=-
0.170, p=0.037), in older children (β=0.222, p=0.009) and in those with a higher total 
IQ (β=0.784, p<0.001) (Table 2), but there was no difference in VMI between boys and 
girls (β=0.065, p=0.418). Higher verbal IQ (β=0.419, p<0.001) and performal IQ (β=0.469, 
p<0.001) were both associated with higher VMI performance. Visual perception and 
motor coordination were higher in children with a higher total IQ (β=0.618, p<0.001 and 
β=0.429, p=0.001, resp.). Visual perception was higher in children with higher verbal 
(β=0.339, p=0.005) and performal IQ (β=0.398, p=0.003), but there was no association 
between motor coordination and verbal (β=0.252, p=0.095) or performal IQ (β=0.236, 
p=0.146). Visual perception was also higher in children with a DEL (β=-0.193, p=0.044).
Table 1. Characteristics of the study group at baseline
  Baseline
N (male) 75 (34)
Age (years) 11.8 (8.7, 14.1)
Genetic subtype (n (%))
 Deletion 31 (41%)
 UPD 36 (48%)
 ICD 4 
 Unknown 4 
Total IQ 62 (56, 78)
Age at start of GH treatment (years) 4.5 (2.2, 6.8)
Duration of GH treatment (years) 7.0 (6.0, 8.0)
GH = growth hormone. Age, total IQ, age at start and duration of GH treatment are expressed in median 
(IQR).
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figure 1. VMI performance in children with PWS
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figure 2. VMI performance expressed as age equivalent in children with PWS
SS = standard score. The line of identity (45o) represents the line of 0 standard deviation (SD) and is similar 
to age. The line below represents the -2 SD line for typically developing children. 
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After 2 years of follow-up
In the second assessment after 2 years, 52 children participated and this group did not 
significantly differ from the initial group in gender, genetic subtype and total IQ (p= 
0.317, p= 1.000, p= 0.203, resp.).
There was a trend for VMI decline over the 2 year follow-up  (z= -1.651, p= 0.099). There 
was no change in visual perception (z= -0.233, p= 0.815) and motor coordination (z= 
-0.622, p= 0.534) after 2 years of follow-up. 
dISCuSSIon
Our study shows that visual-motor integration (VMI) in children with PWS is very poor 
compared to typically developing children. The majority of our group had a standard de-
viation score of less than -3. VMI was higher in children with a deletion, in older children 
and in those with a higher total IQ. However, there was no difference in VMI between 
boys and girls. Children scored higher when visual perception and motor coordination 
were tested separately. Visual perception and motor coordination were positively asso-
ciated with total IQ, but only VMI and visual perception were positively associated with 
verbal and performal IQ. During the 2 year follow-up, the visual perception and motor 
coordination did not change, but there was a trend for VMI to decline. 
VMI is the ability to integrate visual perception and motor skills. We tested VMI by ask-
ing children to copy a figure, for which both visual perception and motor coordination 
were required. Visual perception and motor coordination were also tested separately to 
Table 2. VMI in children with PWS
    VMI Visual Perception   Motor Coordination
Model A Model B Model A Model B   Model A Model B
ß P ß     ß P ß P   ß P ß P
Age 0.222 0.009 0.270 0.004 -0.082 0.404 -0.055 0.605 -0.038 0.753 -0.005 0.970
DEL vs mUPD -0.170 0.037 -0.164 0.054 -0.193 0.044 -0.157 0.112 -0.059 0.615 -0.038 0.757
Total IQ 0.784 <0.001 0.618 <0.001 0.429 0.001
Verbal IQ 0.419 <0.001 0.339 0.005 0.252 0.095
Performal IQ 0.469 <0.001 0.398 0.003 0.236 0.146
Overall 
P-value
<0.001 <0.001   <0.001 <0.001   0.004 0.021
Adj. R2   0.602 0.598   0.452 0.456   0.173 0.140
VMI= visual-motor integration. VMI, visual perception, and motor coordination are expressed in standard 
scores. Genetic subtype is classified as follow: DEL=1, mUPD=2. Adjusted for gender. 
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determine if these skills were impaired on their own. As expected, VMI was considerably 
impaired in our study group which resulted in a -3 standard deviation score compared 
to typically developing children. Unexpectedly, the children had lower scores in the no 
time-limit performance of the Beery-VMI than in the other time-limited subtests. As 
Beery-VMI tests the integration of visual perception and motor coordination, the results 
suggest that VMI is more difficult for children with PWS than performing a simplified task, 
either visual or motor, even in the case of time restriction. This poor VMI performance 
explains at least part of the difficulties in daily functioning faced by people with PWS, 
such as the weakness in writing skills. Based on the results of our study, writing could 
better taught by  training the visual and motor skills separately. For example, the visual 
differences between letters could be trained first followed by motor tasks. The actual 
writing of letters should be the last step of the learning process as VMI is the most dif-
ficult step for these children. It is likely that poor VMI skills also contribute to difficulties 
in other motor coordination skills, e.g. getting dressed. For daily practice, visual support 
could be provided by using pictograms. 
The majority of children were eager to finish the tests beyond the permitted time. In our 
analyses, we only used the scores within the time-limit in order to compare the results 
with typically developing peers. But observationally, children were able to score higher 
on the visual and motor tests if there was no time-limit. Future studies on VMI in children 
with PWS could investigate their maximal ability by recording both scores with limited 
and unlimited time setting for the visual and motor tests. Hypotonia, a typical feature 
of PWS, might partly explain why individuals with PWS need more time to complete a 
motor task. 
We expected that VMI would decline over time and thus that the difference in VMI skills 
would increase between children with PWS and their healthy peers. We found, however, 
that there was a trend in VMI decline, as this was at the border of significance. It is most 
likely that the time period of 2 years was too short to show any difference in individual 
VMI performance.   
VMI performance was strongly associated with total IQ, which is in line with an earlier 
report in children with intellectual disability (20). This study suggested that intelligence 
might be particularly related to the planning stage of the VMI task and not so much 
to the motor component of the task. Hypothetically, altered sensory perception due 
to derangement of neurotransmitter balance involving the hypothalamic regions could 
have delayed the processing speed in individuals with PWS (21). In our study group, 2 
boys with an mUPD of 15 and 17 years old scored unexpectedly higher on VMI than their 
peers with the same genetic subtype. Both boys started growth hormone treatment 
around the age of 9 years, were treated for 6 to 7 years, and had a total IQ of 86 and 90, 
resp. Their IQ was in the highest 10% of the total study group.
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We did not find a difference in VMI performance between boys and girls, which is in 
contrast to a previous study in children with intellectual disability reporting that girls 
performed better than boys (20). However, another study in children with 22q11-
deletion also found no difference in VMI performance between boys and girls (13). 
In our study group, 41% of children had a deletion and 48% an mUPD. Earlier studies 
reported a DEL: mUPD ratio of 70:30 (22, 23). The higher frequency of the mUPD type in 
our Dutch study group is most likely related to an increased maternal age, which is in 
line with previous studies in Western Europe (24, 25). 
As the purpose of this study was to investigate the level of VMI in a large group of children 
with PWS, we did not include a comparison group with children with intellectual dis-
ability. Our study, therefore, does not differentiate which characteristics are ‘Prader-Willi 
specific’. However, children with DEL scored higher on VMI and visual perception than 
those with mUPD, which is in line with an earlier finding that children with DEL have 
stronger visual skills (9, 14). Earlier studies showed a beneficial effect of growth hormone 
treatment on motor skills and IQ (3, 6, 7, 15). However, our study was not designed to 
investigate the effect of growth hormone treatment on VMI. 
In conclusion, visual-motor integration performance was very poor (-3 standard devia-
tions) in a large group of 73 children with PWS compared to healthy references. VMI was 
higher in children with a deletion, in older children and in those with a higher total IQ. 
Separation of visual-motor integration tasks into pure visual or motor tasks and allowing 
sufficient time to perform the tasks might improve daily school activities such as writing. 
Our findings provide further insight into the neurocognitive deficiencies in children with 
PWS and how to approach these.
122 Chapter 6
referenCeS
 1. Cassidy SB 1997 Prader-Willi syndrome. J. Med. Genet. 34: 917-923
 2. Aughton DJ, Cassidy SB 1990 Physical features of Prader-Willi syndrome in neonates. Am J Dis 
Child 144: 1251-1254
 3. Reus L, Pelzer BJ, Otten BJ, Siemensma EP, van Alfen-van der Velden JA, Festen DA, Hokken-
Koelega AC, Nijhuis-van der Sanden MW 2013 Growth hormone combined with child-specific 
motor training improves motor development in infants with Prader-Willi syndrome: a random-
ized controlled trial. Res. Dev. Disabil. 34: 3092-3103
 4. Ehara H, Ohno K, Takeshita K 1993 Growth and developmental patterns in Prader-Willi syndrome. 
J. Intellect. Disabil. Res. 37 ( Pt 5): 479-485
 5. Greenswag LR 1987 Adults with Prader-Willi syndrome: a survey of 232 cases. Dev. Med. Child 
Neurol. 29: 145-152
 6. Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega 
AC 2008 Mental and motor development before and during growth hormone treatment in infants 
and toddlers with Prader-Willi syndrome. Clin. Endocrinol. (Oxf ). 68: 919-925
 7. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB 2010 Long-term growth hormone therapy 
changes the natural history of body composition and motor function in children with prader-willi 
syndrome. J. Clin. Endocrinol. Metab. 95: 1131-1136
 8. Beery KE, Beery NA 2004 The Beery-Buktenica developmental test of visual-motor integration: 
Beery VMI with supplemental deveopmental tests of visual perception and motor coordination: 
Administration, scoring and teaching manual. . 6th ed. Minneapolis: NCS Pearson Inc
 9. Dykens EM 2002 Are jigsaw puzzle skills ‘spared’ in persons with Prader-Willi syndrome? J. Child 
Psychol. Psychiatry 43: 343-352
 10. Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T 2004 Behavioral differences among 
subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 
113: 565-573
 11. Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, Roberts S, Bellamy M, Curran SR, 
Sporikou CM, Bolton PF 2005 Prader-Willi syndrome: intellectual abilities and behavioural fea-
tures by genetic subtype. Journal of Child Psychology and Psychiatry 46: 1089-1096
 12. Lo ST, Siemensma E, Collin P, Hokken-Koelega A 2013 Impaired theory of mind and symptoms of 
Autism Spectrum Disorder in children with Prader-Willi syndrome. Res. Dev. Disabil. 34: 2764-2773
 13. Duijff S, Klaassen P, Beemer F, Swanenburg de Veye H, Vorstman J, Sinnema G 2012 Intelligence 
and visual motor integration in 5-year-old children with 22q11-deletion syndrome. Res. Dev. 
Disabil. 33: 334-340
 14. Veltman MW, Thompson RJ, Roberts SE, Thomas NS, Whittington J, Bolton PF 2004 Prader-Willi 
syndrome--a study comparing deletion and uniparental disomy cases with reference to autism 
spectrum disorders. Eur. Child Adolesc. Psychiatry 13: 42-50
 15. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van 
der Velden AA, Otten BJ, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, 
Oostdijk W, Bocca G, Mieke Houdijk EC, van Trotsenburg AS, Hoorweg-Nijman JJ, van Wieringen 
H, Vreuls RC, Jira PE, Schroor EJ, van Pinxteren-Nagler E, Pilon JW, Lunshof LB, Hokken-Koelega AC 
2012 Beneficial Effects of Growth Hormone Treatment on Cognition in Children with Prader-Willi 
Syndrome: A Randomized Controlled Trial and Longitudinal Study. J. Clin. Endocrinol. Metab. 97: 
2307-2314
VMI in PWS 123
6
 16. Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-
de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, 
Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van 
Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC 2013 Eight 
Years of Growth Hormone Treatment in Children With Prader-Willi Syndrome: Maintaining the 
Positive Effects. J. Clin. Endocrinol. Metab. 98: 4013-4022
 17. Wechsler D 2002 Wechsler Intelligence Scale For Children (Dutch Version), manual. Third edition 
ed. London, United Kingdom: Harcourt Assessment
 18. van Pareren YK, Duivenvoorden HJ, Slijper FS, Koot HM, Hokken-Koelega AC 2004 Intelligence 
and psychosocial functioning during long-term growth hormone therapy in children born small 
for gestational age. Journal of Clinical Endocrinoly and Metabolism 89: 5295-5302
 19. Hokken-Koelega AC, van Pareren YK, Arends N 2005 Effects of growth hormone treatment on 
cognitive function and head circumference in children born small for gestational age. Horm. Res. 
64 Suppl 3: 95-99
 20. Memisevic H, Sinanovic O 2012 Predictors of visual-motor integration in children with intellectual 
disability. Int. J. Rehabil. Res. 35: 372-374
 21. Akefeldt A, Ekman R, Gillberg C, Mansson JE 1998 Cerebrospinal fluid monoamines in Prader-Willi 
syndrome. Biol. Psychiatry 44: 1321-1328
 22. Cassidy SB 1984 Prader-Willi syndrome. Curr. Probl. Pediatr. 14: 1-55
 23. Dykens EM, Roof E 2008 Behavior in Prader-Willi syndrome: relationship to genetic subtypes and 
age. J. Child Psychol. Psychiatry 49: 1001-1008
 24. Whittington JE, Butler JV, Holland AJ 2007 Changing rates of genetic subtypes of Prader-Willi 
syndrome in the UK. Eur. J. Hum. Genet. 15: 127-130
 25. Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, Curfs LM 
Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res. Dev. Disabil. 32: 1729-1735
CHAPTER 7 
DEPRESSIVE SYMPTOMS AND 
THE DOPAMINE AND SEROTONIN SYSTEM IN 
CHILDREN WITH PRADER-WILLI SYNDROME 
Sin T. Lo, Durk Fekkes, Philippe J.L. Collin,  
Hokken-Koelega
  Submitted
Anita C.S.
12
3
4
5
6
7
8
9
10
Chapter 7
Depressive symptoms and the dopamine 
and serotonin system in children 
with Prader-Willi syndrome.
Lo ST, Fekkes D, Collin PJL, Hokken-Koelega ACS.
Submitted
CHAPTER 7 
DEPRESSIVE SYMPTOMS AND 
THE DOPAMINE AND SEROTONIN SYSTEM IN 
CHILDREN WITH PRADER-WILLI SYNDROME 
Sin T. Lo, Durk Fekkes, Philippe J.L. Collin,  
Hokken-Koelega
  Submitted
Anita C.S.
126 Chapter 7
abSTraCT
Introduction 
Depressive illness is more common in adults with Prader-Willi syndrome (PWS) than in 
the general population. Data on the presence of depression and its symptoms in chil-
dren with PWS are unknown. Also, information on depressive symptoms in relation with 
precursors and metabolites of the dopamine and serotonin system in children with PWS 
is lacking. 
Methods
In 68 children with genetically confirmed PWS, aged 7 to 17 years, the precursors and 
metabolites of the dopamine (i.e. tyrosine and HVA, resp.) and serotonin system (i.e. 
tryptophan) in plasma were determined during 2 years and compared with healthy 
controls. Depressive symptoms were assessed by the Dutch version of the Children’s 
Depression Inventory. 
Results
None of the children with PWS fulfilled the criteria for depression. 
Dopamine system: Tyrosine-ratio (tyrosine versus competing amino acids) and HVA-
levels were normal, but both declined over 2 years (p<0.001 and p=0.105, resp.). More 
depressive symptoms were correlated with a lower tyrosine-ratio (ρ=-0.457, p=0.011) 
and tended to be correlated with a lower HVA-level (ρ=-0.346, p=0.061). 
Serotonin system: Tryptophan-ratio was higher (p<0.001) in children with PWS than in 
controls and tryptophan-ratio increased over 2 years (p<0.002), but did not correlate 
with depressive symptoms.  
Children with PWS had significantly higher plasma levels of aromatic amino acids 
(tyrosine, tryptophan and phenylalanine), in contrast to normal branched-chain amino 
acid-levels (isoleucine, leucine and valine).
Conclusion
In our study group, none of the children with PWS fulfilled the criteria for depression. 
Children with more depressive symptoms had a lower tyrosine-ratio. Tryptophan-ratio 
was higher than in healthy controls and increased over time, but was not related to 
depressive symptoms. Our findings warrant future studies.    
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InTroduCTIon 
Prader-Willi syndrome (PWS) is a neurogenetic developmental disorder resulting from 
the lack of expression of genes on the paternal chromosome 15 at locus q11-q13, 
caused by deletion (DEL), maternal uniparental disomy (mUPD), imprinting defect, or 
chromosomal translocation (1). The estimated birth incidence rate is 1:15.000 (2, 3). 
PWS is characterized by hypotonia, hypogonadism, hyperphagia, obesity, intellectual 
disability, and behavioral problems. The phenotype of PWS has been explained by hy-
pothalamic dysfunction and dysregulation of neurotransmitters. PWS is also associated 
with a higher risk of psychiatric problems such as depression (4, 5). 
Only few studies have investigated depression in people with PWS. Depression occurs 
approximately in 12% of adults with PWS, mostly combined with psychotic symptoms 
(4, 5). It has been reported that subjects with DEL are more prone to a depression than 
those with an mUPD (5). No studies have yet investigated depressive symptoms in 
children with PWS. 
In case of a depressive illness in PWS, a selective serotonin reuptake inhibitor (SSRI) is 
the most frequently prescribed antidepressant (4). Most antidepressants increase the 
synaptic level of the neurotransmitters serotonin and dopamine in the brain. As aberra-
tions in the levels of neurotransmitters in these systems might be involved in depression 
in PWS (6, 7), it is important to investigate plasma precursors and/or metabolite levels of 
these neurotransmitters to acquire more insight in the dopamine and serotonin system 
in children with PWS.
Dopamine system: Tyrosine is essential in the formation of catecholamines such as do-
pamine, and norepinephrine. Plasma tyrosine has to enter the brain via the blood-brain 
barrier for the formation of dopamine in the brain (Figure 1). At the blood-brain barrier, 
tyrosine competes with tryptophan, phenylalanine, isoleucine, leucine and valine (com-
peting amino acids) to pass this barrier (8). After entering the brain, tyrosine is firstly 
converted to L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (Figure 1). 
Subsequently, L-DOPA is converted to dopamine by decarboxylation, and then mainly to 
homovanillic acid (HVA) and in a smaller percentage to norepinephrine. In humans, HVA 
is the major dopamine metabolite. After passing the blood-brain barrier, HVA is measur-
able in plasma. As a result, approximately 40% of plasma HVA (pHVA) originates from 
the brain and serves therefore as a proxy for central dopamine neuronal metabolism 
and hence central dopamine activity (9). Thus, a lower level of pHVA indicates a lower 
concentration of central dopamine. To estimate the level of dopamine in the brain, the 
ratio of tyrosine to competing amino acids passing the blood-brain barrier, expressed 
as Tyr-ratio, and the plasma level of the major dopamine metabolite HVA can be used 
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(9). A lower Tyr-ratio suggests a decreased availability of tyrosine for the formation of 
dopamine in the brain. 
Serotonin system: Serotonin is biochemically derived from tryptophan in the brain, 
which is one of the eight essential amino acids that cannot be synthesized in the human 
body and must be supplied by diet. Plasma tryptophan has to enter the brain via the 
same blood-brain barrier as tyrosine for the subsequent formation of serotonin (Figure 
1). Tryptophan is firstly converted to 5-hydroxytryptophan by tryptophan hydroxylase 
and subsequently to serotonin by aromatic amino acid decarboxylase (Figure 1). The 
action is terminated by reuptake in the presynaptic element or by metabolization by 
monoamine oxidase to the metabolite 5-hydroxyindoleacetic acid (5-HIAA). The level 
of the serotonin precursor tryptophan entering the blood-brain barrier could therefore 
be an indicator of central serotonin concentration. This is depicted as Trp-ratio (ratio of 
tryptophan to competing amino acids passing the blood-brain barrier). An earlier study 
showed that the Trp-ratio is lower in adults with depression than in healthy adults (10). 
A lower Trp-ratio may cause a lower availability of tryptophan to the central nervous 
system, resulting in lower serotonin levels in the brain. 
To the best of our knowledge, no study has investigated the correlation between 
depressive symptoms and plasma tyrosine-ratio, HVA and tryptophan-ratio in children 
with PWS. We, therefore, investigated the depressive symptoms in children with PWS in 
relation to these biomarkers in this exploratory study. We hypothesized that children 
with PWS have a higher prevalence of depression with a lower plasma tyrosine-ratio 
Tyrosine  Tyrosine   L-DOPA Dopamine    HVA       HVA
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figure 1. Dopamine and serotonin system
BBB= blood-brain barrier; Competing AA* are tryptophan, phenylalanine, isoleucine, leucine and 
valine, competing AA** are tyrosine, phenylalanine, isoleucine, leucine and valine. L-DOPA = 
L-3,4-dihydroxyphenylalanine; HVA = homovanillic acid; 5-HTP = 5-hydroxytryptophan; 5-HIAA= 
5-hydroxyindoleacetic acid. Neurotransmitter precursors and metabolite analyzed in this article are 
depicted in bold. 
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and HVA-level, and a lower tryptophan-ratio than healthy controls and that these levels 
deteriorate over time. We expected that children with more depressive symptoms had a 
lower plasma tyrosine-ratio, HVA-level and tryptophan-ratio. 
MeThodS
The inclusion criteria for the present study were children with genetically confirmed 
PWS and aged 7-17 years. Sixty-eight children of the Dutch PWS Cohort Study (11) 
participated in the present study. All participants were treated with growth hormone 1 
mg/m2/day (Genotropin). Five children were treated with psychotropic medication; two 
boys were treated with antipsychotics after their first episode with a psychosis and three 
were treated for increased compulsive behavior, increased irritability and aggression. 
The study was approved by Medical Ethics Committee of the Erasmus Medical Center 
Rotterdam. Written informed consent was obtained from all parents or carers, informed 
consent was obtained from children of 12 years or older, and assent below the age of 
12 years.
Children’s Depression Inventory
The Dutch translation of the Children’s Depression Inventory (CDI) was used to rate 
severity and symptoms of depression and/or a dysthymic disorder in children with PWS 
(12). The CDI has been developed by Maria Kovacs (13) and is based on the Beck De-
pression Inventory, which is a self-rated instrument for adults (14). It is one of the most 
common used instruments to screen for depression in children. The CDI is a 27-item, 
self-rated and symptom-oriented scale suitable for children and adolescents aged 7 to 
18 years. The items of the CDI are grouped into five factor areas, including Negative 
Mood, Interpersonal Problems, Ineffectiveness, Anhedonia, and Negative Self Esteem. 
Responses to the CDI are rated as: 0 =never or absent, 1=sometimes or somewhat, and 
2=always or present. The total score ranges from 0 to 54 with a higher score indicating 
more symptoms of depression. As the CDI requires insight in one’s own thoughts and 
feelings, only children with sufficient language development and self-awareness partici-
pated in this test. For that reason, also the five children with psychotropic medication 
could not participate in the CDI. The CDI has a high internal consistency and test-retest 
reliability (13). To minimize the effect of reading mistakes, all items of the CDI were read 
to the child by a trained medical researcher (SL) who also recorded the answers.
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Biochemical analyses
PWS group
Fasting blood samples were taken once a year for 2 years. Within 3 hours, blood was 
centrifuged for 20 min at 2650  g and 20°C, and the obtained plasma was stored at -80°C 
until analysis.  
Plasma amino acids were analyzed by high performance liquid chromatography (HPLC) 
using pre-column derivatization with o-phthaldialdehyde (15). The coefficient of 
intra-variation for all amino acids determined in the present study were below 4% and 
were highly correlated to levels from other laboratories with a correlation coefficient 
of r=0.999 (16). Tyr-ratio was calculated by dividing the total tyrosine level by the sum 
of the competing amino acids, i.e.  tryptophan, phenylalanine, isoleucine, leucine, and 
valine, which compete for the transport of tyrosine through the blood-brain barrier. The 
Trp-ratio was calculated in the same manner by substituting total tyrosine level for total 
tryptophan level and by replacing tryptophan for tyrosine as competing amino acid. 
Plasma homovanillic acid (pHVA)-levels were measured in 0.4 ml plasma by reversed-
phase HPLC after removal of the proteins with 4.2% sulphosali cylic acid. The internal 
standards were isoprenaline and α-methyl 5-HT. Three μl samples were injected onto a 
reversed phase column (Zorbax Eclipse XDB-C8, 5 μm particle size, 250 x 3 mm; Agilent 
Technologies, Waldbronn, Germany) which was protected by a Hypersil ODS guard 
column (20 x 2.1 mm, 5 μm; Agilent). The HPLC apparatus consisted of an HP 1200 Series 
quaternary pump, on-line degasser and autosampler (Agilent Technologies, Waldbronn, 
Germany). The mobile phase consisted of 80 mM sodium acetate, 0.27 mM disodium 
EDTA, 0.74 mM heptane sulphonic acid and 13% methanol, pH 3.95. The flow rate was set 
at 0.4 ml/min and the column temperature was 45°C. The effluent was monitored by an 
electrochemical detector consisting of a VT-03 flow cell (0.33 μl) equipped with a glassy 
carbon electrode and the Intro controller (Antec Leyden, Leiden, The Netherlands). The 
oxidation potential was maintained between 0.68 and 0.72 V (versus Ag/AgCl reference 
electrode), the sensitivity range was 0.2 nA/V and the time constant was set at 2 sec. 
Noise was reduced with a Link low-pass filter using a cut-off frequency of 0.055 Hz . Data 
were collec ted on-line and processed by the Kroma PC Integra tion Pack data acqui sition 
system (Kontron Instruments, Milan, Italy). Quantification was done by measuring peak 
heights. The mean recovery (± SD) of HVA added to the plasma samples was 95 ± 7%. 
Variation coefficients were less than 5% (17). 
    
Healthy controls
Raw data on plasma amino acid levels of healthy controls were provided by Hammarqvist 
et al  (18). In summary, the control group consisted of 10 age-matched healthy children 
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aged 7-15 years undergoing elective surgery, such as hernia repair, orchidopexy, opera-
tion due to hydronephrosis and antireflux operation. Amino acid levels were determined 
by ion-exchange chromatography, which is described in detail in the original article (18). 
HPLC and ion-exchange chromatography resulted in similar plasma amino acid levels 
(r=0.997, p<0.001) (16). No pHVA-levels were assessed in the healthy controls. 
Data-analyses
CDI raw scores were calculated as z-scores, with a higher z-score depicting more depres-
sive symptoms. The z-scores were categorized as following: 0= <-2, 1= -2 till -1, 2= -1 
till 0, 3= 0 till 1, 4= 1 till 2, 5= >2. Age and Tyr-ratio, pHVA, and Trp-ratio were expressed 
as median (interquartile range (IQR)). Associations between baseline levels of Tyr-ratio, 
pHVA, Trp-ratio, and age were calculated with linear regression analysis. Fisher’s exact 
test was used to calculate differences between genders and genotypes. Mann-Whitney 
U-test was used to test for differences in Tyr-ratio, pHVA, and Trp-ratio between the 
PWS group and healthy controls. Kruskal-Wallis test was used to analyze the difference 
between CDI z-scores and Tyr-ratio and Trp-ratio. To analyze the change in Tyr-ratio, 
pHVA, and Trp-ratio over time, Linear Mixed Models were used, which was adjusted for 
gender and genetic subtype (gender coded as: 1=boys, 2=girls; genetic subtype coded 
as: 1=DEL, 2=mUPD) and age.  
Statistical analyses were performed with SPSS 20.0 (SPSS Inc., Chicago, IL). All statistical 
tests were two-sided. A p-value of <0.05 was considered statistically significant. 
reSuLTS
Baseline
Median (interquartile range (IQR)) age of the total PWS group (n=68) was 11.3 (8.8, 14.2) 
years and 37 (54%) were male (Table 1). 28 had DEL (41%), 32 mUPD (47%), 4 an imprint-
ing defect, and in 4 children the genetic subtype was unknown. 
Assessment of depressive symptoms in children with PWS
Thirty of 68 children (44%) with PWS had sufficient language and self-awareness to 
complete the Children’s Depression Inventory (CDI). Their median (IQR) age was 13.2 
(11.2, 15.9) years and 13 (43%) were male. Ten had DEL (33%) and 17 mUPD (57%). Me-
dian (IQR) IQ was 68 (59, 83). Depressive symptoms were expressed as z-scores, with a 
higher z-score representing more depressive symptoms. Four children had a CDI z-score 
<-2, eleven between -2 and -1, and fifteen between -1 and 0. None of the participants 
had a z-score higher than 0, and therefore none of the children fulfilled the diagnosis 
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of depression. More depressive symptoms was associated with an older age (ρ= 0.381, 
p=0.034), but not with IQ (ρ= 0.212, p=0.270).
Older age was not correlated with a higher IQ (ρ= -0.088, p=0.645). The four most rated 
symptoms were lack of friends in 17 of 30 children (57%), self-devaluation compared to 
peers in 8 of 30 (27%), difficulty in making decisions in 6 of 30 (20%), and being tired 
in 7 of 30 (23%) children. The PWS group without assessment of depressive symptoms 
(n=33), including 5 children with psychotropic medication, was significantly younger 
(median (IQR) age of 10.4 (8.5, 13.8) versus 13.2 (11.2, 15.9) years, resp., p=0.004) and had 
a lower IQ than the group with CDI assessment (median (IQR) IQ of 59 (57, 76) versus 68 
(59, 83), resp., p=0.041).  
Dopaminergic factors in children with PWS and healthy controls
Total group 
In children with PWS, median (IQR) plasma tyrosine was 55 (51, 61) μmol/l, Tyr-ratio 12.3 
(10.9, 13.6) and pHVA 42.8 (36.3, 53.1) nmol/l (Table 2). Plasma tyrosine was significantly 
higher than in healthy controls (p<0.005), but Tyr-ratio was similar (p=0.094). Between 
the group with and without CDI assessment, no difference was found in Tyr-ratio 
(p=0.348) and pHVA (p=0.345). 
Age was neither associated with Tyr-ratio (β=-0.089, p=0.415) nor with pHVA-level (β=-
1.377, p=0.076). No difference in these two parameters was found between children with 
DEL and mUPD, boys and girls, or children with and without psychotropic medication.
Table 1. Characteristics of the study groups
PWS group Healthy 
controls* 
p-value2
Total group CDI assessment No CDI assessment p-value1
N (male) 68 (37) 30 (13) 38 (25) 0.133 10 (7) 0.495
Age (years) 11.3 (8.8, 14.2) 13.0 (11.2, 15.9) 10.6 (8.6, 13.8) 0.005 11.0 (8.5, 12.0) 0.331
IQ 62 (56, 78) 69 (59, 83) 59 (57, 76) 0.041 n/a
Genetic 
subtype (n (%))
Deletion 28 (41%) 10 18 0.186
mUPD 32 (47%) 17 15
ICD 4 2 2
Unknown 4 1 3
Data expressed as median (IQR) or number (%) * Data of the healthy controls (18). P-value1 represents 
the p-value between the PWS group with and without CDI assessment, p-value2 represents the p-value 
between the total PWS group and healthy controls. N/a= not available. 
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PWS children with assessment of depression
Thirty children with PWS completed the CDI assessment of depression in addition to 
the assessment of Tyr-ratio and pHVA-level. Median (IQR) Tyr-ratio was 12.7 (11.3, 13.9) 
μmol/l and pHVA 43.5 (36.8, 53.9) nmol/l (Table 2). A higher CDI z-score, indicating more 
depressive symptoms, was significantly correlated with a lower Tyr-ratio (ρ= -0.457, 
p=0.011), and tended to be correlated with a lower pHVA-level (ρ= -0.346, p=0.061). 
Figure 2 shows the Tyr-ratio per subgroup of CDI z-score. 
Table 2. Plasma amino acids and HVA in children with PWS at baseline 
Amino acids PWS group p-value1 Healthy controls p-value2
Total group 
(n=68)
CDI assessment 
(n=30)
no CDI 
assessment 
(n=38)
Tyr-ratio 12.3 (10.9, 13.6) 12.7 (11.3, 13.9) 11.8 (10.7, 13.5) 0.348 11.7 (10.2, 12.4) 0.094
pHVA  42.8 (36.3, 53.1) 43.5 (36.8, 53.9) 41.5 (35.2, 50.9) 0.345 n/a
Trp-ratio 8.9 (7.9, 10.3) 8.9 (7.7, 10.1) 8.9 (8.0, 10.5) 0.450 6.8 (6.6, 7.7) P<0.001
Competing 
amino acids
Tyrosine 55 (51, 61) 58 (52, 61) 53 (49, 60) 0.228 46 (43, 54) 0.004
Tryptophan 41 (36, 47) 42 (36, 46) 40 (37, 51) 0.577 31 (30, 34) P<0.0001
Phenylalanine 47 (44, 51) 48 (44, 50) 47 (44, 52) 0.861 42 (39, 47) 0.040
Isoleucine 53 (48, 59) 51 (49, 58) 54 (47, 59) 0.740 51 (41, 57) 0.552
Leucine 106 (94, 113) 106 (95, 115) 106 (94, 114) 0.851 107 (88, 121) 0.660
Valine 203 (189, 224) 205 (181, 224) 200 (195, 226) 0.654 194 (164, 221) 0.213
Plasma amino acids are expressed in μmol/l, pHVA in nmol/l. Data are expressed in median (IQR 
(=interquartile range)). CDI = Children’s Depression Inventory. P-value1 represents the p-value between 
the PWS group with and without CDI assessment, p-value2 represents the p-value between the total PWS 
group and healthy controls.
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Follow-up during 2 years
During the follow-up of 2 years in the total group of children with PWS, Tyr-ratio de-
creased significantly from 12.6 (12.0-13.1) at baseline to 11.8 (11.3-12.4) μmol/l after 2 
years (p<0.001). The pHVA-levels tended to decrease from 48.4 (43.7-53.2) at baseline to 
43.7 (36.9-50.5) after 2 years (p=0.105).
Serotonergic factor in children with PWS and healthy controls
Total group 
In children with PWS, median (IQR) plasma tryptophan was 41 (36, 47) μmol/l and 
Trp-ratio 8.9 (7.9, 10.3) (Table 2), which were both significantly higher than in healthy 
controls (p<0.0001 and p<0.001, resp.). No difference was found between the group 
with and without CDI assessment in Trp-ratio (p=0.450).
Trp-ratio was not associated with age (β=-0.131, p=0.094). No difference in Trp-ratio 
was found between children with DEL and mUPD, boys and girls, or children with and 
without psychotropic medication. 
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figure 2. Correlation between tyrosine-ratio and depressive symptoms in children with PWS
Higher CDI z-score represents more depressive symptoms. *A higher CDI Z-score correlated with a 
lower Tyr-ratio (p=0.010). CDI z-score >0 is not depicted in this figure as none of our participants had a 
z-score >0. 
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PWS children with assessment for depression
Thirty children with PWS completed the CDI assessment for depression in addition to 
the assessment of Trp-ratio. Median (IQR) Trp-ratio was 8.9 (7.7, 10.1) μmol/l (Table 2). 
A higher CDI z-score, indicating more depressive symptoms, was not correlated with a 
lower Trp-ratio (ρ= -0.053, p=0.779).
Follow-up during 2 years
In children with PWS, the Trp-ratio increased significantly from 8.7 (8.4-9.0) at baseline to 
9.8 (9.4 -10.3) μmol/l after 2 years (p<0.002). 
Competing amino acids
In children with PWS, levels of branched-chain amino acids were similar compared to 
healthy controls (median (IQR) plasma isoleucine 53 (48, 59), leucine 106 (94, 113), and 
valine 203 (189, 224) μmol/l), but in contrast, the aromatic amino acids were higher, i.e. 
median (IQR) plasma tyrosine was 55 (51, 61), tryptophan 41 (36, 47), and phenylalanine 
47 (44, 51) μmol/l (p<0.005, p<0.0001, p<0.05, resp.). 
dISCuSSIon
In our study group, none of the children with PWS fulfilled the criteria for the diagnosis 
of depression. 
Both markers of the dopaminergic system, the plasma tyrosine-ratio, an indicator 
of tyrosine availability for central dopamine synthesis, and plasma HVA, the major 
metabolite of dopamine, were normal in children with PWS, but declined over 2 years. 
More depressive symptoms were correlated with a lower tyrosine-ratio indicating lower 
tyrosine availability for central dopamine synthesis. 
The marker of the serotonin system, the plasma tryptophan-ratio, an indicator of tryp-
tophan availability for central serotonin synthesis, was higher in children with PWS than 
in controls and increased over 2 years (p<0.002). However, this marker did not correlate 
with depressive symptoms.  Plasma aromatic amino acid-levels were higher in children 
with PWS than in healthy controls, in contrast to normal levels of the branched-chain 
amino acids.
Assessment of depressive symptoms
We did not find the diagnosis of depression in our children with PWS aged 7 to 17 years. 
Lack of friends was the most prominent symptom and reported by approximately half 
of children with PWS. Weaknesses in social skills is part of the behavioural phenotype of 
PWS (19-22). Social disabilities have also been reported by parents (19-24). Remarkably, 
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children with PWS were aware of their limited number of friends. Our study also shows 
that children with PWS like to be similar as peers and sibs, but their social deficits chal-
lenge them to make friends. A quarter of them confirmed feelings of self-devaluation, 
difficulty in making decisions and being tired. It has been suggested that the tiredness is 
related to the abnormal body composition and general hypotonia in children with PWS, 
resulting in moving slowly, being underactive, doing little, e.g. only sitting and watching 
others (25). Additionally, daytime sleepiness and sleep abnormalities as sleep-related 
breathing disorders are common features in PWS (26-29), which contributes to being 
tired. 
Three of the 27 items in the Children’s Depression Inventory (sleeping problems, lack in 
appetite, and being worried about pain) rarely occurred in the children with PWS. Chil-
dren with PWS would therefore potentially score three points less than the maximum 
score of 30 points. A possible explanation that we did not find depression in our group 
of children could be the long-term effect of GH treatment. We previously demonstrated 
that growth hormone treatment improved cognition in children with PWS, particularly 
in those with lower cognitive functioning (30). It cannot be excluded that long-term 
growth hormone treatment played a role in the neurodevelopment, and future studies 
are warranted to show if the current generation of children with PWS who are treated 
with GH from a young age onwards, have a lower risk of developing depression later in 
life. 
Dopaminergic factors
We found that the plasma Tyr-ratio, an indicator of tyrosine availability for central dopa-
mine synthesis, was relatively low and decreased over time while the plasma level of the 
dopamine metabolite HVA showed a trend of decreasing levels. In contrast, Akefeldt et 
al. found higher levels of HVA in cerebrospinal fluid compared to healthy controls (31). 
Remarkably, all three aromatic amino acids (tyrosine, tryptophan, phenylalanine) were 
significantly higher in children with PWS than in healthy controls, which was not the case 
for the branched-chain amino acids (isoleucine, leucine, valine). It is therefore unlikely 
that these differences in the amino acids are explained by dietary reasons, which would 
have resulted in aberrations in both aromatic and branched-chain amino acids.
Serotonergic factors
In contrast to our expectation, we found that the Trp-ratio, an indicator of tryptophan 
availability for central serotonin synthesis, was higher in children with PWS compared 
to healthy controls. One explanation could be that the serotonin system in children 
with PWS is compensating for a serotonin deficiency or accelerated breakdown of se-
rotonin in the brain, resulting in increased levels of the serotonin precursor. However, 
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a serotonin deficiency seems unlikely as Akefeldt et al. found as higher levels of the 
serotonin metabolite 5-HIAA in cerebrospinal fluid in children and adolescents with 
PWS compared to a healthy control group, independent of age, body mass index and 
intelligence (31). Unfortunately, no cerebrospinal fluid was available and thus we were 
unable to determine 5-HIAA. 
It has been shown that serotonin reuptake inhibitors have beneficial effects in reducing 
irritability in children with autism (32, 33). Based on clinical experience, these inhibitors 
also seem to benefit children with PWS, which is suggestive for a suboptimal serotonin 
system in PWS. The exact mechanism behind the increased levels of the serotonin 
precursor and metabolite remains, however, unknown, thus further investigations are 
warranted.
Limitation and future research
This study was conducted as an exploratory study to determine possible predictors 
for depression in the dopamine and serotonin system in children with PWS, but we 
acknowledge some limitations.
We investigated depressive symptoms using a structured interview with the children 
themselves. It remains challenging to screen for an internalizing disorder as depression 
in people with an intellectual disability. First, they may present depression with different 
symptoms such as irritability, either with or without aggression (34). Second, due to the 
delayed mental development in children with PWS, it might be difficult to be aware of 
thoughts of guilt, helplessness, and hopelessness and how to describe these. In healthy 
children, a mental age of 8 years is required before children can reflect on these abstract 
items. We investigated the presence of depression and depressive symptoms in children 
with PWS to reveal their inner thoughts. To minimize errors, we only included children 
who were able to answer the questions in the test example, which was nearly half of 
the total group. Interestingly, although the excluded group was significantly younger 
and had a lower IQ, analyses of the dopamine and serotonergic factors were not sig-
nificantly different in children with and without evaluation of depressive symptoms. 
Thus, although a smaller group of children with PWS could complete the assessment on 
depressive symptoms, it is likely that our results on amino acids represent characteristics 
of the total PWS group. 
We used data of plasma amino acids in healthy children originating from another study 
with a similar method of amino acid analysis (18). This age-matched control group was, 
however, small. Based on our findings, it seems worthwhile to study dopaminergic and 
serotonergic factors in a longer follow-up study with a larger PWS and control group. 
New insights in the functioning of the dopamine and serotonin system are warranted 
for the early identification and treatment of depression in people with PWS and thus the 
quality of life of people with PWS.
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In conclusion, our study shows that none of the children with PWS fulfilled the criteria 
for depression, but the feeling of lack of friends, self-devaluation, difficulty in making 
decisions and being tired were reported. Tryptophan-ratio in children with PWS was 
higher than in healthy controls, but it was not related to depressive symptoms. However, 
children with more depressive symptoms had a lower tyrosine-ratio and HVA-level. Aro-
matic amino acid-levels were higher in children with PWS than in healthy controls, but 
levels of branched-chain amino acids were similar. Future research is needed to show 
if these findings could predict the increased incidence of depression in people with 
Prader-Willi syndrome later in life. 
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GeneraL dISCuSSIon
In November 2010, the study resulting in this thesis was started to investigate psychi-
atric disorders (PD) in children with Prader Willi syndrome (PWS), also called PD-study. 
The participating children originated from the Dutch randomized controlled growth 
hormone trial and the ongoing Dutch PWS Cohort study. The PD-study was started due 
to increasing number of questions by parents and health professionals about behavioral 
problems and psychiatric symptoms in children with PWS. Although knowledge about 
these two topics was increasing, most studies were conducted in adults or in a wide 
age-range and growth hormone (GH) status was often unknown. 
This thesis describes the prevalence of psychiatric disorders, the behavioral phenotype 
and level of adaptive functioning in children with PWS. In addition, we investigated the 
effect of long-term growth hormone treatment on behavior and adaptive functioning.
The present chapter discusses the findings of our studies in view of the current literature. 
Additionally, clinical implications of our results are presented and recommendations for 
future research are provided. 
8.1 Psychiatric disorders
People with PWS have an increased risk for psychiatric disorders. Those with mUPD are 
more prone to a psychosis than those with a deletion (1-4). However, studies about 
psychiatric disorders in children with PWS were very rare (5, 6). We therefore conducted 
a study to investigate the prevalence of psychiatric disorders in 61 children with PWS. 
We found that none of the children (median age 11.8 years) developed schizophrenia 
or other psychotic symptoms during 2 years of follow-up, and that only 2 boys had 
psychotic symptoms prior to the study, of which one had a relapse of psychotic symp-
toms during the study. The most common behavioral disorder was oppositional defiant 
disorder, found in 20% of our study group. 
In contrast to earlier reports in adults, we did not find psychotic symptoms in children 
with PWS, except in the abovementioned boy with the relapsing symptoms. One expla-
nation could be that our study group is relatively young. On the other hand, the age at 
onset of psychosis has been reported between 13 and 19 years (4). Another explanation 
could be the structured multidisciplinary care for our study group. All children were 
3-monthly seen by their pediatricians and the Dutch PWS team (7). The guidance by 
a multidisciplinary team, early start of physiotherapy, speech therapy, family and so-
cial support might have improved the mental health of these children and prevented 
psychiatric illness. Also, children were referred to a child-psychiatrist when any sign 
of psychopathology was suspected. Three children were treated with psychotropic 
medication prior to this study due to increased irritability, aggression and compulsive 
behavior. Early treatment might have prevented the first signs or deterioration of 
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psychiatric disorders. An alternative explanation could be that GH contributed to the 
neurodevelopment, leading to a lower risk for psychiatric disorders as we also found 
that long-term GH treatment improved cognitive functioning (8).  
The prevalence of oppositional defiant disorder (ODD) in children with PWS aged 7 to 17 
years was 20%. The presence of ODD was not associated with age, gender, genetic sub-
type or IQ. A child with ODD increases stress in the family (9, 10). It is therefore important 
to be aware of ODD in children with PWS, in order to prevent overestimation of the 
child’s capacity with regard to language skills, emotional skills and social functioning. 
It also means that families require practical advices how to approach their child. Over-
estimation could be decreased by breaking down larger tasks into clearly defined small 
steps, and allowing more time to rest. Communication with the child with PWS should 
be clear and concise by describing tasks simply, using short sentences, and avoiding 
abstract language (11). 
As reported earlier, we also found a high rate of hoarding/collecting objects and insist-
ing on (hygienic) routines in children with PWS (12, 13), which was not different between 
children with an mUPD or DEL. Parents mentioned that their child with PWS often 
resumed compulsive activity after interruption, and often waited with resuming until 
the parent had left the immediate area. The majority of children with PWS would not hit 
or kick the parent who intervened and would not hurt themselves after interruption of 
a compulsion. 
Our study shows the prevalence of psychiatric and behavioral disorders in children 
with PWS. Schizophrenia and other psychotic symptoms were rare in our large group 
of children with PWS who were all treated with long-term GH. Oppositional defiant 
disorder was the most common behavioral disorder which requires practical advices 
and guidance for parents and carers of children with PWS.
8.2 Theory of Mind and Autism Spectrum Disorder
There was very limited information about the Theory of Mind (ToM) development and 
prevalence of autism spectrum disorder (ASD) in children with PWS. The Theory of 
Mind describes the level of emotion recognition, awareness of ones own thoughts and 
of others, abstract language usage, and the ability to feel empathy for others. In this 
study, we investigated the ToM and the prevalence and symptoms of ASD. Our results 
demonstrated that children with PWS are severely impaired in their ToM-development. 
More delay in ToM was associated with an older age and lower total IQ, but not with 
genetic subtype. Additionally, we found that 36% of children with PWS fulfills the criteria 
for ASD. This was also not associated with genetic subtype. Within ASD, symptoms of 
maladaptive behavior were most prominent. 
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Our finding of a higher ToM in those with a higher IQ is in line with previous studies in 
people with an intellectual disability (14-16). This raises the question if the impaired ToM 
in our study group is affected by PWS specifically, or by the intellectual disability due to 
PWS. In contrast to our findings, an earlier study found more problems in ToM in those 
with an mUPD (17). The marked delay in ToM requires an adjusted approach of children 
with PWS. Children with PWS are impaired in feeling empathy for others and have 
therefore difficulties in social reciprocity. Family and carers should be informed about 
the delayed ToM development and be aware of the risk to overestimate the empathetic 
abilities of their child with PWS.  
The prevalence of 36% having ASD was in line with earlier studies (18, 19). Children 
with PWS show, however, an atypical profile of ASD, i.e. they especially have difficulties 
in maladaptive behavior and not in being obsessed about light and sound or making 
contact with others. Although 36% of our participants fulfilled the criteria for ASD, even 
more children had autistic symptoms but did not meet all criteria for ASD. Thus, many 
more than one-third of children with PWS would benefit from a structured approach as 
used in children with autism. We could not confirm that ASD is more common in those 
with an mUPD (17). It might be that the long-term GH treatment in our study group had 
also a beneficial effect on social cognitive functioning, especially for those with more 
social impairments. This would be in accordance with our previous study showing that 
long-term GH treatment improves cognition in children with PWS (8). 
Our study demonstrates that children with PWS have a markedly impaired Theory of 
Mind. In addition, 36% of children fulfills the criteria for Autism Spectrum Disorder, in 
which maladaptive behavior is the most prominent impairment. These findings high-
light the need for caretakers to adjust to the child’s level of social cognitive functioning 
to prevent overestimation of the empathetic and abstract language abilities in the child 
with PWS.  
8.3 Behavior
Information about the effect of GH treatment on behavior in children with PWS was 
very scarce. Our study investigated the effect of GH treatment on behavior in children 
with PWS during our 2-year randomized controlled GH trial and during at least 8 years 
of continuous GH treatment.
We found that children with PWS display similar problem behavior as a reference 
population with a comparable intellectual disability. However, they showed particu-
larly problems with social abilities as problem behavior, indicating that there is a more 
socially-related problem behavior. In contrast to our expectations, which were based 
on parental reports and our clinical experience, our study did not show improvement 
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but also no deterioration during long-term GH treatment on behavioral problems in 
children with PWS. 
Behavior in children with PWS was not clearly influenced by GH treatment, while we did 
find a significant effect of GH on cognitive functioning in our patients (8). Similar find-
ings were found in short children born small for gestational age (SGA). In short children 
born SGA, long-term GH treatment had beneficial effect on cognition, while attention 
deficits, especially accurateness and impulsiveness did not change during GH treatment 
(20, 21). The authors concluded that attention deficits were related to being born SGA, 
and we might draw a comparable conclusion for the behavioral problems in PWS. 
Another explanation why we could not find an effect of GH treatment on behavior might 
be the type of questionnaires we used in our study. Parents had to score behavior of 
their children with PWS on a 3-point scale (‘0=not true’, ‘1=sometimes or somewhat 
true’, ‘2=often true or very true’) in both questionnaires. On this sort of scale, it is only 
possible for parents to indicate if certain behaviors occur often, sometimes or never in 
their child. As PWS is associated with certain typical behavioral problems, for example 
temper tantrums, obsessive-compulsive and preservative behavior (6), all children 
display this behavior to a greater or lesser extent. These typical behavioral problems 
might get milder during GH treatment, but will probably never disappear completely. 
Thus, parents will never score ‘0’ on these particular behavioral problems, thereby saying 
that this behavior never occurs in their child. It is therefore very likely, that also if the 
behavioral problems in their child decreased during GH treatment, parents scored in 
the same way as prior to start of treatment. Remarkably, most parents did notice subtle 
changes, which they reported during their visits to our hospital. Our data are in line 
with those of a 2-year GH-controlled study in children with PWS (22), in which parents 
reported improved behavior during GH treatment during open interviews, while this 
was not the case in the untreated controls. Also in their study, structured behavioral 
questionnaires with a 3-point scale did not show differences in behavior between GH 
treated and untreated patients. 
Behavioral problems in children with PWS were comparable to children with a similar 
intellectual disability, but they had relatively more socially-related problems. Children 
with PWS experienced particularly more problems in being tuned to the social situation, 
and understanding social information and had more stereotyped behavior. This social 
impairment is typically found in people with PWS and many of their social behaviors ap-
pear to be on the same continuum of social deficits found in autism spectrum disorder 
(e.g. social withdrawal, poor peer relationships, lack of empathy) (11, 23, 24). 
In conclusion, our study shows that problem behavior in children with PWS is com-
parable with a reference population with a comparable intellectual disability. Within 
problem behavior, socially-related problems were the most prominent ones. Parents 
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noticed improvements in behavior during GH treatment, but tests did not confirm an 
improvement of behavioral problems in children with PWS, albeit also no deterioration.
8.4 Adaptive functioning
Only few studies investigated the adaptive functioning in people with PWS (17, 25). 
Adaptive functioning describes the ability to deal with daily activities which are required 
in the personal and sociocultural environment and forms an essential part of the be-
havioral phenotype (26). It includes skills in communication (receptive, expressive, and 
written), daily living (personal care, domestic tasks and within the community), social 
functioning (interpersonal relationships, play and leisure time, and coping skills), and 
motor functioning (gross and fine). We investigated the level of adaptive functioning 
and the effect of short-term and long-term GH treatment on adaptive functioning in 
children with PWS aged 7 to 17 years. Our results showed that children with PWS are 
impaired in their adaptive skills. The developmental delay was larger when children 
were older or had a lower IQ. Although no effect of short-term GH treatment was found 
on adaptive functioning, we showed that an earlier age at start of GH treatment during 
infancy was associated with improved adaptive functioning after long-term GH treat-
ment.   
Our data are in line with earlier findings that children with PWS have a marked delay in 
adaptive functioning, including social functioning (5, 27). Additionally, social disabilities 
in PWS are more impaired than in other children with intellectual disability, indicating 
that the impaired social functioning is specific for PWS (10, 23). In our large group of 
children with PWS, we did not find a difference in daily living skills between those with 
a deletion and mUPD, which is in contrast to an earlier study (17). 
The maladaptive functioning has a major impact on the daily life of children with PWS 
and their families. Not only does it highlight the need to adjust daily tasks to the level 
of the child, it has also consequences for the care by parents and carers. Although some 
children were able to perform some adaptive skills themselves, they needed supervi-
sion and it was difficult to perform the tasks within a certain time limit. Our finding that 
an earlier start of GH treatment during the infancy improves the adaptive skills on the 
long-term is therefore important to improve the quality of life of the children with PWS 
and their families. 
Our study demonstrates that children have a marked delay in adaptive functioning, and 
supervision and adjustments are usually required. The earlier the GH treatment was 
started during infancy, the better the adaptive skills on the long-term. 
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8.5 Visual-motor Integration
We also investigated the visual-motor integration in 73 children with PWS. Our data 
showed that the level of visual-motor integration was 3 standard deviations lower com-
pared to healthy references. Older children, those with a DEL or a higher IQ were less 
impaired in visual-motor integration. Simplifying visual-motor tasks by dividing tasks 
into a visual task and a motor task resulted in better scores of approximately 1 standard 
deviation lower compared to healthy references for both tasks, indicating that children 
with PWS have problems with combining these tasks at the same moment. A follow-up 
of 2 years did not show changes in visual-motor integration in children with PWS. 
Impairment in visual-motor integration has implications in daily life. Most tasks at school 
require visual-motor integration, such as writing, mathematic formulations, and draw-
ing. Our data show that it is important to simplify tasks by breaking them into visual 
tasks and motor tasks, and allow the child to acquire these separate tasks first. After 
obtaining these individual skills, tasks requiring both visual and motor integration, 
should be introduced as the final step.
VMI performance was strongly associated with total IQ, which is in line with an earlier 
report in children with intellectual disability (28), suggesting that intelligence might be 
particularly related to the planning stage of the VMI task and not so much to the motor 
component of the task. Children with DEL scored higher on VMI and visual perception 
than those with mUPD, which is in line with an earlier finding that children with DEL 
have stronger visual skills (19, 29)
This study shows that the visual-motor integration in children with PWS is very impaired. 
It is therefore important to simplify tasks into purely visual and motor tasks as it will 
improve performance. We suggest to implement this in the learning process of the child 
with PWS, as it will improve their daily functioning.
8.6 Depressive symptoms and the dopamine and serotonin system
People with PWS have an increased risk in developing depression compared to a 
healthy population. It has been described that changes in the dopamine and serotonin 
system are related to depression. In this explorative study, we investigated depressive 
symptoms and precursors and metabolites of dopamine (i.e. tyrosine and HVA) and 
serotonin (i.e. tryptophan) in plasma of in children with PWS. We found that none of the 
children with PWS fulfilled all criteria for a depression. However, approximately half of 
the children reported the feeling of lack of friends. Weaknesses in social skills are part 
of the behavioral phenotype of PWS and reported by parents as well (17, 19, 30). Our 
assessment shows that children with PWS were aware of their limited number of friends, 
but their social deficits challenged them to make friends. 
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Plasma tyrosine was higher in children with PWS than in healthy controls, but tyrosine-
ratio, an indicator of tyrosine availability for central dopamine synthesis, and HVA-levels 
were normal. A lower tyrosine-ratio was related with more depressive symptoms. Plasma 
tryptophan and tryptophan-ratio, an indicator of tryptophan availability for central sero-
tonin synthesis, were higher in children with PWS than in healthy controls. Our finding 
that the tryptophan-ratio is increased in children with PWS suggests a possible dysfunc-
tion in the serotonin system in children with PWS. One explanation could be that the 
serotonin system in children with PWS is compensating for a serotonin deficiency in the 
brain, resulting in increased levels of the serotonin precursor. However, a serotonin de-
ficiency seems unlikely as higher serotonin metabolites (5-HIAA) in cerebrospinal fluid 
were found by Akefeldt et al. (31). Remarkably, the aromatic amino acid-levels (tyrosine, 
tryptophan, and phenylalanine) were higher than in healthy children, but this was not 
the case for branched-chain amino acids. The exact mechanism behind the increased 
levels of the aromatic amino acids, tryptophan-ratio and serotonin metabolite in PWS 
remain, however, unknown. Further investigation is warranted as it might lead to early 
identification and treatment of depression in people with PWS and thus improve the 
quality of life of people with PWS.
Our exploratory study did not find depression in children with PWS, but we found de-
pressive symptoms. We also found changes in the plasma precursors and metabolites of 
the dopamine and serotonin system which might contribute to the increased risk for a 
depression in people with PWS later in life. 
8.7 General conclusions
In this thesis, we described several aspects of the psychiatric and behavioral phenotype 
in children with PWS, such as social functioning, psychiatric disorders, behavior, adap-
tive functioning, visual-motor integration and depressive symptoms and its relation to 
the dopamine and serotonin system, using specific tools in a large cohort of children 
with PWS participating in the Dutch PWS studies. 
We found more problems and delay in social development than we expected. Our study 
showed that the Theory of Mind-development in children with PWS was 3 standard 
deviation scores lower compared with healthy peers and autism spectrum disorder 
was found in 36% of children with PWS. These social disabilities increase the risk of 
overestimation of the child by its environment, leading to more stress with a higher 
susceptibility to behavioral problems or even psychiatric disorders. Our findings have 
therefore important implications for the guidance of the child and adolescent with PWS.
First, it is important to inform parents, family, and other caretakers about the delay in 
social and adaptive skills in PWS, and how to approach the child. Our findings of the 
Theory of Mind assessment showed that children with PWS have difficulties in feeling 
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empathy for others and have problems in social reciprocity. Most children were able 
to recognize emotions and aware of their own thinking (e.g. ‘I think it rains’), but it was 
difficult for them to be aware of the thoughts of others (e.g. ‘I think that John thinks it 
is raining’). Carers should therefore be aware of these social limitations and be concise 
in their communication. Second, one third of children with PWS fulfilled the criteria for 
autism spectrum disorder, but an even larger percentage showed autistic traits without 
fulfilling the diagnosis. A structured approach in communication and daily life, as being 
used in children with autism, could improve the daily life of children with PWS. Third, we 
found that an earlier start of GH treatment was associated with less delay in adaptive 
functioning on the long-term. GH treatment appears thus not only beneficial for body 
composition, bone mineral density, motor skills and cognition, but also for adaptive 
functioning. 
The present study also showed that psychotic symptoms or depression were rare in 
children with PWS, but the prevalence of oppositional defiant disorder was unexpect-
edly high. This finding stresses once again that raising a child with PWS is challenging, 
especially if the child is showing oppositional defiant behavior. Families should be aware 
of the high prevalence of this behavior and receive practical advices how to approach 
the child. 
At last but not least, we found increased levels of the serotonin precursor tryptophan 
and its ratio in children with PWS. An earlier study also found increased levels of the 
serotonin metabolite 5-HIAA in cerebrospinal fluid (31). These findings suggest that the 
serotonin system might function suboptimally in children with PWS, although the exact 
mechanism remains unknown. Further investigations are warranted to study if these 
changes could explain the increased risk for a depression in people with PWS later in life.
8.8 Practical consequences for parents and carers
Our findings on ToM are essential in the approach of these children. Both children with 
DEL and mUPD are delayed in ToM development, which might result in an increased risk 
to overestimate their empathetic abilities. Due to the relatively stronger verbal develop-
ment of children with mUPD compared to those with DEL, children with mUPD are often 
overestimated in their ability to feel empathy for others. Most children with PWS did not 
have any problems in recognizing emotions, but false belief (the individual’s compre-
hension of another person’s mistaken belief ) was more difficult. The most difficult was 
second belief, which is the inference of someone’s belief about another’s belief such as 
‘I think that you think…’. As major impairments were found in the ToM, carers should 
adjust their communication and mention why and what they are thinking. For example, 
instead of saying “Clean up your toys” to the child with PWS, the caretaker should say: 
“John, put your toys in the basket in the coming five minute”. The latter communica-
tion will be much clearer for children with PWS because the caretaker’s thinking is said 
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aloud which is much easier for the child to understand. The theory of this way of com-
munication is explained in the Dutch book called ‘Geef me de Vijf ’ (‘Give me the Five’) 
by Colette de Bruin, who introduced to use the five elements: who, what, where, when 
and how for structured communication as used in children with autism. When children 
show increased irritability or more behavioral problems, we suggest to determine the 
developmental level of the child, including social cognition. These developmental 
assessments are useful to inform parents and carers about the child’s developmental 
age and how to approach their child.  This will contribute in understanding the child 
to prevent overestimation which could result in frustration and bursts of emotional 
disturbance such as temper tantrums.   
Approximately one-third of children with PWS had ASD, but even a greater percentage 
showed autistic traits. We therefore advise parents to implement structure in the child’s 
daily living, such as in communication (using the five elements of who, what, where, 
when and how), in daily routines and tasks. 
Children with intellectual disability can experience their daily life in another perspec-
tive than their healthy peers and events or changes which will be unnoticed by people 
with normal intelligence, can be highly stressful for children with PWS (such as holidays, 
changing of seasons, Sinterklaas, and fireworks, but also unplanned visits or changes 
during the day). Due to the intellectual disability and the hypotonia in children with 
PWS, adaptive functioning is also delayed. The early start of GH treatment should be 
considered to improve adaptive functioning on the long-term, besides the beneficial 
effects of growth hormone on body composition, bone mineral density, motor abilities 
and cognition 
It remains challenging to find the right balance between stimulating adaptive skills in 
children with PWS and protecting them from danger. Certain ‘risky’ daily livings skills 
such as cooking, being part of traffic by walking or cycling alone, or using money are 
often activities that are avoided by parents to prevent their children from dangerous 
situations or troubles. 
Visual-motor integration is an important skill in daily life. We found that combining 
visual skills and motor skills at the same time is very difficult for the children. In the 
learning process of writing and daily skills, we suggest to allow the children to acquire 
the visual and motor skills first and to allow them sufficient time to learn and later on to 
complete their visual-motor tasks. 
8.8 Directions for future research
In this thesis, we presented the impaired Theory of Mind (ToM)-development in chil-
dren with PWS. As the ToM is fundamental in social functioning, it may be worthwhile 
to investigate if ToM-development could be improved by providing a ToM-training to 
children with PWS. Some children are already introduced to ToM-training by family or 
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school. Studying the effect of a ToM-training in children with PWS may result in new 
insights how to guide children with PWS in their social impairments. 
We investigated behavioral problems in children with PWS and found that oppositional 
defiant disorder was present in one of five children. Further follow-up of these children is 
needed to investigate if they are more prone to psychotic disorders later in life. Psychotic 
disorders were rare in our study group aged 7 to 17 years. Future studies should include 
more adolescents and young adults to investigate at what age psychiatric problems do 
occur, and if GH treatment can prevent or limit the severity of psychiatric disorders in 
young adults with PWS. Clinically, it is also important to investigate the effect of tes-
tosterone replacement therapy on behavior, as parents and health professionals may 
unnecessarily limit the prescription of testosterone replacement due to concerns about 
deterioration of behavior. Selective serotonin reuptake inhibitors (SSRIs) are prescribed 
to children with PWS who experience mood disorders, but also in case of increased ir-
ritability or compulsive behavior. The effect of SSRIs on these disorders has, however, not 
yet been studied in children with PWS.
Our previous study showed beneficial effects of long-term GH treatment on cognitive 
functioning (8). This might be due to a beneficial effect of GH on brain structures and 
networks involved in cognition or behavior. Brain imaging studies in patients with PWS 
will provide more insight in the relation between brain abnormalities and cognitive 
dysfunctions or behavioral problems and how GH affects the brain and behavior.
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Pd-STudy
Psychiatric disorders
- Psychotic symptoms and depression are 
uncommon
- 20% of children with PWS fulfills criteria for 
oppositional defiant disorders
► Be aware of overestimation of mental and 
physical skills 
► Guidance for families how to approach child
Theory of Mind (ToM) and Autism 
Spectrum Disorder (ASD)
- Severe delay in ToM
- More delay in ToM with older age 
and lower IQ
- 36% have ASD
- ASD mainly due to maladaptive 
behavior
► Be aware of overestimation in 
social cognition
► Adjusted approach including
• structured communication
• adjustments to the child’s level 
at home and school 
• being clear and consistent
Behavior 
- Similar problem behavior as children with 
comparable intellectual disability
- Problems with social abilities most pronounced
- No effect during short- or long-term GH 
treatment
► No deterioration of behavior during long-term 
GH treatment 
Visual-motor integration (VMI)
- VMI is severely impaired
- Simplifying into pure visual or 
motor tasks improves VMI
► Allow more time for VMI-tasks
► Allow to acquire visual and 
motor skills first
Depression and dopamine and serotonin system
- No depression found in children with PWS
- Aromatic amino acid-levels are higher than in healthy 
controls
- Dopamine: more depressive symptoms correlated with lower 
plasma tyrosine-ratio
- Serotonin: tryptophan-ratio significantly higher than in 
healthy controls
Adaptive functioning
- Severe delay in adaptive 
functioning
- More delay with older age 
and lower IQ
- No effect during short-term 
GH treatment
- Less delay when GH 
treatment was started at 
earlier age
► Beneficial effect of early start 
of GH on adaptive skills
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SuMMary 
Chapter 1
This chapter provides information on the genetic cause, symptoms, behavioral pheno-
type and psychiatric disorders in children and adolescents with Prader-Willi syndrome 
(PWS).
Chapter 2
Reports about psychiatric disorders in children with PWS are very limited. We therefore 
studied 61 children with PWS aged 7 to 17 years using the Diagnostic Interview Sched-
ule for Children (DISC) and Compulsive Behaviour Checklist (CBC). Thirty-eight of 61 
children were retested after 2 years. Prior to the study, only two boys were known with 
psychotic symptoms and treated with antipsychotics. At baseline, none of the other 
children fulfilled the criteria for schizophrenia or other psychotic disorders. After 2 years, 
none of the children had schizophrenia or other psychotic disorders. Oppositional defi-
ant disorder (ODD) was the most common diagnosis and present in 20% of children with 
PWS, and was not associated with age, gender, genetic subtype, or total IQ. The most 
common compulsions were hoarding and fixed hygiene sequences.
In conclusion, in our large group of 61 children with PWS, 59 had no psychotic disorder. 
Oppositional defiant disorder was the most common disorder. The prevalence of the 
psychiatric disorders did not change during the 2-year follow-up. 
Chapter 3
Social cognitive functioning was studied by testing the Theory of Mind (ToM) and 
symptoms of Autism Spectrum Disorder (ASD) in children with Prader-Willi syndrome 
(PWS). The ToM describes the cognitive capacity to infer in the mental state of oneself 
and others, i.e. the ability to be conscious of ‘I think that …’,  ‘I think that you think…’ 
and ‘I think that you think that he thinks ….’. We studied 66 children with PWS aged 7 
to 17 years with growth hormone treatment and used the Theory of Mind test-R and 
the Diagnostic Interview Social Communication disorders. Median Total ToM score was 
3 standard deviations lower than healthy peers. The ToM score was positively associated 
with total IQ, in particular verbal IQ. We found no difference in Total ToM SDS between 
children with a deletion and those with an mUPD. One-third of children with PWS scored 
positive for ASD. The prevalence of ASD was not associated with total IQ and did not 
differ between genetic subtypes, or boys and girls. Most prominent aberration in ASD 
was maladaptive behavior. 
In conclusion, our findings demonstrate a markedly reduced level of social cognitive 
functioning, which has consequences for the approach of children with PWS. Parents 
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and caretakers are advised to test the developmental age of children with PWS and to 
adjust to the child’s level of social functioning in communication and social demands. 
Chapter 4
Based on clinical experience and parents’ reports, we expected that behavior would 
improve after long-term growth hormone treatment in children with PWS. In this study, 
we investigated behavior in children with PWS and the effects of growth hormone treat-
ment in 44 prepubertal children aged 3.5 to 14 years in a randomized controlled trial 
during 2 years (RCT), followed by a longitudinal study during 8 years of growth hormone 
treatment. Behavior was measured annually by the Developmental Behavior Checklist 
for children with intellectual disability (DBC) and a Dutch questionnaire to evaluate social 
behavioral problems in children, the Children’s Social Behavior Questionnaire (CSBQ). 
We found that problem behavior measured by the DBC in children with PWS was similar 
compared to children with a comparable intellectual disability. However, they showed 
particularly problems with social abilities, indicating that there is a more socially-related 
problem behavior. A lower IQ was associated with more self-absorbed behavior, more 
communication problems and more problem behavior in general. Problem behavior 
measured by the CSBQ was similar compared to children with a comparable intellectual 
disability, but children with PWS scored significantly higher on the ‘Not tuned’, ‘Under-
standing’ (understanding social information such as jokes or main conclusion from 
stories), and ‘Stereotyped’ subscales than the CSBQ total score. 
In contrast to our experience and parents reports, our study shows no improvement but 
also no deterioration of behavioral problems in children with PWS during long-term GH 
treatment.
In conclusion, children with PWS showed similar problem behavior as a reference 
population with a comparable intellectual disability. Social problems were the most pro-
nounced in children with PWS. In contrast to our expectations and parents’ reports, our 
study showed no improvement during long-term growth hormone treatment, but also 
no deterioration of their behavioral problems. It might be that the questionnaires were 
not sufficiently sensitive to find the subtle improvements of behavior during growth 
hormone treatment as was reported by parents. 
Chapter 5
The aim of this study was to investigate the effect of growth hormone treatment on 
adaptive functioning in children with PWS. Adaptive functioning describes the ability 
to deal with daily activities including skills in communication (receptive, expressive, and 
written), daily life (personal care, domestic tasks and within the community), social func-
tioning (interpersonal relationships, play and leisure time, and coping skills), and motor 
functioning (gross and fine). We used the Vineland Adaptive Behavior Scale (VABS) to 
Summary 163
9
assess adaptive functioning during a randomized controlled trial and after 7 years of 
growth hormone treatment. In the RCT, 75 children (42 infants and 33 prepubertal chil-
dren) with PWS were included. Subsequently, 53 children were treated with long-term 
growth hormone. Our study demonstrates a marked delay in adaptive functioning in 
infants and children with Prader-Willi syndrome, which was associated with older age 
and lower intelligence. Results show that the earlier growth hormone treatment was 
started during infancy, the better the adaptive skills were on the long-term. 
In conclusion, adaptive functioning in children with PWS is impaired, but an earlier start 
of growth hormone treatment during infancy results in better adaptive skills on the 
long-term.
Chapter 6
Information about visual-motor integration (VMI) in children with PWS was scarce. We 
determined VMI in 73 children with PWS aged 7 to 17 years who were all treated with 
growth hormone. Beery Visual-motor Integration test, which consisted of a visual-motor 
integration test (no time-limit), a visual integration subtest and a motor perception sub-
test (both limited in time) were assessed at start of the study and after 2 years. Children 
with PWS scored 3 standard deviations lower in visual-motor integration and 1 standard 
deviation lower in visual perception and motor coordination compared to healthy chil-
dren. Scores on visual-motor integration were higher in children with a deletion, in older 
children, and in those with a higher total IQ. Scores on visual perception were higher in 
children with a deletion and higher total IQ, but scores on motor coordination were only 
higher in those with a higher total IQ. Visual perception and motor coordination were 
not associated with age or gender. Neither visual perception and motor coordination, 
nor visual-motor integration had improved in the second assessment after 2 years. 
In conclusion, the VMI is poor in children with PWS. Children scored higher on the time-
limited subtests for visual perception and motor coordination than on the combined 
test for visual-motor integration, indicating that children with PWS have problems 
combining these tasks at the same moment. Separation of visual and motor tasks prior 
to the integration of visual and motor tasks and allowing sufficient time to learn and 
perform these tasks will improve daily activities, both at home and at school.   
Chapter 7 
No studies had investigated whether depressive symptoms correlate with biomarkers 
of the dopamine and serotonin system in children with PWS. In this exploratory study, 
we investigated depressive symptoms using the Dutch version of the Children’s Depres-
sion Inventory (n=30), and determined precursors and a metabolite of the dopamine 
and serotonin system during 2 years in children with PWS aged 7 to 17 years (n=68) 
compared to healthy controls (n=10). None of the children fulfilled the criteria for the 
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diagnosis of depression. The four most rated depressive symptoms were lack of friends 
(57% of the children), self-devaluation compared to peers (27%), difficulty in making 
decisions (20%), and being tired (23%). 
Our study showed that the plasma precursor availability and metabolite of dopamine 
were decreased in case more depressive symptoms were present which suggests a de-
creased dopamine synthesis. The level of these biomarkers of dopamine also decreased 
during 2 years of follow-up. The plasma precursor availability of serotonin was signifi-
cantly higher in children with PWS than in healthy controls, but it was not related with 
depressive symptoms. During 2 years of follow-up, the plasma precursor availability of 
serotonin increased. Interestingly, plasma levels of the aromatic amino acids (i.e. tyro-
sine, tryptophan, and phenylalanine) were increased compared to healthy controls, but 
levels of branched-chain amino acids were similar. 
In conclusion, depression is uncommon in children with PWS. We found differences in 
the biomarkers of the dopamine and serotonin system compared to healthy controls and 
changes over time. Remarkably, aromatic amino acid-levels were increased in children 
with PWS, but the exact mechanism is unclear. Further research is needed to show if the 
changes in precursors and metabolites of the dopamine and serotonin system in plasma 
could predict the increased incidence of depression in people with PWS later in life.
Chapter 8
In the general discussion, we discuss our findings in a broader context. We present our 
general conclusions in relation to current literature. We give practical implications for 
parents and caregivers and provide directions for future research.
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SaMenVaTTInG
Hoofdstuk 1
Dit hoofdstuk geeft een korte introductie over het Prader-Willi syndroom (PWS) en be-
schrijft de genetische oorzaken van het syndroom, de symptomen, het gedragsfenotype 
en de weinige literatuur over psychiatrische stoornissen bij mensen met PWS. 
Hoofdstuk 2
Er waren tot de start van huidige studies weinig studies bekend die de psychiatrische 
stoornissen bij kinderen met PWS beschreven. We hebben daarom 61 kinderen met 
PWS in de leeftijd van 7 tot 18 jaar onderzocht met de Diagnostic Interview Schedule 
for Children (DISC) en Compulsive Behaviour Checklist (CBC). Na 2 jaar werden 38 van 
de 61 kinderen opnieuw getest. Voor start van de studie waren 2 jongens bekend met 
psychotische symptomen en behandeld met antipsychotica. Bij start van de studie 
scoorde geen van de andere kinderen positief voor schizofrenie of andere psychotische 
stoornissen. Geen van de kinderen had een psychotische stoornis tijdens de studie. 
Oppositioneel opstandig gedrag was de meest voorkomende diagnose met een preva-
lentie van 20% bij kinderen met PWS. Dit was niet geassocieerd met leeftijd, geslacht, 
genetisch subtype of IQ. De meest voorkomende compulsies waren het verzamelen van 
spullen en een vaste routine in hygiëne-activiteiten. 
Concluderend, in onze groep van 61 kinderen met PWS had 59 geen psychotische stoor-
nis. Oppositioneel opstandig gedrag was de meest voorkomende stoornis. Wij vonden 
geen verslechtering in het psychisch welzijn gedurende de vervolgstudie van 2 jaar. 
Hoofdstuk 3
In deze studie werd het sociaal cognitief functioneren onderzocht bij kinderen met PWS 
door de Theory of Mind (ToM) en symptomen passend bij Autisme Spectrum Stoornis-
sen (ASS) te bestuderen. De ToM is de cognitieve vaardigheid om je bewust te zijn van 
je eigen gedachten en die van een ander, dat wil zeggen gedachten als ‘Ik denk dat…’, 
‘Ik denk dat jij denkt …’ en ‘Ik denk dat jij denkt dat hij denkt …’. We onderzochten 66 
kinderen met PWS in de leeftijd van 7 tot 18 jaar en gebruikten hiervoor de testen 
Theory of Mind test-R en de Diagnostic Interview Social Communication disorders. De 
mediaan van de totale ToM-score was 3 standaard deviaties lager dan leeftijdsgenoten. 
De ToM score was positief geassocieerd met IQ, met name het verbale IQ. We vonden 
geen verschil in totale ToM score tussen kinderen met een deletie en mUPD. Een op 
de drie kinderen scoorde positief voor ASS en dit was niet geassocieerd met totaal 
IQ. Er was geen verschil in de prevalentie van ASS tussen kinderen met een deletie of 
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mUPD, en tussen jongens en meisjes. Binnen de ASS hadden zij vooral symptomen van 
maladaptief gedrag. 
Concluderend, onze bevindingen wijzen naar een aanzienlijk verminderd sociaal func-
tioneren, dat consequenties heeft voor de manier waarop kinderen met PWS benaderd 
moeten worden. Wij adviseren ouders en verzorgers om de ontwikkelingsleeftijd van 
kinderen met PWS te testen en de communicatie en de sociale verwachtingen aan te 
passen aan de sociale ontwikkelingsleeftijd van het kind met PWS. 
Hoofdstuk 4
Gedragsproblemen komen veel voor bij kinderen met PWS, maar er was nog weinig 
bekend over het effect van groeihormoonbehandeling op het gedrag van de kinderen, 
ondanks het feit dat ouders gedragsverbeteringen rapporteerden tijdens de groeihor-
moonbehandeling. We hebben daarom het effect van groeihormoonbehandeling op 
het gedrag onderzocht in een gerandomiseerde en gecontroleerde groeihormoonstu-
die gedurende 2 jaar bij 42 kinderen met PWS in de leeftijd 3.5 tot 14 jaar. Na afloop 
van de gerandomiseerde studie werden de kinderen verder vervolgd in de PWS Cohort 
studie waarin we het effect van 8 jaar groeihormoonbehandeling op het gedrag heb-
ben onderzocht. Het gedrag van de kinderen werd jaarlijks geëvalueerd met behulp 
van 2 oudervragenlijsten, namelijk de gedragsvragenlijst voor verstandelijk beperkte 
kinderen (VOG) en de vragenlijst voor inventarisatie van sociale problemen bij kinderen 
(VISK). Uit ons onderzoek kwam naar voren dat het probleemgedrag bij kinderen met 
PWS gemeten met de VOG overeenkwam met kinderen met een vergelijkbare verstan-
delijke beperking. Echter, kinderen met PWS hadden relatief meer sociale problemen. 
Probleemgedrag gemeten met de VISK wees uit dat sociale problematiek bij kinderen 
met PWS vergelijkbaar is met die van kinderen met een vergelijkbare verstandelijke be-
perking, maar meer voorkomt vergeleken met gezonde leeftijdsgenoten. Kinderen met 
PWS laten relatief meer problemen zien op de onderdelen onaangepast gedrag, niet 
begrijpen van sociale informatie zoals grapjes of de kern van een gesprek en zij hebben 
meer stereotiep gedrag. In tegenstelling tot onze verwachtingen gaf langdurig groei-
hormoonbehandeling geen verbetering op het gedrag, maar ook geen verslechtering. 
Concluderend, kinderen met PWS hadden dezelfde mate van probleemgedrag als andere 
kinderen met een verstandelijke beperking, maar lieten vooral sociale problemen zien. 
In tegenstelling tot onze verwachting lieten onze resultaten geen veranderingen zien op 
gedrag tijdens langdurige groeihormoonbehandeling. Mogelijk waren de vragenlijsten 
niet gevoelig genoeg om subtiele verbeteringen in het gedrag te objectiveren. 
Hoofdstuk 5
In deze studie werd het effect van groeihormoonbehandeling op het adaptief functio-
neren bij kinderen met PWS onderzocht. Adaptief functioneren omschrijft in hoeverre 
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een individu functioneert in het dagelijkse leven op het gebied van communicatie (be-
grijpen, luisteren en spreken, schrijven), dagelijks leven (zelfverzorging, huishoudelijke 
taken, maatschappelijk), sociaal functioneren (interpersoonlijke relaties, spelen en vrije 
tijd, sociale vaardigheden) en motoriek (grof en fijn). Hiervoor gebruikten wij de Vin-
eland Adaptive Behavior Scales (VABS) tijdens de gerandomiseerde en gecontroleerde 
studie en na 7 jaar groeihormoonbehandeling. In de gerandomiseerde studie werden 
75 kinderen (42 peuters en 33 prepubertaire kinderen) met PWS geïncludeerd. Ouders 
van 53 kinderen werden opnieuw benaderd voor de VABS-afname na 7 jaar groeihor-
moonbehandeling bij het kind. Wij vonden een opmerkelijke vertraging in de ontwik-
keling van het adaptief functioneren bij kinderen met PWS. Kinderen die ouder waren 
of een lagere intelligentie hadden, hadden een grotere achterstand van het adaptief 
functioneren dan hun gezonde leeftijdsgenoten. Wij vonden tevens dat kinderen beter 
scoorden op het adaptief functioneren indien zij als peuter eerder waren behandeld 
met groeihormoon.  
Concluderend, het adaptief functioneren is vertraagd bij kinderen met PWS. Een eerdere 
start van groeihormoonbehandeling op de peuterleeftijd leidt tot betere adaptieve 
vaardigheden op de lange termijn.
Hoofdstuk 6
Er was nog weinig bekend over de visueel-motorische integratie (VMI) bij kinderen 
met PWS. Wij hebben de VMI onderzocht in 73 kinderen met PWS in de leeftijd van 7 
tot 18 jaar die allen werden behandeld met groeihormoon. Hiervoor werden de Beery 
Visual Motor Integration test, welke bestond uit de visueel-motorische integratie test 
(zonder tijdslimiet), alsmede de visuele perceptie subtest en de motorische coördinatie 
subtest (beide met tijdslimiet) gebruikt, bij start en na 2 jaar studie. Kinderen met PWS 
scoorden 3 standaard deviaties lager in visueel-motorische integratie, en 1 standaard 
deviatie lager in visuele perceptie en motorische coördinatie in vergelijking met ge-
zonde leeftijdsgenoten. Kinderen met een deletie en een hoger IQ hadden een betere 
visueel-motorische integratie. Motorische coördinatie was alleen beter in geval van een 
hoger IQ. Visuele perceptie en motorische coördinatie waren beide niet geassocieerd 
met leeftijd of geslacht. Na 2 jaar studie werd geen verbetering gezien in de visuele 
perceptie, motorische coördinatie, en visueel-motorische coördinatie,. 
Concluderend, laten onze data zien dat kinderen met PWS zwak scoren op de visueel-
motorische integratie, waarbij de visuele perceptie en de motorische coördinatie tege-
lijkertijd getest worden. Zij scoorden beter indien de visuele perceptie en motorische 
coördinatie apart werden getest. Dit geeft aan dat het voor kinderen met PWS moeilijker 
is om tegelijkertijd visuele en motorische taken uit te voeren. In de praktijk betekent 
dit dat dagelijkse activiteiten thuis of op school verbeterd kunnen worden door taken 
met visueel-motorische integratie eerst op te delen in alleen een visuele of motorische 
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taak, voldoende tijd hiervoor te geven en dan pas de visueel-motorische integratie te 
oefenen. 
Hoofdstuk 7
Er waren nog geen studies verricht naar het voorkomen van depressieve symptomen 
bij kinderen met PWS en naar een eventuele relatie tussen depressieve symptomen en 
biomarkers van het dopamine- en serotoninesysteem. Daarom hebben we de aanwezig-
heid van depressieve symptomen onderzocht in 30 kinderen met PWS tussen de 7 en 
17 jaar met de Nederlandse versie van de Children’s Depression Inventory. Tevens heb-
ben wij in het plasma de beschikbaarheid van de precursor en de concentratie van de 
metaboliet van het dopamine- en serotoninesysteem bepaald bij 68 kinderen met PWS 
gedurende 2 jaar en vergeleken met 10 gezonde leeftijdsgenoten. Geen van de kinderen 
met PWS voldeed aan de criteria van de diagnose depressie. De 4 meest voorkomende 
depressieve symptomen waren gebrek aan vrienden (57% van de kinderen), gevoelens 
van minderwaardigheid ten opzichte van leeftijdsgenoten (27%), moeite hebben om 
beslissingen te nemen (20%), en moe voelen (23%). 
Onze studie laat zien dat de beschikbaarheid van de precursor en concentratie van 
de metaboliet van dopamine verlaagd zijn indien er meer depressieve symptomen 
bestaan, welke kan wijzen op een verminderde dopaminesynthese. De concentratie van 
deze biomarkers van dopamine verminderde in de loop van 2 jaar. De beschikbaarheid 
van de precursor van serotonine was significant hoger bij kinderen met PWS dan bij 
gezonde leeftijdsgenoten, maar dit was niet gerelateerd aan depressieve symptomen. 
Gedurende 2 jaar nam de beschikbaarheid van de precursor van serotonine toe. Tevens 
vonden wij dat plasma concentraties van de gearomatiseerde aminozuren (tyrosine, 
tryptofaan en phenylalanine) verhoogd waren vergeleken met gezonde controles, maar 
de concentraties van vertakte keten aminozuren was normaal. Het is nog onbekend hoe 
deze verschillen kunnen worden verklaard.
Concluderend, depressie is zeldzaam bij kinderen met PWS. Wij vonden verschillen in de 
biomarkers van het dopamine- en serotoninesysteem vergeleken met gezonde contro-
les en veranderingen van deze biomarkers gedurende 2 jaar. Het was opvallend dat de 
concentraties van de gearomatiseerde aminozuren verhoogd waren in vergelijking met 
gezonde controles. Verdere studies zijn nodig om te onderzoeken of plasma precursors 
en metabolieten van het dopamine- en serotoninesysteem kunnen voorspellen of een 
persoon met PWS een hogere kans heeft op het ontwikkelen van depressie op oudere 
leeftijd.  
Hoofdstuk 8
In de algemene discussie bespreken we onze bevindingen in een bredere context. We 
presenteren onze algemene conclusies in relatie tot de huidige literatuur. Wij sluiten het 
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hoofdstuk af met de praktische adviezen voor ouders en verzorgers en suggesties voor 
toekomstig onderzoek.
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List of abbreviations
LIST of abbreVIaTIonS
ADHD Attention Deficit Hyperactivity Disorder
ASD Autism Spectrum Disorder
BMI Body Mass Index
CAAs Competing Amino Acids
CBC Compulsive Behavior Checklist
CDI Children’s Depression Inventory
CSBQ Children’s Social Behavior Questionnaire
DBC Developmental Behavior Checklist
DEL Deletion
DISC Diagnostic Interview Schedule for Children
DISCO Diagnostic Interview Social and Communication disorders
DNA Deoxyribonucleic adic
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